TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF - Patent application
Compounds targeting CDK14, CDK15, CDK16, and CDK18 provide therapeutic benefits for cancer, diabetes, and neurological disorders, and regulate spermatogenesis, addressing the lack of effective CDK modulators in current therapies.
Patent Information
- Application Number
- JP2020573003
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-06-25
- Filing Date
- 2019-06-24
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2039-06-24
AI Technical Summary
Current therapies lack effective modulators for cyclin-dependent kinases (CDKs), particularly CDK14, CDK15, CDK16, CDK17, and CDK18, which are involved in various diseases including cancer, neurological disorders, and metabolic disorders, necessitating the development of selective inhibitors to target these kinases for therapeutic intervention.
Development of compounds represented by formulas (I) and (I') that inhibit the activity of CDK14, CDK15, CDK16, and CDK18, including their selective inhibitors, which can be used as therapeutics for diseases such as cancer, diabetes, and neurological disorders, and as male contraceptives.
The compounds effectively inhibit the activity of CDK14, CDK15, CDK16, and CDK18, providing therapeutic benefits for cancer, diabetes, and neurological disorders, and offer a potential male contraceptive option by regulating spermatogenesis.
Smart Images

Figure 0007590185000387 
Figure 0007590185000388 
Figure 0007590185000389
Abstract
Description
[Technical Field]
[0001] Related Applications This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 62 / 689,551, filed June 25, 2018, which is incorporated herein by reference. [Background technology]
[0002] Background of the Invention Members of the cyclin-dependent kinase (CDK) family play critical regulatory roles in proliferation. There are currently 20 known mammalian CDKs. Evidence indicates that certain TAIRE family kinases, including CDK14 (also known as PFTAIRE1 or PFTK1), as well as CDK15, CDK16, CDK17, and CDK18, play a role in cancer progression. Therefore, targeting TAIRE family kinases is a promising therapeutic strategy in cancer. CDK14 is involved in promoting cell motility in cancer. For example, CDK14 has been shown to be a key regulator of tumor proliferation, invasion, and epithelial-to-mesenchymal transition in pancreatic cancer (Zheng, L., Zhou, Z. & He, Z. Knockdown of PFTK1 inhibits tumor cell proliferation, invasion, and epithelial-to-mesenchymal transition in pancreatic cancer. Int. J. Clin. Exp. Pathol., 8, 14005-12 (2015)); hepatocellular carcinoma (Sun, T. et al., PFTK1 interacts with cyclin Y to activate non-canonical Wnt signaling in hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 449, 163-8 (2014)); and gastric cancer (Yang, L. et al. PFTK1 Promotes Gastric Cancer Progression by Regulating Proliferation, Migration, and Invasion. PLoS ONE, 10, e0140451 (2015)). CDK14 has also been identified as a contributor to neurological diseases and disorders, including gliosis (Duan C, et al., J. Mol Neurosci. 2015).Additional evidence suggests that certain TAIRE family kinases play roles in other cancers and other diseases (including, but not limited to, metabolic and neurological disorders) and male reproduction. CDK18 is involved in diabetes, and CDK17 and CDK18 are involved in Alzheimer's disease, and targeting these TAIRE kinases may be a promising therapeutic strategy for these diseases (Potential roles of PCTAIRE-2, PCTAIRE-3, and P-histone H4 in amyloid precursor protein-dependent Alzheimer's pathology. Oncotarget. 2016). CDK16 is involved in several types of cancer and spermatogenesis (Zi Z. et al., pLoS Genet. 2015). CDK15 is involved in cancer apoptosis (ALS2CR7(CDK15) attenuates TRAIL-induced apoptosis by inducing phosphorylation of survivin Thr34. Biochemical and Biophysical Research Communications. 2014). The TAIRE family of cyclin-dependent kinases consists of CDK14, CDK15, CDK16, CDK17, and CDK18, all of which bind to cyclin Y (Mikolcevic, P. et al., Cell Cycle, 2012, 11 (20), 3758-68). Cyclin Y can activate these kinases and target them to the plasma membrane. See ibid. These kinases are highly conserved but poorly characterized. Nevertheless, TAIRE family kinases are frequently overexpressed in a wide variety of cancers and are associated with invasive, migratory, and proliferation phenotypes. These oncogenic cytoplasmic traits can be reduced by RNAi-induced knockdown of one or more of the TAIRE kinases or cyclin Y.(Yang, L. et al., PloS One 2015, 10 (10), e0140451; Liu, M. H.; et al., Knockdown of PFTK1 Expression by RNAi Inhibits the Proliferation and Invasion of Human Non-Small Lung Adenocarcinoma Cells. Oncology Research 2016, 24 (3), 181-7; Zhu, J.; et al., Knockdown of PFTAIRE Protein Kinase 1 (PFTK1) Inhibits Proliferation, Invasion, and EMT in Colon Cancer Cells. Oncology Research 2016, 24 (3), 137-44; Zheng, L.; et al., Knockdown of PFTK1 inhibits tumor cell proliferation, invasion and epithelial-to-mesenchymal transition in pancreatic cancer. Int’l J. Clinical and Experimental Pathology 2015, 8 (11), 14005-12; Zhang, W. et al., PFTK1 regulates cell proliferation, migration and invasion in epithelial ovarian cancer. Int’l J. Biological Macromolecules 2016, 85, 405-16; Zi, Z. et al., CCNYL1, but Not CCNY, Cooperates with CDK16 to Regulate Spermatogenesis in Mouse. PLoS Genetics 2015, 11 (8), e1005485)。
[0003] CDK14 has been shown to regulate Wnt signaling during mitosis and is overexpressed in many Wnt-dependent cancers, including colorectal and ovarian cancers. (Davidson, G. et al., Cell cycle control of wnt receptor activation. Developmental Cell 2009, 17 (6), 788-99; Zhou, Y. et al., Spontaneous genomic alterations in a chimeric model of colorectal cancer enable metastasis and guide effective combinatorial therapy. PloS One 2014, 9 (8), e105886. Ou-Yang, J. et al., Cyclin-Dependent Kinase 14 Promotes Cell Proliferation, Migration, and Invasion in Ovarian Cancer by Inhibiting Wnt Signaling Pathway. Gynecologic and Obstetric Investigation 2017, 82 (3), 230-239) CDK16 is essential for spermatogenesis, and therefore, inhibitors of CDK16 may be developed as a type of male contraceptive. (Mikolcevic, P.; et al., Cyclin-dependent kinase 16 / PCTAIRE kinase 1 is activated by cyclin Y and is essential for spermatogenesis. Molecular and Cellular Biology 2012, 32 (4), 868-79; Zi, Z. et al., CCNYL1, but Not CCNY, Cooperates with CDK16 to Regulate Spermatogenesis in Mouse. PLoS Genetics 2015, 11 (8), e1005485).Due to the important regulatory functions of kinases such as CDKs, including CDK14, CDK15, CDK16, CDK17, and CDK18, in cell cycle control, cell proliferation, differentiation, and apoptosis, it is important to develop modulators of these kinase activity, including selective modulators (e.g., selective inhibitors), for use as research tools and therapeutic agents in the treatment of various diseases and as agents for male contraception. Summary of the Invention
[0004] SUMMARY OF THE INVENTION Described herein are compounds represented by Formula (I') or (I), as well as their salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs, and mixtures thereof. Compounds represented by Formula (I') or (I), as well as their pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions, may inhibit the activity of a kinase (e.g., a CDK) in a biological sample or subject. In some embodiments, the kinase is a cyclin-dependent kinase (CDK). In some embodiments, the CDK is CDK14. In some embodiments, the CDK is CDK15, CDK16, CDK17, or CDK18. In some embodiments, the compounds represented by Formula (I') and (I) are selective for CDK14 compared to other kinases. Described herein are methods of using the compounds of the present invention, as well as pharmaceutically acceptable salts, solvates, hydrates, polymorphs, cocrystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof, to study the inhibition of kinases (e.g., CDK14, CDK15, CDK16, CDK17, CDK18) or as therapeutics for the prevention and / or treatment of diseases associated with overexpression and / or aberrant (e.g., increased or unwanted) activity of kinases (e.g., CDK14, CDK15, CDK16, CDK17, CDK18). The compounds described herein may be useful for treating and / or preventing diseases or conditions, e.g., diseases (e.g., proliferative diseases (e.g., cancer), metabolic disorders (e.g., diabetes), autoimmune diseases, or neurological diseases (e.g., Alzheimer's disease, gliosis, spinal cord injury)) in a subject in need thereof. The compounds described herein may be useful in male contraception (e.g., by reducing or inhibiting spermatogenesis or reducing male fertility) in fertile, healthy male subjects. Also provided are uses, pharmaceutical compositions, and kits that include the compounds described herein.
[0005] In one aspect, the present disclosure provides a compound of formula (I'): [ka] and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, wherein R 1 , R 2 , R 3 ', R, n, L, X, and Y1 are as defined herein. 3 In some embodiments, R' is a warhead that binds covalently or non-covalently to a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18). In some embodiments, the warhead binds non-covalently to a CDK, e.g., CDK15, CDK16, CDK17, CDK18. In some embodiments, the warhead binds covalently to a CDK, e.g., CDK14. In some embodiments, R 3 ' is R 3 In some embodiments, the compound of formula (I') is represented by formula (I):
[0006] In one aspect, the present disclosure provides a compound of formula (I): [ka] and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, wherein R 1 , R 2 , R 3 , R, n, L, X, and Y1 are as defined herein. 3is a warhead that covalently or non-covalently binds to a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18). In some embodiments, the warhead non-covalently binds to a CDK, e.g., CDK15, CDK16, CDK17, CDK18. In some embodiments, the warhead covalently binds to a CDK, e.g., CDK14.
[0007] Exemplary compounds represented by formula (I) and (I') include, but are not limited to, the following: [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof.
[0008] In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound described herein and, optionally, a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition described herein comprises a therapeutically or prophylactically effective amount of a compound described herein. The pharmaceutical composition may be useful for treating and / or preventing a disease (e.g., a proliferative disease, a metabolic disorder, an autoimmune disease, or a neurological disease) in a subject in need thereof, or for inhibiting the activity of a protein kinase (e.g., CDK14, CDK15, CDK16, CDK17, CDK18) in a subject, biological sample, tissue, or cell. In some embodiments, the proliferative disease is cancer (e.g., lung cancer, breast cancer, liver cancer, pancreatic cancer, gastric cancer, ovarian cancer, colon cancer, colorectal cancer). In some embodiments, the cancer is carcinoma.
[0009] In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound described herein and, optionally, a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition described herein comprises a therapeutically or prophylactically effective amount of a compound described herein. The pharmaceutical composition may be useful for treating a disease (e.g., a proliferative disease, a metabolic disorder, an autoimmune disease, or a neurological disease) in a subject in need thereof, or for inhibiting the activity of a protein kinase (e.g., a CDK) in a subject, a biological sample, a tissue, or a cell. In some embodiments, the disease is a proliferative disease (e.g., a cancer (e.g., lung cancer, breast cancer, liver cancer, pancreatic cancer, gastric cancer, ovarian cancer, colon cancer, colorectal cancer)). In some embodiments, the cancer is cancer. In some embodiments, the disease is a metabolic disorder (e.g., diabetes). In some embodiments, the disease is an autoimmune disease (e.g., systemic lupus erythematosus, rheumatoid arthritis). In some embodiments, the disease is a neurological disease (e.g., Alzheimer's disease, gliosis, spinal cord injury).
[0010] In another aspect, described herein are methods of treating and / or preventing a disease (e.g., a proliferative disease, a metabolic disorder, an autoimmune disease, or a neurological disease). Exemplary proliferative diseases that may be treated include diseases associated with overexpression or increased activity of CDK, e.g., cancer. In some embodiments, the cancer is cancer. In some embodiments, the cancer is selected from the group consisting of lung cancer, breast cancer, liver cancer, pancreatic cancer, gastric cancer, ovarian cancer, colon cancer, and colorectal cancer. In some embodiments, the disease is a metabolic disorder (e.g., diabetes). In some embodiments, the disease is a neurological disease (e.g., Alzheimer's disease, gliosis, spinal cord injury).
[0011] Another aspect relates to a method of inhibiting the activity of a kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) in a biological sample (e.g., a cell, a tissue) using a compound described herein. In another aspect, described herein is a method of inhibiting the activity of a kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) in a subject using a compound described herein. In some embodiments, the method involves inhibition of CDK14.
[0012] Described herein are methods of administering an effective amount of a compound as described herein, or a pharmaceutical composition thereof, to a subject in need thereof. Also described are methods of contacting a cell with an effective amount of a compound as described herein, or a pharmaceutical composition thereof. In some embodiments, the methods described herein further include administering an additional pharmaceutical agent to the subject. In some embodiments, the methods described herein further include contacting the cell with an additional pharmaceutical agent (e.g., an antiproliferative agent). In some embodiments, the additional pharmaceutical agent is a kinase inhibitor (e.g., an inhibitor of a CDK).
[0013] In another aspect, the present disclosure provides compounds of formula (I') or (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof, for use in treating a disease (e.g., a proliferative disease, a metabolic disorder, an autoimmune disease, or a neurological disease) in a subject.
[0014] Another aspect of the present disclosure relates to a kit comprising a container together with a compound or pharmaceutical composition thereof as described herein. The kits described herein may contain a single dose or multiple doses of the compound or pharmaceutical composition. The kits may be useful in the methods of the present disclosure. In some embodiments, the kits further contain instructions for using the compound or pharmaceutical composition. The kits described herein may also contain information (e.g., prescribing information) from regulatory authorities such as the U.S. Food and Drug Administration (FDA), if necessary.
[0015] The details of one or more embodiments of the invention are set forth herein. Other features, objects, and advantages of the invention will be apparent from the detailed description, examples, drawings, and claims.
[0016] definition Definitions of specific functional groups and chemical terms are described in more detail below. Chemical elements are defined in accordance with the Handbook of Chemistry and Physics, 75 th The elements are identified in accordance with the CAS version of the Periodic Table of the Elements, inside cover Ed., and specific functional groups are generally defined as described therein. In addition, the general rules of organic chemistry, as well as specific functional moieties and reactivities, are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith and March, March's Advanced Organic Chemistry, 5 th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3 rdEdition, Cambridge University Press, Cambridge, 1987. The present disclosure is not intended to be limited in any way by the exemplary recitation of substituents presented herein.
[0017] The compounds described herein may contain one or more asymmetric centers, and therefore may exist in various isomeric forms, such as enantiomers and / or diastereomers.For example, the compounds described herein may be in the form of individual enantiomers, diastereomers, or geometric isomers, or may be in the form of a mixture of stereoisomers (including racemic mixtures and mixtures enriched with one or more stereoisomers).Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high-pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric synthesis. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725(1977); Eliel, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions p. 268 (EL Eliel, Ed., University of Notre Dame Press, Notre Dame, IN 1972). The present invention additionally encompasses the compounds described herein as individual isomers substantially free of other isomers, or alternatively, as mixtures of various isomers.
[0018] When a range of values is listed, it is intended to encompass each value and subrange within the range. For example, "C 1~6 ” is C1, C2, C3, C4, C5, C6, C 1~6 , C 1~5 , C 1~4, C 1~3 , C 1~2 , C 2~6 , C 2~5 , C 2~4 , C 2~3 , C 3~6 , C 3~5 , C 3~4 , C 4~6 , C 4~5 , and C 5~6 It is intended to cover alkyls of the formula:
[0019] "Hydrocarbon chain" refers to a substituted or unsubstituted divalent alkyl, alkenyl, or alkynyl group. The hydrocarbon chain includes at least one chain, each node of which includes at least one carbon atom between two radicals of the hydrocarbon chain ("carbon unit"). For example, the hydrocarbon chain -C A H(C B H2C C H3)- is a compound with only one carbon unit, C A The term "C x "Hydrocarbon chain" (where x is a positive integer) refers to a hydrocarbon chain that contains x carbon unit(s) between the two radicals of the hydrocarbon chain. If x is a feasible value greater than 1, the smallest feasible x is used in the definition of the hydrocarbon chain. For example, -CH(C2H5)- is a C1 hydrocarbon chain; [ka] is a C3 hydrocarbon chain. A wide range of values (e.g., C 1~6When the term "hydrocarbon chain" is used, the meaning of the range is as described herein. The hydrocarbon chain may be saturated (e.g., -(CH2)4-). The hydrocarbon chain may also be unsaturated and include one or more C=C and / or C-C bonds anywhere along the hydrocarbon chain. Illustratively, -CH=CH-(CH2)2-, -CH2-CC-CH2-, and -CC-CH=CH- are all examples of unsubstituted and unsaturated hydrocarbon chains. In some embodiments, the hydrocarbon chain is unsubstituted (e.g., -(CH2)4-). In some embodiments, the hydrocarbon chain is substituted (e.g., -CH(C2H5)- and -CF2-). Any two substituents on the hydrocarbon chain may be joined to form an optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl ring. Illustratively, [ka] [ka] are all examples of hydrocarbon chains. In contrast, in some embodiments, [ka] is not within the scope of the hydrocarbon chains described herein.
[0020] "Alkyl" refers to the radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 20 carbon atoms ("C 1~20 In some embodiments, it refers to the radical of a linear or branched saturated hydrocarbon group having from 1 to 10 carbon atoms ("C 1~10 In some embodiments, an alkyl group has 1 to 9 carbon atoms ("C 1~9 In some embodiments, the alkyl group has 1 to 8 carbon atoms ("C 1~8 In some embodiments, the alkyl group has 1 to 7 carbon atoms ("C1~7 In some embodiments, an alkyl group has 1 to 6 carbon atoms ("C 1~6 In some embodiments, an alkyl group has 1 to 5 carbon atoms ("C 1~5 In some embodiments, an alkyl group has 1 to 4 carbon atoms ("C 1~4 In some embodiments, an alkyl group has 1 to 3 carbon atoms ("C 1~3 In some embodiments, an alkyl group has 1 to 2 carbon atoms ("C 1~2 In some embodiments, the alkyl group has 1 carbon atom ("C alkyl"). In some embodiments, the alkyl group has 2 to 6 carbon atoms ("C 2~6 alkyl). C 1~6 Examples of alkyl groups include methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), and n-hexyl (C6). Additional examples of alkyl groups include n-heptyl (C7), n-octyl (C8), and the like. Unless otherwise specified, each instance of an alkyl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted alkyl") or substituted with one or more substituents ("substituted alkyl"). In certain embodiments, an alkyl group is an unsubstituted C 1~10 In some embodiments, the alkyl group is a substituted C 1~10 It is alkyl.
[0021] "Alkenyl" refers to the radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms and one or more carbon-carbon double bonds but no triple bonds ("C 2~20 In some embodiments, an alkenyl group has 2 to 10 carbon atoms ("C 2~10In some embodiments, an alkenyl group has 2 to 9 carbon atoms ("C 2~9 In some embodiments, an alkenyl group has 2 to 8 carbon atoms ("C 2~8 In some embodiments, an alkenyl group has 2 to 7 carbon atoms ("C 2~7 In some embodiments, an alkenyl group has 2 to 6 carbon atoms ("C 2~6 In some embodiments, an alkenyl group has 2 to 5 carbon atoms ("C 2~5 In some embodiments, an alkenyl group has 2 to 4 carbon atoms ("C 2~4 In some embodiments, the alkenyl group has 2 to 3 carbon atoms ("C 2~3 In some embodiments, the alkenyl group has two carbon atoms ("C2 alkenyl"). The one or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). C 2~4 Examples of alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like. 2~6 Examples of alkenyl groups include the aforementioned C 2~4 Alkenyl groups include pentenyl (C5), pentadienyl (C5), hexenyl (C6), and the like. Additional examples of alkenyl include heptenyl (C7), octenyl (C8), octatrienyl (C8), and the like. Unless otherwise specified, each instance of an alkenyl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted alkenyl") or substituted with one or more substituents ("substituted alkenyl"). In certain embodiments, an alkenyl group is an unsubstituted C 2~10 In some embodiments, the alkenyl group is a substituted C 2~10 It is alkenyl.
[0022] "Alkynyl" refers to the radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon-carbon triple bonds, and optionally, one or more double bonds ("C 2~20 In some embodiments, an alkynyl group has 2 to 10 carbon atoms ("C 2~10 In some embodiments, an alkynyl group has 2 to 9 carbon atoms ("C 2~9 In some embodiments, an alkynyl group has 2 to 8 carbon atoms ("C 2~8 In some embodiments, an alkynyl group has 2 to 7 carbon atoms ("C 2~7 In some embodiments, an alkynyl group has 2 to 6 carbon atoms ("C 2~6 In some embodiments, an alkynyl group has 2 to 5 carbon atoms ("C 2~5 In some embodiments, an alkynyl group has 2 to 4 carbon atoms ("C 2~4 In some embodiments, an alkynyl group has 2 to 3 carbon atoms ("C 2~3 In some embodiments, the alkynyl group has two carbon atoms ("C2 alkynyl"). The one or more carbon-carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl). C 2~4 Examples of alkynyl groups include, but are not limited to, ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), and the like. 2~6 Examples of alkenyl groups include the aforementioned C 2~4 Alkynyl groups include pentynyl (C5), hexynyl (C6), and the like. Additional examples of alkynyl include heptynyl (C7), octynyl (C8), and the like. Unless otherwise specified, each instance of an alkynyl group is independently optionally substituted, i.e., unsubstituted (an "unsubstituted alkynyl") or substituted with one or more substituents (a "substituted alkynyl"). In certain embodiments, an alkynyl group is an unsubstituted C 2~10In some embodiments, the alkynyl group is a substituted C 2~10 It is alkynyl.
[0023] "Carbocyclyl" or "carbocyclic" means a ring structure having from 3 to 10 ring carbon atoms ("C 3~10 refers to the radical of a non-aromatic cyclic hydrocarbon group having 3 to 8 ring carbon atoms ("C 3~8 In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms ("C 3~6 In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms ("C 3~6 In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms ("C 5~10 Carbocyclyl). 3~6 Carbocyclyl groups include, but are not limited to, cyclopropyl (C), cyclopropenyl (C), cyclobutyl (C), cyclobutenyl (C), cyclopentyl (C), cyclopentenyl (C), cyclohexyl (C), cyclohexenyl (C), cyclohexadienyl (C), and the like. Exemplary C 3~8 The carbocyclyl group may be any of the aforementioned C 3~6 Carbocyclyl groups include cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptanyl (C7), bicyclo[2.2.2]octanyl (C8), and the like. Exemplary C 3~10 The carbocyclyl group may be any of the aforementioned C 3~8 Carbocyclyl groups, as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C 10 ), cyclodecenyl (C 10 ), octahydro-1H-indenyl (C9), decahydronaphthalenyl (C 10 ), spiro[4.5]decanyl (C 10), and the like. As the above examples illustrate, in certain embodiments, a carbocyclyl group is either monocyclic ("monocyclic carbocyclyl") or contains a fused, bridged, or spiro ring system, such as a bicyclic ring system ("bicyclic carbocyclyl"), and can be saturated or partially unsaturated. "Carbocyclyl" also refers to a ring system in which a carbocyclic ring, as defined above, is fused with one or more aryl or heteroaryl groups, where the point of attachment is on the carbocyclic ring, and in such instances the number of carbon atoms is designated through the number of carbon atoms in the carbocyclic ring system. Unless otherwise specified, each instance of a carbocyclyl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted carbocyclyl") or substituted with one or more substituents ("substituted carbocyclyl"). In certain embodiments, a carbocyclyl group is an unsubstituted C 3~10 In some embodiments, the carbocyclyl group is a substituted C 3~10 It is a carbocyclyl.
[0024] In some embodiments, a "carbocyclyl" is a monocyclic saturated carbocyclyl group having from 3 to 10 ring carbon atoms ("C 3~10 In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms ("C 3~8 In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms ("C 3~6 In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms ("C 5~6 In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms ("C 5~10 Cycloalkyl). C 5~6 Examples of cycloalkyl groups include cyclopentyl (C5) and cyclohexyl (C5). 3~6 Examples of cycloalkyl groups are the aforementioned C 5~6 Cycloalkyl groups include cyclopropyl (C3) and cyclobutyl (C4). 3~8Examples of cycloalkyl groups are the aforementioned C 3~6 Cycloalkyl groups include cycloalkyl groups, as well as cycloheptyl (C7) and cyclooctyl (C8). Unless otherwise specified, each instance of a cycloalkyl group is independently unsubstituted ("unsubstituted cycloalkyl") or substituted with one or more substituents ("substituted cycloalkyl"). In certain embodiments, a cycloalkyl group is an unsubstituted C 3~10 In some embodiments, the cycloalkyl group is a substituted C 3~10 It is cycloalkyl.
[0025] "Heterocyclyl" or "heterocyclic" refers to the radical of a 3- to 10-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, where each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("3- to 10-membered heterocyclyl"). The point of attachment in a heterocyclyl group containing one or more nitrogen atoms can be a carbon atom or a nitrogen atom, where valence allows. A heterocyclyl group can be monocyclic ("monocyclic heterocyclyl") or a fused, bridged, or spiro ring system, such as a bicyclic ring system ("bicyclic heterocyclyl"), and can be saturated or partially unsaturated. A heterocyclyl bicyclic ring system can include one or more heteroatoms in one or both rings. "Heterocyclyl" also encompasses ring systems in which a heterocyclic ring is fused to one or more carbocyclyl groups, as defined above, where the point of attachment is on either the carbocyclyl ring or the heterocyclic ring, or to one or more aryl or heteroaryl groups, as defined above, where the point of attachment is on the heterocyclic ring; in such instances, the number of ring members is designated through the number of ring members in the heterocyclyl ring system. Unless otherwise specified, each instance of heterocyclyl is independently optionally substituted, i.e., unsubstituted ("unsubstituted heterocyclyl") or substituted with one or more substituents ("substituted heterocyclyl"). In certain embodiments, a heterocyclyl group is an unsubstituted 3- to 10-membered heterocyclyl. In certain embodiments, a heterocyclyl group is a substituted 3- to 10-membered heterocyclyl.
[0026] In some embodiments, heterocyclyl groups are 5-10 membered non-aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms, where each heteroatom is independently selected from the group consisting of nitrogen, oxygen, sulfur, boron, phosphorus, and silicon ("5-10 membered heterocyclyl"). In some embodiments, heterocyclyl groups are 5-8 membered non-aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms, where each heteroatom is independently selected from the group consisting of nitrogen, oxygen, and sulfur ("5-8 membered heterocyclyl"). In some embodiments, heterocyclyl groups are 5-6 membered non-aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms, where each heteroatom is independently selected from the group consisting of nitrogen, oxygen, and sulfur ("5-6 membered heterocyclyl"). In some embodiments, 5-6 membered heterocyclyls have 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5- to 6-membered heterocyclyl has 1 to 2 ring heteroatoms selected from nitrogen, oxygen, and sulfur, In some embodiments, the 5- to 6-membered heterocyclyl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.
[0027] Exemplary 3-membered heterocyclyl groups containing one heteroatom include, but are not limited to, aziridinyl, oxiranyl, and thiiranyl. Exemplary 4-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azetidinyl, oxetanyl, and thietanyl. Exemplary 5-membered heterocyclyl groups containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclyl groups containing three heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, triazinyl. Exemplary 7-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azepanyl, oxepanyl, and thiepanyl. Exemplary 8-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azocanyl, oxecanyl, and thiocanyl. Exemplary 5-membered heterocyclyl groups (also referred to herein as 5,6-bicyclic heterocyclic rings) fused to a C6 aryl ring include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, etc. Exemplary 6-membered heterocyclyl groups (also referred to herein as 6,6-bicyclic heterocyclic rings) fused to an aryl ring include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, etc.
[0028] "Aryl" refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 pi electrons shared among the cyclic array) having 6 to 14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system ("C 6~14 In some embodiments, an aryl group has 6 ring carbon atoms ("C aryl"; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms ("C 10 aryl"; e.g., naphthyl, such as 1-naphthyl and 2-naphthyl). In some embodiments, the aryl group has 14 ring carbon atoms ("C 14 "Aryl"; for example, anthracyl). "Aryl" also encompasses ring systems in which the aryl ring is fused with one or more carbocyclyl or heterocyclyl groups, as defined above, but where the radical or point of attachment is on the aryl ring. In such instances, the number of carbon atoms is designated through the number of carbon atoms in the aryl ring system. Unless otherwise specified, each instance of an aryl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted aryl") or substituted with one or more substituents ("substituted aryl"). In certain embodiments, an aryl group is an unsubstituted C 6~14 In some embodiments, the aryl group is a substituted C 6~14 It is aryl.
[0029] "Aralkyl" is a subset of alkyl and aryl and refers to an optionally substituted alkyl group substituted by an optionally substituted aryl group. In some embodiments, an aralkyl is an optionally substituted benzyl. In some embodiments, an aralkyl is benzyl. In some embodiments, an aralkyl is an optionally substituted phenethyl. In some embodiments, an aralkyl is phenethyl.
[0030] "Heteroaryl" refers to a radical of a 5-10-membered monocyclic or polycyclic (e.g., bicyclic, tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 pi electrons shared among the cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, where each heteroatom is independently selected from the group consisting of nitrogen, oxygen, and sulfur ("5-10-membered heteroaryl"). In heteroaryl groups containing one or more nitrogen atoms, the point of attachment can be a carbon atom or a nitrogen atom, valence permitting. Heteroaryl polycyclic ring systems can contain one or more heteroatoms in one or both rings. "Heteroaryl" encompasses ring systems in which a heteroaryl ring is fused with one or more carbocyclyl or heterocyclyl groups, as defined above, where the point of attachment is on the heteroaryl ring. In such instances, the number of ring members is designated through the number of ring members in the heteroaryl ring system. "Heteroaryl" also encompasses ring systems in which a heteroaryl ring is fused to one or more aryl groups, as defined above, but where the point of attachment is on either the aryl or heteroaryl ring. In such instances, the number of ring members is designated as the number of ring members in the fused polycyclic (aryl / heteroaryl) ring system. In bicyclic heteroaryl groups in which one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, etc.), the point of attachment can be on either ring, i.e., on either the ring with a heteroatom (e.g., 2-indolyl) or the ring without a heteroatom (e.g., 5-indolyl).
[0031] In some embodiments, heteroaryl groups are 5-10 membered aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, where each heteroatom is independently selected from the group consisting of nitrogen, oxygen, and sulfur ("5-10 membered heteroaryl"). In some embodiments, heteroaryl groups are 5-8 membered aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, where each heteroatom is independently selected from the group consisting of nitrogen, oxygen, and sulfur ("5-8 membered heteroaryl"). In some embodiments, heteroaryl groups are 5-6 membered aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, where each heteroatom is independently selected from the group consisting of nitrogen, oxygen, and sulfur ("5-6 membered heteroaryl"). In some embodiments, 5-6 membered heteroaryls have 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, a 5- to 6-membered heteroaryl has 1 to 2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, a 5- to 6-membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Unless otherwise specified, each instance of a heteroaryl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted heteroaryl") or substituted with one or more substituents ("substituted heteroaryl"). In some embodiments, a heteroaryl group is an unsubstituted 5- to 14-membered heteroaryl. In some embodiments, a heteroaryl group is a substituted 5- to 14-membered heteroaryl.
[0032] Exemplary 5-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyrrolyl, furanyl, and thiophenyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, but are not limited to, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, but are not limited to, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, but are not limited to, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, but are not limited to, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6-bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzisothiazolyl, benzothiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, but are not limited to, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.
[0033] "Heteroaralkyl" is a subset of alkyl and heteroaryl, and refers to an optionally substituted alkyl group substituted by an optionally substituted heteroaryl group.
[0034] "Partially unsaturated" refers to a group that includes at least one double or triple bond. "Partially unsaturated" ring systems are also intended to encompass rings with multiple sites of unsaturation, but are not intended to include aromatic groups (e.g., aryl or heteroaryl groups) as defined herein. Similarly, "saturated" refers to a group that contains no double or triple bonds, i.e., all single bonds.
[0035] When the alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups are divalent bridging groups, the suffix -ene is used and they are further referred to as, for example, alkylene, alkenylene, alkynylene, carbocyclylene, heterocyclylene, arylene, and heteroarylene.
[0036] The term "optionally substituted" refers to substituted or unsubstituted.
[0037] Alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups are optionally substituted (e.g., a "substituted" or "unsubstituted" alkyl group, a "substituted" or "unsubstituted" alkenyl group, a "substituted" or "unsubstituted" alkynyl group, a "substituted" or "unsubstituted" carbocyclyl group, a "substituted" or "unsubstituted" heterocyclyl group, a "substituted" or "unsubstituted" aryl group, or a "substituted" or "unsubstituted" heteroaryl group). In general, the term "substituted," whether preceded by the term "optionally," means that at least one hydrogen atom present on the group (e.g., a carbon atom or a nitrogen atom) is replaced with a permissible substituent (e.g., a substituent that results in a stable compound (e.g., a compound that does not undergo spontaneous transformation, such as by rearrangement, cyclization, elimination, or other reaction)). Unless otherwise specified, a "substituted" group has a substituent at one or more substitutable positions of the group; when substituted at more than one position in any given structure, the substituents are either the same or different at each position. The term "substituted" is intended to include substitution with all permissible substituents of organic compounds, any substituent described herein, that results in the formation of a stable compound. The present invention contemplates any and all such combinations in order to arrive at stable compounds. For purposes of this invention, heteroatoms such as nitrogen may have hydrogen substituents and / or any suitable substituents as described herein that satisfy the valence of the heteroatom and result in the formation of a stable moiety.
[0038] Exemplary carbon atom substituents include, but are not limited to, halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR aa , -ON(R bb )2, -N(R bb )2, -N(R bb )3 + X - , -N(OR cc )R bb , -SH, -SR aa , -SSR cc、-C(=O)R aa 、-CO2H、-CHO、-C(OR cc )2、-CO2R aa 、-OC(=O)R aa 、-OCO2R aa 、-C(=O)N(R bb )2、-OC(=O)N(R bb )2、-NR bb C(=O)R aa 、-NR bb CO2R aa 、-NR bb C(=O)N(R bb )2、-C(=NR bb )R aa 、-C(=NR bb )OR aa 、-OC(=NR bb )R aa 、-OC(=NR bb )OR aa 、-C(=NR bb )N(R bb )2、-OC(=NR bb )N(R bb )2、-NR bb C(=NR bb )N(R bb )2、-C(=O)NR bb SO2R aa 、-NR bb SO2R aa 、-SO2N(R bb )2、-SO2R aa 、-SO2OR aa 、-OSO2R aa 、-S(=O)R aa 、-OS(=O)R aa 、-Si(R aa )3、-OSi(R aa )3-C(=S)N(R bb )2、-C(=O)SR aa 、-C(=S)SR aa 、-SC(=S)SR aa 、-SC(=O)SR aa 、-OC(=O)SR aa 、-SC(=O)OR aa 、-SC(=O)R aa 、-P(=O)(R aa)2, -P(=O)(OR cc )2, -OP(=O)(R aa )2, -OP(=O)(OR cc )2, -P(=O)(N(R bb )2)2, -OP(=O)(N(R bb )2)2, -NR bb P(=O)(R aa )2, -NR bb P(=O)(OR cc )2, -NR bb P(=O)(N(R bb )2)2, -P(R cc )2, -P(OR cc )2, -P(R cc )3 + X - , -P(OR cc )3 + X - , -P(R cc )4, -P(OR cc )4, -OP(R cc )2, -OP(R cc )3 + X - , -OP(OR cc )2, -OP(OR cc )3 + X - , -OP(R cc )4, -OP(OR cc )4, -B(R aa )2, -B(OR cc )2, -BR aa (OR cc ), C 1~10 Alkyl, C 1~10 Perhaloalkyl, C 2~10 Alkenyl, C 2~10 Alkynyl, Hetero C 1~10 Alkyl, Hetero C 2~10 Alkenyl, Hetero C 2~10 Alkynyl, C 3~10 Carbocyclyl, 3- to 14-membered heterocyclyl, C 6~14aryl, and 5- to 14-membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd substituted with a group; where X - is the counterion; Alternatively, two geminal hydrogens on a carbon atom can be bonded to a group =O, =S, or =NN(R bb )2, =NNR bb C(=O)R aa , =NNR bb C(=O)OR aa , =NNR bb S(=O)2R aa , =NR bb , or =NOR cc has been replaced by; R aa Independently, for each case, C 1~10 Alkyl, C 1~10 Perhaloalkyl, C 2~10 Alkenyl, C 2~10 Alkynyl, Hetero C 1~10 Alkyl, Hetero C 2~10 Alkenyl, Hetero C 2~10 Alkynyl, C 3~10 Carbocyclyl, 3-14 membered heterocyclyl, C 6~14 aryl, and 5- to 14-membered heteroaryl, or two R aa groups are joined to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered heteroaryl ring, where each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd substituted with a group; R bb In each case, independently, hydrogen, -OH, -OR aa , -N(R cc )2, -CN, -C(=O)R aa , -C(=O)N(R cc)2, -CO2R aa , -SO2R aa , -C(=NR cc ) OR aa , -C(=NR cc )N(R cc )2, -SO2N(R cc )2, -SO2R cc , -SO2OR cc , -SOR aa , -C(=S)N(R cc )2, -C(=O)SR cc , -C(=S)SR cc , -P(=O)(R aa )2, -P(=O)(OR cc )2, -P(=O)(N(R cc )2)2, C 1~10 Alkyl, C 1~10 Perhaloalkyl, C 2~10 Alkenyl, C 2~10 Alkynyl, Hetero C 1~10 Alkyl, Hetero C 2~10 Alkenyl, Hetero C 2~10 Alkynyl, C 3~10 Carbocyclyl, 3- to 14-membered heterocyclyl, C 6~14 aryl, and 5- to 14-membered heteroaryl, or two R bb groups are joined to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered heteroaryl ring, where each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd substituted with a group; where X - is the counterion; R cc In each case, independently, hydrogen, C 1~10 Alkyl, C 1~10 Perhaloalkyl, C 2~10 Alkenyl, C 2~10 Alkynyl, Hetero C 1~10 Alkyl, Hetero C 2~10 Alkenyl, Hetero C 2~10 Alkynyl, C 3~10Carbocyclyl, 3- to 14-membered heterocyclyl, C 6~14 aryl, and 5- to 14-membered heteroaryl, or two R cc groups are joined to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered heteroaryl ring, where each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd substituted with a group; R dd In each case, independently, halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR ee , -ON(R ff )2, -N(R ff )2, -N(R ff )3 + X - , -N(OR ee )R ff , -SH, -SR ee , -SSR ee , -C(=O)R ee , -CO2H, -CO2R ee , -OC(=O)R ee , -OCO2R ee , -C(=O)N(R ff )2, -OC(=O)N(R ff )2, -NR ff C(=O)R ee , -NR ff CO2R ee , -NR ff C(=O)N(R ff )2, -C(=NR ff ) OR ee , -OC(=NR ff )R ee , -OC(=NR ff ) OR ee , -C(=NR ff )N(R ff )2, -OC(=NR ff )N(R ff )2, -NR ff C(=NR ff )N(R ff)2, -NR ff SO2R ee , -SO2N(R ff )2, -SO2R ee , -SO2OR ee , -OSO2R ee , -S(=O)R ee , -Si(R ee )3, -OSi(R ee )3, -C(=S)N(R ff )2, -C(=O)SR ee , -C(=S)SR ee , -SC(=S)SR ee , -P(=O)(OR ee )2, -P(=O)(R ee )2, -OP(=O)(R ee )2, -OP(=O)(OR ee )2, C 1~6 Alkyl, C 1~6 Perhaloalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, Hetero C 1~6 Alkyl, Hetero C 2~6 Alkenyl, Hetero C 2~6 Alkynyl, C 3~10 Carbocyclyl, 3-10 membered heterocyclyl, C 6~10 aryl, and 5- to 10-membered heteroaryl, where each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R gg substituted with a group or two geminal R dd The substituents may be joined to form =O or =S; where X - is the counterion; R ee Independently, for each case, C 1~6 Alkyl, C 1~6 Perhaloalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, Hetero C 1~6 Alkyl, Hetero C 2~6 Alkenyl, Hetero C 2~6 Alkynyl, C3~10 Carbocyclyl, C 6~10 aryl, 3- to 10-membered heterocyclyl, and 3- to 10-membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently selected from 0, 1, 2, 3, 4, or 5 R gg substituted with a group; R ff In each case, independently, hydrogen, C 1~6 Alkyl, C 1~6 Perhaloalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, Hetero C 1~6 Alkyl, Hetero C 2~6 Alkenyl, Hetero C 2~6 Alkynyl, C 3~10 Carbocyclyl, 3-10 membered heterocyclyl, C 6~10 aryl, and 5- to 10-membered heteroaryl, or two R ff groups are joined to form a 3- to 10-membered heterocyclyl ring or a 5- to 10-membered heteroaryl ring, where each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R gg substituted with a group; and R gg In each case, independently, halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC 1~6 Alkyl, -ON(C 1~6 alkyl)2, -N(C 1~6 alkyl)2, -N(C 1~6 Alkyl)3 + X - , -NH(C 1~6 alkyl)2 + X - , -NH2(C 1~6 alkyl) + X - , -NH3 + X -, -N(OC 1~6 Alkyl)(C 1~6 alkyl), -N(OH)(C 1~6 alkyl), -NH(OH), -SH, -SC 1~6 Alkyl, -SS(C 1~6 alkyl), -C(=O)(C 1~6 alkyl), -CO2H, -CO2(C 1~6 alkyl), -OC(=O)(C 1~6 alkyl), -OCO2(C 1~6 alkyl), -C(=O)NH2, -C(=O)N(C 1~6 alkyl)2, -OC(=O)NH(C 1~6 alkyl), -NHC(=O)(C 1~6 alkyl), -N(C 1~6 alkyl)C(=O)(C 1~6 alkyl), -NHCO2(C 1~6 alkyl), -NHC(=O)N(C 1~6 alkyl)2, -NHC(=O)NH(C 1~6 alkyl), -NHC(=O)NH2, -C(=NH)O(C 1~6 alkyl), -OC(=NH)(C 1~6 alkyl), -OC(=NH)OC 1~6 Alkyl, -C(=NH)N(C 1~6 alkyl)2, -C(=NH)NH(C 1~6 alkyl), -C(=NH)NH2, -OC(=NH)N(C 1~6 alkyl)2, -OC(NH)NH(C 1~6 alkyl), -OC(NH)NH2, -NHC(NH)N(C 1~6 alkyl)2, -NHC(=NH)NH2, -NHSO2(C 1~6 alkyl), -SO2N(C 1~6 alkyl)2, -SO2NH(C 1~6 alkyl), -SO2NH2, -SO2C 1~6 Alkyl, -SO2OC 1~6 Alkyl, -OSO2C 1~6 Alkyl, -SOC 1~6 Alkyl, -Si(C 1~6 alkyl)3, -OSi(C 1~6alkyl)3-C(=S)N(C 1~6 alkyl)2, C(=S)NH(C 1~6 alkyl), C(=S)NH2, -C(=O)S(C 1~6 alkyl), -C(=S)SC 1~6 Alkyl, -SC(=S)SC 1~6 Alkyl, -P(=O)(OC 1~6 alkyl)2, -P(=O)(C 1~6 alkyl)2, -OP(=O)(C 1~6 alkyl)2, -OP(=O)(OC 1~6 Alkyl)2, C 1~6 Alkyl, C 1~6 Perhaloalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, Hetero C 1~6 Alkyl, Hetero C 2~6 Alkenyl, Hetero C 2~6 Alkynyl, C 3~10 Carbocyclyl, C 6~10 aryl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl; or two geminal R gg The substituents may be joined to form =O or =S; where X - is the counter ion.
[0039] A "counterion" or "anionic counterion" is a negatively charged group associated with a positively charged group to maintain electronic neutrality. Anionic counterions can be monovalent (i.e., contain one formal negative charge). Anionic counterions can also be multivalent, such as divalent or trivalent (i.e., contain more than one formal negative charge). Exemplary counterions are halide ions (e.g., F - , Cl - , Br - , I - ), NO3 - , ClO4 - , O.H. - , H2PO4 - , HCO3 - , HSO4 -, sulfonate ions (e.g., methanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, 10-camphorsulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1-sulfonic acid-5-sulfonic acid, ethane-1-sulfonic acid-2-sulfonic acid, etc.), carboxylate ions (e.g., acetic acid, propanoic acid, benzoic acid, glyceric acid, lactic acid, tartaric acid, glycolic acid, glyconic acid, etc.), BF4 - , PF4 - , PF6 - , AsF6 - , SbF6 - , B[3,5-(CF3)2C6H3]4] - , B(C6F5)4 - , BPh4 - , Al(OC(CF3)3)4 - , and carborane anions (e.g., CB 11 H 12 - or (HCB 11 Me5Br6) - Exemplary counterions, which may be multivalent, include CO3 2- , HPO4 2- , PO4 3- , B4O7 2- , SO4 2- , S2O3 2- , carboxylate anions (e.g., tartaric acid, citric acid, fumaric acid, maleic acid, malic acid, malonic acid, glyconic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, salicylic acid, phthalic acid, aspartic acid, glutamic acid, etc.), and carboranes.
[0040] "Halo" or "halogen" refers to fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br), or iodine (iodo, -I).
[0041] The term "acyl" refers to a group having the general formula -C(=O)R X1 , -C(=O)OR X1 , -C(=O)-OC(=O)R X1 , -C(=O)SR X1, -C(=O)N(R X1 )2, -C(=S)R X1 , -C(=S)N(R X1 )2, and -C(=S)S(R X1 ), -C(=NR X1 )R X1 , -C(=NR X1 ) OR X1 , -C(=NR X1 )SR X1 , and -C(=NR X1 )N(R X1 )2, where R X1 is hydrogen; halogen; substituted or unsubstituted hydroxyl; substituted or unsubstituted thiol; substituted or unsubstituted amino; substituted or unsubstituted acyl, cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched alkyl; cyclic or acyclic, substituted or unsubstituted, branched or unbranched alkenyl; substituted or unsubstituted alkynyl; substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aliphaticoxy, heteroaliphaticoxy, alkyloxy, heteroalkyloxy, aryloxy, heteroaryloxy, aliphaticthioxy, heteroaliphaticthioxy, alkylthioxy, heteroalkylthioxy, arylthioxy, heteroarylthioxy, mono- or di-aliphaticamino, mono- or di-heteroaliphaticamino, mono- or di-alkylamino, mono- or di-heteroalkylamino, mono- or di-arylamino, or mono- or di-heteroarylamino; or two R X1The groups taken together form a 5- to 6-membered heterocyclic ring. Exemplary acyl groups include aldehydes (-CHO), carboxylic acids (-COH), ketones, acyl halides, esters, amides, imines, carbonates, carbamates, and ureas. Acyl substituents include, but are not limited to, any of the substituents described herein that result in the formation of a stable moiety (e.g., aliphatic, alkyl, alkenyl, alkynyl, heteroaliphatic, heterocyclic, aryl, heteroaryl, acyl, oxo, imino, thioxo, cyano, isocyano, amino, azido, nitro, hydroxyl, thiol, halo, aliphatic amino, heteroaliphatic amino, alkylamino, heteroalkylamino, arylamino, heteroarylamino, alkylaryl, arylalkyl, aliphaticoxy, heteroaliphaticoxy, alkyloxy, heteroalkyloxy, aryloxy, heteroaryloxy, aliphaticthioxy, heteroaliphaticthioxy, alkylthioxy, heteroalkylthioxy, arylthioxy, heteroarylthioxy, acyloxy, etc., each of which may be further substituted or unsubstituted).
[0042] "Alkoxy" or "alkoxyl" refers to a radical of the formula: --O-alkyl.
[0043] Nitrogen atoms may be substituted or unsubstituted, where valence allows, and include primary, secondary, tertiary, and quaternary nitrogen atoms. Exemplary nitrogen atom substituents include, but are not limited to, hydrogen, -OH, -OR aa , -N(R cc ) 2 , -CN, -C(=O)R aa , -C(=O)N(R cc )2, -CO2R aa , -SO2R aa , -C(=NR bb )R aa , -C(=NR cc ) OR aa , -C(=NR cc )N(R cc )2, -SO2N(R cc)2, -SO2R cc , -SO2OR cc , -SOR aa , -C(=S)N(R cc )2, -C(=O)SR cc , -C(=S)SR cc , -P(=O)(OR cc ) 2. -P(=O)(R aa )2, -P(=O)(N(R cc ) 2 ) 2. C 1~10 Alkyl, C 1~10 Perhaloalkyl, C 2~10 Alkenyl, C 2~10 Alkynyl, Hetero C 1~10 Alkyl, Hetero C 2~10 Alkenyl, Hetero C 2~10 Alkynyl, C 3~10 Carbocyclyl, 3- to 14-membered heterocyclyl, C 6~14 aryl, and 5- to 14-membered heteroaryl, or two R attached to the N atom cc The groups are linked to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered heteroaryl ring, where each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd substituted with a group, where R aa , R bb , R cc , and R dd is as defined above.
[0044] In certain embodiments, the substituent present on the nitrogen atom is a nitrogen protecting group (also referred to as an amino protecting group). Nitrogen protecting groups include, but are not limited to, -OH, -OR aa , -N(R cc )2, -C(=O)R aa , -C(=O)N(R cc )2, -CO2R aa , -SO2R aa, -C(=NR cc )R aa , -C(=NR cc ) OR aa , -C(=NR cc )N(R cc )2, -SO2N(R cc )2, -SO2R cc , -SO2OR cc , -SOR aa , -C(=S)N(R cc )2, -C(=O)SR cc , -C(=S)SR cc , C 1~10 Alkyl (e.g., aralkyl, heteroaralkyl), C 2~10 Alkenyl, C 2~10 Alkynyl, C 3~10 Carbocyclyl, 3- to 14-membered heterocyclyl, C 6~14 and 5- to 14-membered heteroaryl groups, where each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aralkyl, aryl, and heteroaryl independently contains 0, 1, 2, 3, 4, or 5 R dd substituted with a group, where R aa , R bb , R cc , and R dd is as defined herein. Nitrogen protecting groups are well known in the art and are described in Protecting Groups in Organic Synthesis, TW Greene and PGM Wuts, 3 rd edition, John Wiley & Sons, 1999, which is incorporated herein by reference.
[0045] For example, a nitrogen protecting group such as an amide group (e.g., —C(═O)R aa) include, but are not limited to, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl derivatives, benzamide, p-phenylbenzamide, o-nitrophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (N'-dithiobenzyloxyacylamino)acetamide, 3-(p-hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitrocinnamic acid amide, N-acetylmethionine derivatives, o-nitrobenzamide, and o-(benzoyloxymethyl)benzamide.
[0046] Nitrogen protecting groups such as carbamate groups (e.g., -C(=O)OR aa) include, but are not limited to, methyl carbamate, ethyl carbamate, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluorenylmethyl carbamate, 2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), ...Tmoc), 2-trichloroethyl carbamate (Tmoc), 2-trichloroethyl carbamate (Tmoc), 2-trichloroethyl carbamate (Tmoc), 2-trichloroethyl carbamate (Tmoc), 2-trichloroethyl carbamate (Tmoc), 2-trichloroethyl carbamate (Tmoc), 2-trichloroethyl carbamate (Tmoc), 2-trichloroethyl carbamate (Tmoc), 2-trichloroethyl carbamate (Tmoc), 2-trichloroethyl carbamate (Tm Methylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1-methylethyl carbamate (Adpoc), 1,1-dimethyl-2-haloethyl carbamate, 1,1-dimethyl-2,2-dibromoethyl carbamate (DB-t-BOC), 1,1-dimethyl-2,2,2-trichloroethyl carbamate (TCBOC), 1-methyl-1-(4-biphenylyl)ethyl carbamate (Bpoc), 1-(3,5-di-t-butylphenyl)-1-methylethyl carbamate (t -Bumeoc), 2-(2'- and 4'-pyridyl)ethyl carbamate (Pyoc), 2-(N,N-dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate (BOC), 1-adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropyl allyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkyldithiocarbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz), p-nitrilebenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, [2-(1,3-dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenylcarbamate (Mtpc), 2,4-dimethylthiophenylcarbamate (Bmpc), 2-phosphonioethyl carbamate (Peoc), 2-triphenylphosphonioisopropylcarbamate (Ppoc), 1,1-dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl carbamate, 5-benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6-chloro Monylmethyl carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitrobenzyl carbamate, phenyl(o-nitrophenyl)methyl carbamate, t-amyl carbamate, S-benzylthiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl carbamate, p-decyloxybenzyl carbamate, 2, 2-Dimethoxyacyl vinyl carbamate, o-(N,N-dimethylcarboxamido)benzyl carbamate, 1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl carbamate, 1,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, isobornyl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(p'-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate, 1 -methylcyclohexyl carbamate, 1-methyl-1-cyclopropylmethyl carbamate, 1-methyl-1-(3,5-dimethoxyphenyl)ethyl carbamate, 1-methyl-1-(p-phenylazophenyl)ethyl carbamate, 1-methyl-1-phenylethyl carbamate, 1-methyl-1-(4-pyridyl)ethyl carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate, and 2,4,6-trimethylbenzylcarbamate.
[0047] Nitrogen protecting groups such as sulfonamide groups (e.g., -S(=O)R aa ) include, but are not limited to, p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide amide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), β-trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4-(4',8'-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide.
[0048] Other nitrogen protecting groups include, but are not limited to, phenothiazinyl-(10)-acyl derivatives, N'-p-toluenesulfonylaminoacyl derivatives, N'-phenylaminothioacyl derivatives, N-benzoylphenylalanyl derivatives, N-acetylmethionine derivatives, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N-1,1,4,4-tetramethyl Disilylazacyclopentane adducts (STABASE), 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-ones, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-ones, 1-substituted 3,5-dinitro-4-pyridones, N-methylamine, N-allylamine, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(1-isopropyl-4-nitro-2-oxo-3-pyrroline-3)-ones, -yl)amine, quaternary ammonium salt, N-benzylamine, N-di(4-methoxyphenyl)methylamine, N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr), N-[(4-methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenylamine (PhF), N-2,7-dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fcm), N-2-picolylamino N'-oxide, N-1,1-dimethyl Thiomethyleneamine, N-benzylideneamine, Np-methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine, N-(N',N'-dimethylaminomethylene)amine, N,N'-isopropylidenediamine, Np-nitrobenzylideneamine, N-salicylideneamine, N-5-chlorosalicylideneamine, N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N-cyclohexylideneamine, N-(5,5-dimethyl-3-oxo-1-cyclohexenyl)amine, N-borane derivatives, N-diphenylboronic acid derivatives, N-[phenyl(pentaacylchromium or tungsten)acyl]amine, N-copper chelate, N-zinc chelate, N-nitroamine, N-nitrosamine, amine N-oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidate, dibenzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamide, o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide, and 3-nitropyridine sulfenamide (Npys).
[0049] In certain embodiments, the substituent present on the oxygen atom is an oxygen protecting group (also referred to herein as a "hydroxyl protecting group"). Oxygen protecting groups include, but are not limited to, -R aa , -N(R bb )2, -C(=O)SR aa , -C(=O)R aa , -CO2R aa , -C(=O)N(R bb )2, -C(=NR bb )R aa , -C(=NR bb ) OR aa , -C(=NR bb )N(R bb )2, -S(=O)R aa , -SO2R aa , -Si(R aa )3, -P(R cc )2, -P(R cc )3 + X - , -P(OR cc )2, -P(OR cc )3 + X - , -P(=O)(R aa )2, -P(=O)(OR cc )2, and -P(=O)(N(Rbb )2)2, where R aa , R bb , and R cc is as defined herein. Oxygen protecting groups are well known in the art and are described in Protecting Groups in Organic Synthesis, TW Greene and PGM Wut, 3 rd edition, John Wiley & Son, 1999, which is incorporated herein by reference.
[0050] Exemplary oxygen protecting groups include, but are not limited to, methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), t-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2-methoxyethoxymethyl, and the like. methyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl S,S-dioxide, 1-[(2-chloro-4-methyl)phenyl] [Chemical]-4-methoxypiperidin-4-yl (CTMP), 1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-trichloro ethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl, t-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl (Bn), p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl N-oxide, diphenylmethyl, p,p'-Dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, α-naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4'-bromophenacyloxyphenyl)diphenylmethyl, 4,4',4''-tris(4,5-dichlorophthalimidophenyl)methyl, 4,4',4''-tris(levulinoyloxyphenyl)methyl, 4,4',4''-tris(benzoyloxyphenyl)methyl Bis(4',4''-diphenyl)methyl, 3-(imidazol-1-yl)bis(4',4''-dimethoxyphenyl)methyl, 1,1-bis(4-methoxyphenyl)-1'-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, 1,3-benzodisulfuran-2-yl, benzisothiazolyl S,S-dioxide, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (I PDMS), diethylisopropylsilyl (DEIPS), dimethylhexylsilyl, t-butyldimethylsilyl (TBDMS), t-butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), t-butylmethoxyphenylsilyl (TBMPS), formic acid, benzoyl formate, acetic acid, chloroacetic acid, dichloroacetic acid, trichloroacetic acid, trifluoroacetic acid, methoxyacetic acid, triphenylmethoxyacetic acid, phenoxyacetic acid, p-Chlorophenoxyacetic acid, 3-phenylpropionic acid, 4-oxopentanoate (levuriate), 4,4-(ethylenedithio)pentanoate (levurinoyl dithioacetal), pivalic acid, adamantoate, crotonic acid, 4-methoxycrotonic acid, benzoic acid, p-phenylbenzoic acid, 2,4,6-trimethylbenzoic acid (mesitoic acid), alkyl methyl carbonate, 9-fluorenylmethyl carbonate (Fmoc), alkyl ethyl carbonate, alkyl 2,2,2-Trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl)ethyl carbonate (Psec), 2-(triphenylphosphonio)ethyl carbonate (Peoc), alkyl isobutyl carbonate, alkyl vinyl carbonate, alkyl allyl carbonate, alkyl p-nitrophenyl carbonate, alkyl benzyl carbonate, alkyl p-methoxybenzyl carbonate, alkyl 3,4-dimethoxybenzyl carbonate, alkyl o-nitrobenzyl carbonate, alkyl p-nitrobenzyl carbonate, alkyl S-benzyl thiocarbonate, 4-ethoxy-1-naphthyl carbonate, methyl dithiocarbonate, 2-iodobenzoic acid, 4-azidobutyrate, 4-nitro-4-methylpentanoate, o-(di bromomethyl)benzoic acid, 2-formylbenzenesulfonic acid, 2-(methylthiomethoxy)ethyl, 4-(methylthiomethoxy)butyric acid, 2-(methylthiomethoxymethyl)benzoic acid, 2,6-dichloro-4-methylphenoxyacetic acid, 2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetic acid, 2,4-bis(1,1-dimethylpropyl)phenoxyacetic acid, chlorodiphenylacetic acid, isobutyric acid, monosuccinic acid, (E)-2-methyl-2-butenoic acid, o-(methoxyacyl)benzoic acid, α-naphthoate, nitric acid, alkyl N,N,N',N'-tetramethylphosphorodiamidate, alkyl N-phenylcarbamate, boric acid, dimethylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate, sulfuric acid, methanesulfonic acid (mesylate), benzylsulfonic acid, and tosylic acid (Ts).
[0051] In certain embodiments, the substituent present on the sulfur atom is a sulfur protecting group (also referred to as a "thiol protecting group"). Sulfur protecting groups include, but are not limited to, -R aa , -N(R bb )2, -C(=O)SR aa , -C(=O)R aa , -CO2R aa , -C(=O)N(R bb )2, -C(=NR bb )Raa , -C(=NR bb ) OR aa , -C(=NR bb )N(R bb )2, -S(=O)R aa , -SO2R aa , -Si(R aa )3, -P(R cc )2, -P(R cc )3 + X - , -P(OR cc )2, -P(OR cc )3 + X - , -P(=O)(R aa )2, -P(=O)(OR cc )2, and -P(=O)(N(R bb )2)2, where R aa , R bb , and R cc is as defined herein. Sulfur protecting groups are well known in the art and are described in Protecting Groups in Organic Synthesis, TW Greene and PGM Wut, 3 rd edition, John Wiley & Son, 1999, which is incorporated herein by reference.
[0052] As used herein, "leaving group" (LG) is an art-recognized term that refers to a molecular fragment that leaves with an electron pair in heterolytic bond cleavage, where the molecular fragment is an anionic or neutral molecule. As used herein, a leaving group can be an atom or group that can be displaced by a nucleophile. See, e.g., Smith, March, Advanced Organic Chemistry 6th ed. (501-502). Exemplary leaving groups include, but are not limited to, halo (e.g., chloro, bromo, iodo) and activated substituted hydroxyl groups (e.g., -OC(=O)SR). aa, -OC(=O)R aa , -OCO2R aa , -OC(=O)N(R bb )2, -OC(=NR bb )R aa , -OC(=NR bb ) OR aa , -OC(=NR bb )N(R bb )2, -OS(=O)R aa , -OSO2R aa , -OP(R cc )2, -OP(R cc )3, -OP(=O)2R aa , -OP(=O)(R aa )2, -OP(=O)(OR cc )2, -OP(=O)2N(R bb )2, and -OP(=O)(NR bb )2, where R aa , R bb , and R ccis as defined herein). Examples of suitable leaving groups include, but are not limited to, halogen (such as F, Cl, Br, or I (iodine)), alkoxycarbonyloxy, aryloxycarbonyloxy, alkanesulfonyloxy, arenesulfonyloxy, alkyl-carbonyloxy (e.g., acetoxy), arylcarbonyloxy, aryloxy, methoxy, N,O-dimethylhydroxylamino, pixyl, and haloformates. In some cases, the leaving group is a sulfonate ester such as toluenesulfonate (tosylate, -OTs), methanesulfonate (mesylate, -OMs), p-bromobenzenesulfonyloxy (brosylate, -OBs), or trifluoromethanesulfonate (triflate, -OTf). In some cases, the leaving group is a brosylate such as p-bromobenzenesulfonyloxy. In some cases, the leaving group is a nosylate such as 2-nitrobenzenesulfonyloxy. In some embodiments, the leaving group is a sulfonate-containing group. In some embodiments, the leaving group is a tosylate group. The leaving group may also be a phosphine oxide (e.g., formed during the Mitsunobu reaction) or an internal leaving group such as an epoxide or cyclic sulfate. Other non-limiting examples of leaving groups are water, amines, ammonia, alcohols, ether moieties, sulfur-containing moieties, thioether moieties, zinc halides, magnesium moieties, diazonium salts, and copper moieties.
[0053] The term "pharmaceutically acceptable salt" refers to a salt that is suitable, within the bounds of sound medical wisdom, for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, etc., commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19 (incorporated herein by reference). Pharmaceutically acceptable salts of the compounds of the present invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts of amino groups formed with inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid), or with organic acids (such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid), or by using other methods known in the art (such as ion exchange). Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, and 2-hydroxy-ethanesulfonate. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium, and N-methyl-N ... + (C 1~4 Alkyl)4 -Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc. Further pharmaceutically acceptable salts include, where appropriate, non-toxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkylsulfonates, and arylsulfonates.
[0054] The term "solvate" refers to a form of a compound associated with a solvent, usually via a solvolysis reaction. This physical association may involve hydrogen bonding. Conventional solvents include water, methanol, ethanol, acetic acid, DMSO, THF, diethyl ether, and the like. The compound of formula (I') or (I) may be prepared, for example, in crystalline form, and may be solvated. Suitable solvates include pharmaceutically acceptable solvates, and further include both stoichiometric and non-stoichiometric solvates. In some instances, the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. "Solvate" encompasses both solution-phase and isolatable solvates. Representative solvates include hydrates, ethanolates, and methanolates.
[0055] The term "hydrate" refers to a compound associated with water. Typically, the number of water molecules contained in a hydrate of a compound is a fixed ratio to the number of compound molecules in the hydrate. Thus, a hydrate of a compound may be represented, for example, by the general formula R·xH2O (where R is the compound and x is a number greater than 0). A given compound may form more than one type of hydrate, including, for example, a monohydrate (x is 1), a lower hydrate (x is a number greater than 0 and less than 1, for example, a hemihydrate (R·0.5H2O)), and a polyhydrate (x is a number greater than 1, for example, a dihydrate (R·2H2O) and a hexahydrate (R·6H2O)).
[0056] The term "tautomer" refers to compounds that are interchangeable forms of a particular compound structure and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the shifting of π electrons and atoms (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the aci- and nitro-forms of phenylnitromethane, which are also formed by treatment with acid or base.
[0057] Tautomeric forms may also be relevant in obtaining optimal chemical reactivity and biological activity of a compound of interest.
[0058] It will also be understood that compounds that have the same molecular formula but that differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed "isomers." Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers."
[0059] Stereoisomers that are not mirror images of one another are called "diastereomers," and those that are non-superimposable mirror images of each other are called "enantiomers." When a compound has an asymmetric center (e.g., it is bonded to four different groups), a pair of enantiomers is possible. Enantiomers can be characterized by the absolute configuration of their asymmetric center and are described by the R- and S-sequencing rules of Cahn and Prelog or by the way the molecule rotates the plane of polarized light, and are designated as dextrorotatory or levorotatory (i.e., as (+) or (-) isomers, respectively). Chiral compounds can exist as either individual enantiomers or mixtures thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture."
[0060] The term "polymorph" refers to a crystalline form of a compound (or its salts, hydrates, or solvates) in a specific crystal packing arrangement. All polymorphs have the same elemental composition. Different crystalline forms usually have different X-ray diffraction patterns, infrared spectra, melting points, densities, hardness, crystal shape, optical and electrical properties, stability, and solubility. Recrystallization solvents, crystallization rate, storage temperature, and other factors can cause one crystalline form to predominate. Various polymorphs of a compound can be prepared by crystallization under different conditions.
[0061] The term "prodrug" refers to a compound having a cleavable group that becomes a compound of formula (I') or (I) by solvolysis or under physiological conditions (including derivatives of compounds of formula (I') or (I)), which is pharmaceutically active in vivo. Examples include, but are not limited to, choline ester derivatives. Other derivatives of the compounds of the present invention are active in both their acid and acid derivative forms, but the acid-labile form often offers advantages of solubility, tissue compatibility, or delayed release to mammalian organisms (see Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives well known to those skilled in the art, such as esters prepared by reacting a parent acid with a suitable alcohol, or amides prepared by reacting a parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides, and anhydrides derived from acidic groups pendant on the compounds of the present invention are particular prodrugs. In some cases, it is desirable to prepare double ester prodrugs, such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkyl esters. The C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, C7-C8 alkyl esters of the compounds of formula (I') or (I) are also suitable. 12 Substituted aryl and C7-C 12Aryl alkyl esters are sometimes preferred.
[0062] "Subjects" to which administration is contemplated include, but are not limited to, humans (i.e., male or female of any age group, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or elderly adults)) and / or non-human animals, e.g., mammals (e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys); commercially relevant mammals such as cows, pigs, horses, sheep, goats, cats, and / or dogs) and birds (e.g., commercially relevant birds such as chickens, ducks, geese, and / or turkeys). In some embodiments, the animal is a mammal. The animal may be male or female and at any stage of development. The non-human animal may be a transgenic animal.
[0063] The terms "administer," "administering," or "administration" refer to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing a compound of the invention or a pharmaceutical composition thereof.
[0064] The terms "treatment," "treat," and "treating" refer to halting, alleviating, delaying the onset of, or inhibiting the progression of a "condition" as described herein (e.g., a disease, disorder, or condition, or one or more signs or symptoms thereof). In some embodiments, treatment may be administered after one or more signs or symptoms have developed or been observed. In other embodiments, treatment may be administered in the absence of signs or symptoms of a disease or condition. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, e.g., to delay and / or prevent recurrence.
[0065] The terms "disease," "disease," and "disorder" are used interchangeably.
[0066] An "effective amount" of a compound of Formula (I') or (I) refers to an amount sufficient to elicit a desired biological response, i.e., an amount that treats a disease. Those skilled in the art will appreciate that an effective amount of a compound of Formula (I') or (I) may vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the compound, the condition being treated, the mode of administration, and the age and health of the subject. An effective amount encompasses both therapeutic and prophylactic treatments. For example, in the treatment of cancer, an effective amount of a compound of the present invention may reduce tumor burden or halt tumor growth or spread.
[0067] A "therapeutically effective amount" of a compound of Formula (I') or (I) is an amount sufficient to provide a therapeutic benefit in treating a disease or to delay or minimize one or more symptoms associated with a disease. A therapeutically effective amount of a compound means an amount of therapeutic agent alone, or in combination with other therapies, that provides a therapeutic benefit in treating a condition. The term "therapeutically effective amount" can encompass an amount that improves overall therapy, an amount that reduces or avoids the symptoms or causes of a condition, and / or an amount that enhances the therapeutic effectiveness of another therapeutic agent.
[0068] A "prophylactically effective amount" of a compound of Formula (I') or (I) is an amount sufficient to prevent or prevent the recurrence of a disease or one or more symptoms associated with a disease. A prophylactically effective amount of a compound refers to the amount of therapeutic agent alone, or in combination with other agents, that provides a prophylactic benefit in terms of disease prevention. The term "prophylactically effective amount" can encompass an amount that improves overall prophylaxis or an amount that enhances the prophylactic effectiveness of another prophylactic agent.
[0069] "Proliferative disorders" refer to disorders resulting from abnormal growth or expansion of cells by cell doubling (Walker, Cambridge Dictionary of Biology; Cambridge University Press: Cambridge, UK, 1990). Proliferative disorders may be associated with: 1) pathological proliferation of normally quiescent cells; 2) pathological migration of cells from their normal location (e.g., neoplastic cell metastasis); 3) pathological expression of proteolytic enzymes such as matrix metalloproteinases (e.g., collagenase, gelatinase, and elastase); or 4) pathological angiogenesis, such as that seen in proliferative retinopathies and tumor metastasis. Exemplary proliferative disorders include cancer (i.e., "malignant neoplasms"), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases.
[0070] The terms "neoplasm" and "tumor" are used interchangeably and refer to an abnormal mass of tissue, where the growth of the mass exceeds and is out of step with that of normal tissue. A neoplasm or tumor may be "benign" or "malignant" depending on the following characteristics: degree of cellular differentiation (including morphology and functionality), rate of growth, local invasion, and metastasis. "Benign neoplasms" are generally well differentiated, characteristically have slower growth than malignant neoplasms, and remain localized at the site of origin. In addition, benign neoplasms do not possess the propensity to infiltrate, invasive, or metastasize to distant sites. Exemplary benign neoplasms include, but are not limited to, lipoma, chondroma, adenoma, acrochordon, senile hemangioma, seborrheic keratosis, lentigo, and sebaceous hyperplasia. In some cases, a "benign" tumor can later give rise to a malignant neoplasm, which may result from additional genetic alterations in a subpopulation of the tumor's neoplastic cells; these tumors are referred to as "premalignant neoplasms." An exemplary premalignant neoplasm is a teratoma. In contrast, "malignant neoplasms" are generally poorly differentiated (anaplastic) and characterized by rapid growth accompanied by progressive infiltration, invasion, and destruction of surrounding tissue. Moreover, malignant neoplasms generally have the propensity to metastasize to distant sites.
[0071] The terms "metastasis," "metastatic," or "metastasize" refer to the spread or migration of cancerous cells from a primary or original tumor to another organ or tissue, typically identifiable by the presence of a "secondary tumor" or "secondary cell mass" of the tissue type of the primary or original tumor, rather than in the organ or tissue in which the secondary (metastatic) tumor is located. For example, prostate cancer that has migrated to bone is referred to as metastatic prostate cancer, and includes cancerous prostate cancer cells growing in bone tissue.
[0072] The term "cancer" refers to a malignant neoplasm (Stedman's Medical Dictionary, 25th ed.; Hensyl ed.; Williams & Wilkins: Philadelphia, 1990). Exemplary cancers include, but are not limited to, acoustic neuroma; adenocarcinoma; cancer of the adrenal gland; anal cancer; angiosarcoma (e.g., lymphangiosarcoma, lymphangioendothelial sarcoma, angiosarcoma); appendix cancer; benign monoclonal gammopathy; bile duct cancer (e.g., cholangiocarcinoma); bladder cancer; breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast); brain cancer (e.g., meningioma, glioblastoma, glioma (e.g., astrocytoma, oligodendroglioma), medulloblastoma); bronchial cancer; carcinoid tumor; cervical cancer (e.g., cervical adenocarcinoma); choriocarcinoma; chordoma; craniopharyngioma; colorectal cancer cancer) (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma); cancer of connective tissue; epithelial carcinoma; ependymoma; endothelial sarcoma (e.g., Kaposi's sarcoma, multiple idiopathic hemorrhagic sarcoma); endometrial cancer (e.g., uterine cancer, uterine sarcoma); esophageal cancer (e.g., esophageal adenocarcinoma, Barrett's adenocarcinoma); Ewing's sarcoma; eye cancer (e.g., intraocular melanoma, retinoblastoma); familial hypereosinophilia; gallbladder cancer; stomach cancer (e.g., gastric adenocarcinoma); gastrointestinal stromal tumor (GIST); germ cell cancer; head and neck cancer (e.g., head and neck squamous cell carcinoma, oral cancer (e.g., oral squamous cell carcinoma), throat cancer (e.g., laryngeal cancer, pharyngeal cancer, nasopharyngeal carcinoma, oropharyngeal carcinoma); hematopoietic cancer cancers) (e.g., leukemias such as acute lymphoblastic leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acute myeloid leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myeloid leukemia (CML) (e.g., B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL);Hodgkin's lymphoma (HL) (e.g., B-cell HL, T-cell HL) and non-Hodgkin's lymphoma (NHL) (e.g., B-cell NHL such as diffuse large cell lymphoma (DLCL) (e.g., diffuse large B-cell lymphoma)), follicular lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphoma (e.g., mucosa-associated lymphoid tissue (MALT) lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt's lymphoma, lymphoma Lymphomas such as plasmacytic lymphoma (i.e., Waldenstrom's macroglobulinemia), hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, and primary central nervous system (CNS) lymphoma; and precursor T-lymphoblastic lymphoma / leukemia, peripheral T-cell lymphomas (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungoides, Sézary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathic T-cell lymphoma, subcutaneous cellulitis-like T-cell lymphoma, and T-cell NHL, such as anaplastic large cell lymphoma (ANCL) and anaplastic large cell lymphoma (ALCL); mixtures of one or more of the leukemias / lymphomas listed above; and multiple myeloma (MM), heavy chain diseases (e.g., alpha chain diseases, gamma chain diseases, mu chain diseases); hemangioblastoma; hypopharyngeal carcinoma; inflammatory myofibroblastic tumor; immunocytic amyloidosis; kidney cancer (e.g., nephroblastoma, also known as Wilms' tumor, renal cell carcinoma); liver cancer (e.g., hepatocellular carcinoma (HCC), malignant hepatocellular carcinoma); lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung); leiomyosarcoma (LMS); mastocytosis (e.g., systemic mastocytosis); muscle cancer; myelodysplastic syndromes (MDS); mesothelioma; myeloproliferative disorders (MPDs) (e.g., polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myeloid metaplasia (AMM), also known as myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myeloid leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)); neuroblastoma; neurofibromas (e.g., neurofibromatosis (NF) type 1 or 2, schwannomatosis); neuroendocrine cancers (e.g., gastroenteropancreatic neuroendocrine tumors (GEP-NETs), carcinoid tumors);Osteosarcoma (e.g., bone cancer); ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma); papillary adenocarcinoma; pancreatic cancer (e.g., pancreatic adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), pancreatic islet cell tumor); penile cancer (e.g., Paget's disease of the penis and scrotum); pinealoma; primitive neuroectodermal tumor (PNT); plasma cell neoplasm; paraneoplastic syndromes; intraepithelial neoplasia; prostate cancer (e.g., prostatic adenocarcinoma); rectal cancer; rhabdomyosarcoma; salivary gland cancer; skin cancer (e.g., squamous cell carcinoma (SCC), keratoacanthoma (K)) A), melanoma, basal cell carcinoma (BCC); small intestine cancer (e.g., appendix cancer); soft tissue sarcomas (e.g., malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma); sebaceous gland carcinoma; small intestine cancer; sweat gland carcinoma; synovioma; testicular cancer (e.g., seminoma, testicular embryonal carcinoma); thyroid cancer (e.g., papillary thyroid carcinoma, papillary thyroid carcinoma (PTC), medullary thyroid carcinoma); urethral cancer; vaginal cancer; and vulvar cancer (e.g., Paget's disease of the vulva);
[0073] The term "angiogenesis" refers to the formation and growth of new blood vessels. Normal angiogenesis occurs in a subject's healthy body to heal wounds and restore blood flow to tissues after injury. A healthy body controls angiogenesis through a number of means, for example, angiogenesis-stimulating growth factors and angiogenesis inhibitors. Many pathologies, such as cancer, diabetic blindness, age-related macular degeneration, rheumatoid arthritis, and psoriasis, are characterized by abnormal (i.e., increased or excessive) angiogenesis. Abnormal or pathological angiogenesis refers to angiogenesis that exceeds that in the normal body, particularly angiogenesis in adults that is not associated with normal angiogenesis (e.g., menstruation or wound healing). Abnormal angiogenesis can provide new blood vessels to feed diseased tissue and / or destroy normal tissue, and in the case of cancer, the new blood vessels allow tumor cells to escape into the circulation and lodge in other organs (tumor metastasis). In some embodiments, the angiogenesis is pathological angiogenesis.
[0074] "Autoimmune disease" refers to a disease resulting from an inappropriate immune response by a subject's body against substances and tissues normally present in the body. In other words, the immune system mistakes a part of the body for a pathogen and attacks its own cells. This may be restricted to a certain organ (e.g., in autoimmune thyroiditis) or may involve specific tissues in various locations (e.g., Goodpasture's disease, which can affect the basement membrane in both the lungs and kidneys). Treatment of autoimmune diseases is typically by immunosuppression, e.g., medications that reduce the immune response. Exemplary autoimmune diseases include, but are not limited to, glomerulonephritis, Goodpasture's syndrome, necrotizing vasculitis, lymphadenitis, periarteritis nodosa, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, ulcerative colitis, systemic sclerosis, dermatomyositis / polymyositis, antiphospholipid syndrome, scleroderma, pemphigus vulgaris, ANCA-associated vasculitis (e.g., Wegener's granulomatosis, microscopic polyangiitis), uveitis, Sjogren's syndrome, Crohn's disease, Reiter's syndrome, ankylosing spondylitis, Lyme disease, Guillain-Barré syndrome, Hashimoto's thyroiditis, and cardiomyopathies. In some embodiments, the autoimmune disease is rheumatoid arthritis.
[0075] The term "neurological disease" refers to any disease of the nervous system, including diseases involving the central nervous system (brain, brainstem, and cerebellum), the peripheral nervous system (including cranial nerves), and the autonomic nervous system (parts of which are located in both the central and peripheral nervous systems). Neurodegenerative disease refers to a type of neurological disease characterized by the loss of nerve cells, including, but not limited to, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, tauopathy (including frontotemporal dementia), and Huntington's disease. Examples of neurological diseases include, but are not limited to, headache, stupor and coma, dementia, seizures, sleep disorders, trauma, infection, neoplasms, neuro-ophthalmology, movement disorders, demyelinating diseases, spinal cord disorders, and disorders of the peripheral nerves, muscles, and neuromuscular junction. Addiction and mental illness, including, but not limited to, bipolar disorder and schizophrenia, are also included in the definition of neurological disease. Further examples of neurological disorders include acquired epileptic aphasia; acute disseminated encephalomyelitis; adrenoleukodystrophy; agenesis of the corpus callosum; agnosia; Aicardi syndrome; Alexander disease; Alpers disease; alternating hemiplegia; Alzheimer's disease; amyotrophic lateral sclerosis; anencephaly; Angelman syndrome; hemangiomatosis; anoxia; aphasia; apraxia; arachnoid cysts; arachnoiditis; Arnold-Chiari malformation; arteriovenous malformations; Asperger's syndrome; ataxia-telangiectasia; attention-deficit hyperactivity disorder; autism; Autonomic dysfunction; back pain; Batten disease; Behçet's disease; Bell's palsy; benign idiopathic blepharospasm; benign focal muscular atrophy; benign intracranial hypertension; Binswanger's disease; blepharospasm; Bloch-Sulzberger syndrome; brachial plexus injury; brain abscess; brain injury; brain tumor (including glioblastoma multiforme); spinal tumor; Brown-Séquard syndrome; Canavan disease; carpal tunnel syndrome (CTS); burning pain; central pain syndrome; central pontine myelinolysis; head disorders (cephalic disorder); cerebral aneurysm; cerebral arteriosclerosis; cerebral atrophy; cerebral gigantism; cerebral palsy; Charcot-Marie-Tooth disease; chemotherapy-induced neuropathy and neuropathic pain; Chiari malformation; chorea; chronic inflammatory demyelinating polyneuropathy (CIDP); chronic pain; chronic regional pain syndrome; Coffin-Lowry syndrome; persistent vegetative state, including coma; congenital ophthalmoplegia; corticobasal degeneration; cranial arteritis; craniosynostosis; Creutzfeldt-Jakob disease;Cumulative trauma disorder; Cushing's syndrome; Cytomegalic inclusion body disease (CIBD); Cytomegalovirus infection; Opsoclonus-myoclonus syndrome (dancing eyes-dancing feet syndrome); Dandy-Walker syndrome; Dawson disease; Domorsia syndrome; Dejerine-Klumpke palsy; Dementia; Dermatomyositis; Diabetic neuropathy; Diffuse sclerosis; Autonomic dysfunction; Dysgraphia; Dyslexia; Dystonia; Early infantile epileptic encephalopathy; Syringo-sellar syndrome; Encephalitis; Encephalitis; Trigeminal angiomatosis; Epilepsy; Erb's palsy; Essential tremor; Fabry disease; Fahr's syndrome; Syncope; Familial spastic paraplegia; Febrile seizures seizures); Fisher syndrome; Friedreich's ataxia; frontotemporal dementia and other "tauopathies"; Gaucher disease; Gerstmann's syndrome; giant cell arteritis; giant cell inclusion disease; globoid cell leukodystrophy; Guillain-Barré syndrome; HTLV-1-associated myelopathy; Hallervorden-Spatz disease; head injury; headache; hemifacial spasm; hereditary spastic paraplegia; hereditary polyneuropathy ataxia; herpes zoster oticus; herpes zoster; Hirayama syndrome; HIV-associated dementia and neuropathy (see also Neurological symptoms of AIDS); holoprosencephaly; Huntington's disease and other polyglutamine repeat disorders diseases);hydranencephaly;hydrocephalus;hypercortisone;hypoxia;immune-mediated encephalomyelitis;inclusion body myositis;incontinentia pigmenti;infantile phytanic acid storage disease;infantile Refsum disease;episodic spasms;inflammatory myopathy;intracranial cysts;intracranial hypertension;Joubet syndrome;Kerns-Sayre syndrome;Kennedy disease;Kinsbone syndrome;Klippel-Fehr syndrome;Krabbe disease;Kugelberg-Welander disease;kuru;Lafora disease;Lambert-Eaton myasthenic syndrome;Landa U-Kleffner syndrome; Lateral medullary (Wallenberg) syndrome; Learning disabilities; Leigh's disease; Lennox-Gastaut syndrome; Lesch-Nyhan syndrome; Leukodystrophy; Dementia with Lewy bodies; Lissencephaly; Locked-in syndrome; Lou Gehrig's disease (also known as motor neuron disease or amyotrophic lateral sclerosis); Lumbar disc disease; Lyme disease - neurological sequelae; Machado-Joseph disease; Megalocybena; Megaencephaly; Melkerson-Rosenthal syndrome; Meniere's disease; Meningitis; Menkes disease;Metachromatic leukodystrophy; microcephaly; migraine; Miller-Fisher syndrome; minor stroke; mitochondrial cardiomyopathy; Moebius syndrome; monomelic muscular atrophy; motor neuron disease; moyamoya disease; mucopolysaccharidosis; multiinfarct dementia; multifocal motor neuropathy; multiple sclerosis and other demyelinating disorders; multiple system atrophy with postural hypotension; muscular dystrophy; myasthenia gravis; myeloid diffuse sclerosis ;infantile myoclonic encephalopathy;myoclonus;myopathy;congenital myotonia;narcolepsy;neurofibromatosis;neuroleptic malignant syndrome;neurologic manifestations of AIDS;neurologic sequelae of lupus;neuromyotonia;neuronal ceroid lipofuscinosis;neuronal migration disorder;Niemann-Pick disease;O'Sullivan-McLeod syndrome;occipital neuralgia;secondary occult spinal cord insufficiency spinal dysraphism sequence; Ohtahara syndrome; olivopontocerebellar atrophy; opsoclonus-myoclonus; optic neuritis; orthostatic hypotension; overuse syndrome; paresthesia; Parkinson's disease; paramyotonia congenita; paraneoplastic disorders; paroxysmal attacks; Paley-Romberg syndrome; Pelizaeus-Merzbacher disease; periodic paralysis; peripheral neuropathy; painful neuropathy and neuropathic pain; persistent vegetative state; pervasive developmental disorder; photophobic sneeze reflex; phytanic acid storage disease; Pick's disease; pinched nerve nerve); pituitary tumor; polymyositis; porencephaly; post-polio syndrome; post-herpetic neuralgia (PHN); post-infectious encephalomyelitis; post-orthostatic hypotension; Prader-Willi syndrome; primary lateral sclerosis; prion disease; progressive facial hemiatrophy; progressive multifocal leukoencephalopathy; progressive sclerosing poliodystrophy; progressive supranuclear palsy; pseudotumor cerebri; Ramsay-Hunt syndrome (types I and II); Rasmussen encephalitis; reflex sympathetic dystrophy syndrome; Refsum disease; repetitive motion disorder; repetitive stress injuries; restless legs syndrome; retroviral-associated myelopathy; Rett syndrome; Reye's syndrome; chorea; Sandhoff disease; Schilder's disease; schizencephaly; septo-optic dysplasia;Shaken baby syndrome; shingles; Shy-Drager syndrome; Sjögren's syndrome; sleep apnea; Sotos syndrome; spasticity; spina bifida; spinal cord injury; spinal tumor; spinal muscular atrophy; stiff-person syndrome; stroke; Sturge-Weber syndrome; subacute sclerosing panencephalitis; subarachnoid hemorrhage; subcortical arteriosclerotic encephalopathy; Sydenham chorea; syncope; syringomyelia; tardive dyskinesia; Tay-Sachs disease; temporal arteritis; tethered spinal cord syndrome; Thomsen's disease; thoracic outlet syndrome; painful tics; Todd's palsy; Tourette's syndrome; transient ischemic attack; transmissible spongiform encephalopathy; transverse myelitis; traumatic brain injury; This includes gliosis, tremor, trigeminal neuralgia, tropical spastic paresis, tuberous sclerosis, vascular dementia (multi-infarct dementia), temporal arteritis, including vasculitis, von Hippel-Lindau disease (VHL), Wallenberg syndrome, Werdnig-Hoffmann disease, West syndrome, whiplash injury, Williams syndrome, Wilson's disease, and Zellweger syndrome.
[0076] The term "metabolic disorder" refers to any disorder involving alterations in the normal metabolism of carbohydrates, lipids, proteins, nucleic acids, or a combination thereof. Metabolic disorders are associated with either deficiencies or excesses in metabolic pathways that result in imbalances in the metabolism of nucleic acids, proteins, lipids, and / or carbohydrates. Factors that affect metabolism include, but are not limited to, endocrine (hormonal) control systems (e.g., enteroendocrine hormones, including the insulin pathway, GLP-1, PYY, or the like), neural control systems (e.g., GLP-1 in the brain), or the like. Examples of metabolic disorders include, but are not limited to, diabetes (e.g., type I diabetes, type II diabetes, gestational diabetes), hyperglycemia, hyperinsulinemia, insulin resistance, and obesity.
[0077] The term "male contraception" refers to a method that involves inducing contraceptive effects to reduce male fertility. Examples of methods that reduce male fertility include, but are not limited to, inducing azoospermia, oligospermia, or asthenozoospermia; or reducing sperm count, or reducing sperm motility.
[0078] The term "biological sample" refers to any sample, including tissue samples (such as tissue sections and tissue needle biopsies); cell samples (e.g., cytological smears (such as Pap or blood smears) or samples obtained by microdissection); whole organism samples (such as yeast or bacterial samples); or cell fractions, fragments, or organelles (such as those obtained by lysing cells and centrifuging or otherwise separating their components). Other examples of biological samples include blood, serum, urine, semen, feces, cerebrospinal fluid, interstitial fluid, mucus, tears, sweat, pus, biopsy tissue (e.g., obtained by surgical or needle biopsy), nipple aspirate, milk, vaginal fluid, saliva, swabs (such as buccal swabs), or any material containing biomolecules derived from a first biological sample. Biological samples also include those biological samples that are transgenic, such as transgenic oocytes, sperm cells, blastocysts, embryos, fetuses, donor cells, or cell nuclei.
[0079] The term "kinase" refers to any enzyme that catalyzes the addition of a phosphate group to an amino acid residue in a protein. For example, a serine kinase catalyzes the addition of a phosphate group to a serine residue in a protein. In some embodiments, the kinase is a protein kinase. Examples of kinases include, but are not limited to, cyclin-dependent kinases (CDKs, e.g., CDK1, CDK2, CDK2, CDK4, CDK5, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, CDK14, CDK16, and CDK20), mitogen-activated protein kinases (MAPKs, e.g., MAPK1, MAPK3, MAPK4, MAPK6, MAPK7, MAPK8, MAPK9, MAPK10, MAPK11, MAPK12, MAPK13, MAPK14, and MAPK15), glycogen synthase kinase 3 (GSK3, e.g., GSK3α and GSK3β), CDK-like kinases (CLKs, e.g., CLK1, CLK2, CLK3, and CLK4), AGC kinases (e.g., protein kinase A (PKA), protein kinase C (PKC), and protein kinase G (PKG)), Ca 2+ / Calmodulin-dependent protein kinase (CaM kinase, for example, specialized CaM kinase, multifunctional CaM kinase), casein kinase 1 (CK1, for example, CK1 alpha, CK1 beta 1, CK1 gamma 1, CK1 gamma 2, CK1 gamma 3, CK1 delta, CK1 epsilon), STE kinase (for example, homologs of yeast Sterile 7, Sterile 11, or Sterile 20 kinase), tyrosine kinase (TK, for example, receptor tyrosine kinase (RTK), non-receptor tyrosine kinase (nRTK)), and tyrosine kinase-like kinase (TKL, for example, mixed lineage kinase (MLK), RAF, serine threonine kinase receptor (STKR), leucine-rich repeat kinase (LRRK), LIM domain kinase (LIMK), testis-expressed serine kinase (TESK), IL1 receptor-associated kinase (IRAK), receptor-interacting protein kinase (RIPK)).
[0080] The term "CDK" refers to cyclin-dependent kinase. The term "TAIRE family" kinase refers to a subfamily of CDK kinases.
[0081] CDKs are a family of protein serine or threonine kinases whose activity is based on binding to noncatalytic regulatory subunits called cyclins. CDKs are involved in cell cycle regulation. Examples of CDKs include, but are not limited to, CDK14, CDK15, CDK16, CDK17, and CDK18. The process of eukaryotic cell division can be broadly divided into a series of sequential phases designated G1, S, G2, and M. Correct progression through the various phases of the cell cycle has been shown to depend largely on the spatial and temporal regulation of a family of proteins known as cyclin-dependent kinases (CDKs) and a diverse collection of their cognate protein partners, termed cyclins. CDKs are serine-threonine kinase proteins homologous to CDC2 (also known as CDK1), which can utilize ATP as a substrate for the phosphorylation of various polypeptides in sequence-dependent contexts. Cyclins are a family of proteins characterized by a homology region containing approximately 100 amino acids, called the "cyclin box," which is used to bind to and define selectivity for specific CDK partner proteins. Modulation of the expression levels, degradation rates, protein levels, and activity levels of various CDKs and cyclins throughout the cell cycle leads to the cyclical formation of a series of CDK / cyclin complexes, in which the CDKs are enzymatically active. The formation of these complexes controls passage through distinct cell cycle checkpoints, thereby allowing the cell division process to continue. Failure to meet prerequisite biochemical criteria at a given cell cycle checkpoint (e.g., failure to form a required CDK / cyclin complex) can lead to cell cycle arrest and / or cellular apoptosis. Abnormal cell proliferation can often result from the loss of proper cell cycle control. Thus, inhibition of CDK enzymatic activity provides a means by which cells that do not divide normally can stop their division and / or die.The diversity of CDKs, CDK complexes, and their essential roles in mediating the cell cycle provides a wide range of potential therapeutic targets that can be selected on clear biochemical grounds. [Brief explanation of the drawings]
[0082] Brief description of the drawings [Figure 1] FIG. 1 shows an overview of selected exemplary compounds.
[0083] [Figure 2A-B] Figures 2A-2E show the chemical structure of the exemplary CDK inhibitor FMF-04-107-2 (Figure 2A), KiNativ profiling + / - washout (Figure 2B), identification of labeled peptides in CDK14 (Figure 2C), mass spectrometry (MS) labeling of recombinant CDK14 (Figure 2D), and competitive MS labeling of recombinant CDK14 / CDK16 (Figure 2E). [Figure 2C-D] Figures 2C-2D show the identification of labeled peptides in CDK14 (Figure 2C) and mass spectrometry (MS) labeling of recombinant CDK14 (Figure 2D). [Figure 2E] FIG. 2E shows competitive MS labeling of recombinant CDK14 / CDK16 (FIG. 2E).
[0084] [Figure 3A] Figures 3A-3C show the chemical structure (Figure 3A), Kinativ profiling (Figure 3B), and cellular pull-down assay + / - washout (Figure 3C) of an exemplary CDK inhibitor, FMF-04-159-2. [Figure 3B] Figure 3B shows Kinativ profiling. [Figure 3C] FIG. 3C shows the pull-down assay + / - washout of cells.
[0085] [Figure 4] Figures 4A and 4B show dose-dependent CDK14 inhibition by exemplary compounds in a cellular pull-down assay, with Figure 4A showing the procedure and Figure 4B showing the results.
[0086] [Figure 5] Figure 5 shows a literature summary of the reported role of CDK14 in promoting cell motility and epithelial-mesenchymal transition (EMT) during cancer. DETAILED DESCRIPTION OF THE INVENTION
[0087] Detailed Description of Certain Embodiments of the Invention The present disclosure provides selective inhibitors of CDKs (e.g., CDK14, CDK15, CDK16, CDK17, CDK18). In some embodiments, the compounds of the present invention inhibit the activity of cyclin-dependent kinase 14 (CDK14). The present disclosure further provides methods of using the compounds described herein, e.g., as biological probes for studying the inhibition of kinase (e.g., CDKs (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) activity, and e.g., as therapeutic agents in the treatment and / or prevention of diseases associated with overexpression and / or abnormal activity of kinases (e.g., CDKs (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)). In some embodiments, the compounds covalently inhibit CDKs (e.g., CDK14). In some embodiments, the diseases to be treated and / or prevented include, but are not limited to, proliferative diseases, metabolic disorders, autoimmune diseases, and neurological diseases. Proliferative diseases include, but are not limited to, cancer (e.g., lung cancer, breast cancer, liver cancer, pancreatic cancer, gastric cancer, ovarian cancer, colon cancer, colorectal cancer). In some embodiments, the cancer is carcinoma. Metabolic disorders include, but are not limited to, diabetes. Autoimmune diseases include, but are not limited to, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, ulcerative colitis, and systemic sclerosis. Neurological diseases include, but are not limited to, Alzheimer's disease, gliosis, and spinal cord injury. In some embodiments, the cancer is associated with overexpression and / or abnormal activity of kinases (e.g., CDKs (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)). In some embodiments, the compounds described herein are used for male contraception (e.g., reducing or inhibiting spermatogenesis or reducing male fertility) in fertile, healthy male subjects. Also provided by the present disclosure are pharmaceutical compositions, kits, methods, and uses of the compounds of formula (I') or (I) as described herein.
[0088] compound Certain aspects of the present disclosure relate to compounds described herein. The compounds described herein may be useful for treating and / or preventing a disease in a subject (e.g., a proliferative disease (e.g., cancer), a metabolic disorder (e.g., diabetes), an autoimmune disease, or a neurological disease (e.g., Alzheimer's disease, gliosis, spinal cord injury)), or a disease associated with the activity of a protein kinase (e.g., CDK), or for inhibiting the activity of a protein kinase (e.g., CDK) in a subject or biological sample. In some embodiments, the compounds described herein are compounds represented by formula (I') or (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof. In some embodiments, the compounds described herein are compounds represented by formula (I') or (I), or a pharmaceutically acceptable salt thereof.
[0089] In some embodiments, the compounds described herein have formula (I'): [ka] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein: R 1 and each occurrence independently represents halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -OR D1 , -N(R D1a )2, and -SR D1 where R D1 are independently selected from hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group when attached to a sulfur atom; where R D1ais independently selected from the group consisting of hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, and a nitrogen protecting group; or optionally, R D1a when two of these are taken together with their intervening atoms to form a substituted or unsubstituted heterocyclic ring or a substituted or unsubstituted heteroaryl ring; R 2 is hydrogen, halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; Each instance of R is independently selected from the group consisting of hydrogen, optionally substituted alkyl, and a nitrogen protecting group; R x is selected from the group consisting of hydrogen, optionally substituted alkyl, and a nitrogen protecting group; n is 0, 1, 2, 3, 4, or 5; X is N, -NR, as long as valence permits. x -, S, or O; Y1 is N, -NR, as long as valence permits. x -, S, or O; L is an arbitrary substitution C 1~6 a hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain are independently replaced by -C=O-, -O-, -S-, -S(=O)O-, -NR(C=O)-, -NR-, an optionally substituted carbocyclylene, an optionally substituted heterocyclylene, an optionally substituted arylene, or an optionally substituted heteroarylene; R 3 ' is the expression: [ka] [ka] [ka] A warhead represented by the formula: L 3 is a bond or any substitution C 1~4 a hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain are independently —C═O—, —O—, —S—, —NR L3a -, -NR L3a C(=O)-, -C(=O)NR L3a -, -SC(=O)-, -C(=O)S-, -OC(=O)-, -C(=O)O-, -NR L3a C(=S)-, -C(=S)NR L3a -, trans-CR L3b =CR L3b -, cis-CR L3b =CR L3b -, -CC-, -S(=O)-, -S(=O)O-, -OS(=O)-, -S(=O)NR L3a -, -NR L3a S(=O)-, -S(=O)2-, -S(=O)2O-, -OS(=O)2-, -S(=O)2NR L3a -, or -NR L3a S(=O)2-, where R L3a is hydrogen, substituted or unsubstituted C 1~6 alkyl, or nitrogen protecting group, and where R L3b each occurrence is independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R L3b the groups, when joined, form an optionally substituted carbocyclic ring or an optionally substituted heterocyclic ring; L 4 is a bond or an optionally substituted branched or unbranched C 1~6 It is a hydrocarbon chain; R E1 , R E2 , and R E3each independently represents hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —CN, —CHOR EE , -CHN(R EE )2, -CH2SR EE , -OR EE , -N(R EE )2, -Si(R EE )3, or -SR EE However, here R EE each instance of R is independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R EE groups joined to form an optionally substituted heterocyclic ring; or R E1 and R E3 , or R E2 and R E3 , or R E1 and R E2 are joined to form an optionally substituted carbocyclic ring or an optionally substituted heterocyclic ring; R E4 is a leaving group; R E5 is a halogen; R E6 is hydrogen, substituted or unsubstituted C 1~6 alkyl, or nitrogen protecting groups; Each instance of Y is independently O, S, or NR E7 However, here R E7 is hydrogen, substituted or unsubstituted C 1~6 alkyl, or nitrogen protecting groups; a is 1 or 2; and Each instance of z is independently 0, 1, 2, 3, 4, 5, or 6, valence permitting.
[0090] In some embodiments, the compound of formula (I') is represented by formula (I):
[0091] In some embodiments, the compounds described herein have formula (I): [ka] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein: R 1 and each occurrence independently represents halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -OR D1 , -N(R D1a )2, and -SR D1 where R D1 are independently selected from hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group when attached to a sulfur atom; where R D1a is independently selected from the group consisting of hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, and a nitrogen protecting group; or optionally, R D1a when two of these are taken together with their intervening atoms to form a substituted or unsubstituted heterocyclic ring or a substituted or unsubstituted heteroaryl ring; R 2 is hydrogen, halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; Each instance of R is independently selected from the group consisting of hydrogen, optionally substituted alkyl, and a nitrogen protecting group; R xis selected from the group consisting of hydrogen, optionally substituted alkyl, and a nitrogen protecting group; n is 0, 1, 2, 3, 4, or 5; X is N, -NR, as long as valence permits. x -, S, or O; Y1 is N, -NR, as long as valence permits. x -, S, or O; L is an arbitrary substitution C 1~6 a hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain are independently replaced by -C=O-, -O-, -S-, -S(=O)O-, -NR(C=O)-, -NR-, optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, or optionally substituted heteroarylene; R 3 is the expression: [ka] [ka] [ka] A warhead represented by the formula: L 3 is a bond or any substitution C 1~4 a hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain are independently —C═O—, —O—, —S—, —NR L3a -, -NR L3a C(=O)-, -C(=O)NR L3a -, -SC(=O)-, -C(=O)S-, -OC(=O)-, -C(=O)O-, -NR L3a C(=S)-, -C(=S)NR L3a -, trans-CR L3b =CR L3b -, cis-CR L3b =CR L3b -, -CC-, -S(=O)-, -S(=O)O-, -OS(=O)-, -S(=O)NR L3a-, -NR L3a S(=O)-, -S(=O)2-, -S(=O)2O-, -OS(=O)2-, -S(=O)2NR L3a -, or -NR L3a S(=O)2-, where R L3a is hydrogen, substituted or unsubstituted C 1~6 alkyl, or nitrogen protecting group, and where R L3b each occurrence is independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R L3b the groups, when joined, form an optionally substituted carbocyclic ring or an optionally substituted heterocyclic ring; L 4 is a bond or an optionally substituted branched or unbranched C 1~6 It is a hydrocarbon chain; R E1 , R E2 , and R E3 each independently represents hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —CN, —CHOR EE , -CHN(R EE )2, -CH2SR EE , -OR EE , -N(R EE )2, -Si(R EE )3, or -SR EE However, here R EE each instance of R is independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R EE groups joined to form an optionally substituted heterocyclic ring; or R E1 and R E3 , or R E2 and R E3 , or R E1and R E2 are joined to form an optionally substituted carbocyclic ring or an optionally substituted heterocyclic ring; R E4 is a leaving group; R E5 is a halogen; R E6 is hydrogen, substituted or unsubstituted C 1~6 alkyl, or nitrogen protecting groups; Each instance of Y is independently O, S, or NR E7 However, here R E7 is hydrogen, substituted or unsubstituted C 1~6 alkyl, or nitrogen protecting groups; a is 1 or 2; and Each instance of z is independently 0, 1, 2, 3, 4, 5, or 6, valence permitting.
[0092] In some embodiments, formula (I') comprises a substituent R 1 In some embodiments, formula (I') includes the absence of the substituent R 1 In some embodiments, formula (I) includes one or more substituents R 1 In some embodiments, formula (I) includes the absence of the substituent R 1 In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, R 1 is halogen (e.g., F, Cl, Br, or I). 1 is optionally substituted acyl (e.g., —C(═O)Me). 1 In the case of at least one of 1~6 In some embodiments, R 1 is substituted or unsubstituted methyl.1 is substituted or unsubstituted ethyl. 1 is substituted or unsubstituted propyl. 1 In the case of at least one of 2~6 alkenyl). In some embodiments, R 1 In the case of at least one of the following, optionally substituted alkynyl (e.g., substituted or unsubstituted C 2~6 alkynyl). In some embodiments, R 1 At least one instance of R is an optionally substituted carbocyclyl (e.g., a substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl containing zero, one, or two double bonds in the carbocyclic ring system). 1 At least one instance of R is optionally substituted heterocyclyl (e.g., a substituted or unsubstituted 5- to 10-membered monocyclic or bicyclic heterocyclic ring, where one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur). 1 At least one of R is optionally substituted aryl (e.g., substituted or unsubstituted 6- to 10-membered aryl). 1 is benzyl. 1 is substituted or unsubstituted phenyl. 1 is optionally substituted heteroaryl (e.g., a substituted or unsubstituted 5- to 6-membered, monocyclic heteroaryl, where 1, 2, 3, or 4 atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or a substituted or unsubstituted 9- to 10-membered, bicyclic heteroaryl, where 1, 2, 3, or 4 atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur). In certain embodiments, R 1 -OR if at least one of D1(e.g., —OH or —OMe). In some embodiments, R 1 If there is at least one of -N(R D1a )2 (e.g., -NMe2). In some embodiments, R 1 If at least one of D1 (e.g., -SMe). In some embodiments, R 1 If at least one of the following is present, it is halogen or -OR D1 and R D1 is independently selected from hydrogen or optionally substituted alkyl. 1 is -Cl or -F. In some embodiments, R 1 is -OMe or -OEt. 1 is -Cl or -F; and R 1 In some embodiments, n is 2; and R 1 In some embodiments, n is 2; and R 1 In both cases, it is -F.
[0093] In some embodiments, R 1 -OR if at least one of D1 , -N(R D1a )2, or -SR D1 and R D1 is as defined herein. In some embodiments, R D1 is hydrogen. In some embodiments, R D1 is substituted or unsubstituted acyl (e.g., —C(═O)Me). In some embodiments, R D1 is a substituted or unsubstituted alkyl (e.g., substituted or unsubstituted C 1~6 In some embodiments, R D1 is substituted or unsubstituted methyl. In some embodiments, R D1 is substituted or unsubstituted ethyl. In some embodiments, RD1 is substituted or unsubstituted propyl. In some embodiments, R D1 is a substituted or unsubstituted alkenyl (e.g., substituted or unsubstituted C 2~6 alkenyl). In some embodiments, R D1 is a substituted or unsubstituted alkynyl (e.g., substituted or unsubstituted C 2~6 alkynyl). In some embodiments, R D1 is a substituted or unsubstituted carbocyclyl (e.g., a substituted or unsubstituted 3- to 7-membered, monocyclic carbocyclyl containing zero, one, or two double bonds in the carbocyclic ring system). D1 is a substituted or unsubstituted heterocyclyl (e.g., a substituted or unsubstituted 5- to 10-membered monocyclic or bicyclic heterocyclic ring, where one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur). D1 is substituted or unsubstituted aryl (e.g., substituted or unsubstituted 6-10 membered aryl). In some embodiments, R D1 is benzyl. In some embodiments, R D1 is substituted or unsubstituted phenyl. In some embodiments, R D1 is a substituted or unsubstituted heteroaryl (e.g., a substituted or unsubstituted 5- to 6-membered, monocyclic heteroaryl, where one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or a substituted or unsubstituted 9- to 10-membered, bicyclic heteroaryl, where one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur). In some embodiments, R D1 is an oxygen protecting group when attached to an oxygen atom. D1 is a sulfur protecting group when attached to a sulfur atom.
[0094] In some embodiments, R D1a is hydrogen. D1aIn some embodiments, at least one of R D1a is a substituted or unsubstituted alkyl (e.g., substituted or unsubstituted C 1~6 In some embodiments, R D1a is substituted or unsubstituted methyl. D1a is substituted or unsubstituted ethyl. D1a is substituted or unsubstituted propyl. D1a In the case of at least one of the above, substituted or unsubstituted alkenyl (e.g., substituted or unsubstituted C 2~6 alkenyl). In some embodiments, R D1a In the case of at least one of the following, substituted or unsubstituted alkynyl (e.g., substituted or unsubstituted C 2~6 alkynyl). In some embodiments, R D1a At least one of R is a substituted or unsubstituted carbocyclyl (e.g., a substituted or unsubstituted 3- to 7-membered, monocyclic carbocyclyl containing zero, one, or two double bonds in the carbocyclic ring system). D1a At least one instance of R is a substituted or unsubstituted heterocyclyl (e.g., a substituted or unsubstituted 5- to 10-membered monocyclic or bicyclic heterocyclic ring, where one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur). D1a At least one of R is substituted or unsubstituted aryl (e.g., substituted or unsubstituted 6- to 10-membered aryl). D1a is benzyl. D1a is substituted or unsubstituted phenyl. D1ais a substituted or unsubstituted heteroaryl (e.g., a substituted or unsubstituted 5- to 6-membered, monocyclic heteroaryl, where one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or a substituted or unsubstituted 9- to 10-membered, bicyclic heteroaryl, where one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur). D1a In some embodiments, at least one of R is a nitrogen protecting group (e.g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl, or p-toluenesulfonamide (Ts)). D1a When two of these are present, they are taken together with their intervening atoms to form a substituted or unsubstituted heterocyclic ring (e.g., a substituted or unsubstituted 5- to 10-membered monocyclic or bicyclic heterocyclic ring, where one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur), or a substituted or unsubstituted heteroaryl ring (e.g., a substituted or unsubstituted 5- to 6-membered monocyclic heteroaryl, where one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or a substituted or unsubstituted 9- to 10-membered bicyclic heteroaryl, where one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur).
[0095] In one embodiment, the moiety [ka] In some embodiments, the moiety [ka] where R 1 is an optionally substituted alkyl, halogen, or -OR D1where R D1 is optionally substituted alkyl. In some embodiments, the moiety [ka] where R 1 is an optionally substituted alkyl, halogen, or -OR D1 where R D1 is optionally substituted alkyl.
[0096] In one embodiment, the moiety [ka] In some embodiments, the moiety [ka] In some embodiments, the moiety [ka] where R 1 is an optionally substituted alkyl, halogen, or -OR D1 where R D1 is optionally substituted alkyl. In some embodiments, the moiety [ka] where R 1 In some embodiments, the moiety [ka] where R 1 is a halogen, and R 1 -OR for the other D1 where R D1 is optionally substituted alkyl.
[0097] In one embodiment, the moiety [ka] In some embodiments, the moiety [ka] In some embodiments, the moiety [ka] where R 1 is an optionally substituted alkyl, halogen, or -OR D1 where R D1 is optionally substituted alkyl. In some embodiments, the moiety [ka] In some embodiments, the moiety [ka] In some embodiments, the moiety [ka] where R 1 is an optionally substituted alkyl, halogen, or -OR D1 where R D1 is optionally substituted alkyl. In some embodiments, the moiety [ka] In some embodiments, the moiety [ka] In some embodiments, the moiety [ka] where R 1 is an optionally substituted alkyl, halogen, or -OR D1 where R D1 is optionally substituted alkyl. In some embodiments, the moiety [ka] In some embodiments, the moiety [ka] In some embodiments, the moiety [ka] is the expression: [ka] It is expressed as:
[0098] Formula (I') is a group containing a substituent R 2 Formula (I) includes the substituent R 2 In some embodiments, R 2 is hydrogen. In some embodiments, R 2 is a halogen (e.g., F, Cl, Br, or I). In some embodiments, R 2 is optionally substituted acyl (e.g., —C(═O)Me). In some embodiments, R 2 is an optionally substituted alkyl (e.g., substituted or unsubstituted C 1~6 In some embodiments, R 2 is substituted or unsubstituted methyl. In some embodiments, R 2 is substituted or unsubstituted ethyl. In some embodiments, R 2 is unsubstituted ethyl. In some embodiments, R 2is substituted or unsubstituted propyl. In some embodiments, R 2 is unsubstituted n-propyl. In some embodiments, R 2 is unsubstituted methyl or isopropyl. 2 is an optionally substituted alkenyl (e.g., substituted or unsubstituted C 2~6 alkenyl). In some embodiments, R 2 is an optionally substituted alkynyl (e.g., substituted or unsubstituted C 2~6 alkynyl). In some embodiments, R 2 is an optionally substituted carbocyclyl (e.g., a substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl containing zero, one, or two double bonds in the carbocyclic ring system). 2 is an optionally substituted heterocyclyl (e.g., a substituted or unsubstituted 5- to 10-membered monocyclic or bicyclic heterocyclic ring, where one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur). 2 is optionally substituted aryl (e.g., substituted or unsubstituted, 6-10 membered aryl). In some embodiments, R 2 is benzyl. In some embodiments, R 2 is substituted or unsubstituted phenyl. In some embodiments, R 2 is unsubstituted phenyl. In some embodiments, R 2 is an optionally substituted heteroaryl (e.g., a substituted or unsubstituted 5- to 6-membered, monocyclic heteroaryl, where one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or a substituted or unsubstituted 9- to 10-membered, bicyclic heteroaryl, where one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur). In some embodiments, R 2 is an arbitrary substitution C 1~6 It is alkyl or optionally substituted aryl.
[0099] Formula (I') encompasses the case where there are two substituents R. Formula (I) encompasses the case where there are two substituents R. In some embodiments, both instances of R are the same. In some embodiments, each instance of R is different. In some embodiments, at least one instance of R is hydrogen. In some embodiments, both instances of R are hydrogen. In some embodiments, at least one instance of R is optionally substituted alkyl. In some embodiments, at least one instance of R is substituted or unsubstituted alkyl (e.g., substituted or unsubstituted C 1~6 In some embodiments, n is 2 and both instances of R are hydrogen. In some embodiments, one instance of R is hydrogen; and the other instance of R is substituted or unsubstituted alkyl (e.g., substituted or unsubstituted C 1~6 In some embodiments, the moiety: [ka] wherein R is a substituted or unsubstituted alkyl. In some embodiments, the moiety: [ka] where R is a substituted or unsubstituted alkyl.
[0100] Formula (I') includes a substituent X. Formula (I) includes a substituent X. In some embodiments, X is N, -NR, where valence allows.x -, S, or O; where R x is selected from the group consisting of hydrogen, optionally substituted alkyl, and a nitrogen protecting group. x is hydrogen. In some embodiments, R x is optionally substituted alkyl. In some embodiments, R x is a substituted or unsubstituted alkyl (e.g., substituted or unsubstituted C 1~6 In some embodiments, R x is substituted or unsubstituted methyl. In some embodiments, R x is substituted or unsubstituted ethyl. In some embodiments, R x is substituted or unsubstituted propyl. In some embodiments, R x is a nitrogen protecting group (e.g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl, or p-toluenesulfonamide (Ts)). In some embodiments, X is -N-. In some embodiments, X is -NR x In some embodiments, X is -NH-. In some embodiments, X is -N(substituted or unsubstituted alkyl)- (e.g., -N(substituted or unsubstituted C 1~6 In some embodiments, X is -N(nitrogen protecting group)-. In some embodiments, X is S. In some embodiments, X is O.
[0101] Formula (I') includes a substituent Y1. Formula (I) includes a substituent Y1. In some embodiments, Y1 is N, -NR, where valence allows. x -, S, or O; where R x is selected from the group consisting of hydrogen, optionally substituted alkyl, and a nitrogen protecting group. In some embodiments, Y is -N-. In some embodiments, Y is -NR xIn some embodiments, Y is -NH-. In some embodiments, Y is -N(substituted or unsubstituted alkyl)- (e.g., -N(substituted or unsubstituted C 1~6 In some embodiments, Y is -N(nitrogen protecting group)-. In some embodiments, Y is S. In some embodiments, Y is O. In some embodiments, one of X and Y is N and the other is -NR x -(e.g., -NH- or -N(substituted or unsubstituted alkyl)-(e.g., -N(substituted or unsubstituted C 1~6 In some embodiments, one of X and Y is S and the other is —N—.
[0102] In one embodiment, [ka] In one embodiment, [ka] In one embodiment, [ka] [ka] In one embodiment, [ka] It is expressed as:
[0103] In one embodiment, [ka] In one embodiment, [ka] It is expressed as:
[0104] Formula (I') includes a linker L. Formula (I) includes a linker L. In some embodiments, L is an optionally substituted C 1~6 A hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain are independently replaced by -C=O-, -O-, -S-, -S(=O)O-, -NR(C=O)-, -NR-, optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, or optionally substituted heteroarylene, and wherein each instance of R is independently selected from the group consisting of hydrogen, optionally substituted alkyl, and a nitrogen protecting group.
[0105] In some embodiments, L contains up to 20 atoms, excluding hydrogen atoms and substituents. In some embodiments, L contains up to 14 atoms, excluding hydrogen atoms and substituents. In some embodiments, L contains up to 15 atoms, excluding hydrogen atoms and substituents. In some embodiments, L contains up to 12 atoms, excluding hydrogen atoms and substituents. In some embodiments, L contains up to 10 atoms, excluding hydrogen atoms and substituents. In some embodiments, L contains up to 9 atoms, excluding hydrogen atoms and substituents. In some embodiments, L contains up to 6 atoms, excluding hydrogen atoms and substituents. In some embodiments, L contains up to 5 atoms, excluding hydrogen atoms and substituents. In some embodiments, L contains up to 3 atoms, excluding hydrogen atoms and substituents.
[0106] In certain embodiments, any of the atoms in L can be substituted. In certain embodiments, none of the atoms in the linker L are substituted. In certain embodiments, none of the carbon atoms in the linker are substituted.
[0107] In certain embodiments, one or more carbon units of the hydrocarbon chain are independently replaced with at least one instance of -C=O-. In certain embodiments, one or more carbon units of the hydrocarbon chain are independently replaced with at least one instance of -O-. In certain embodiments, one or more carbon units of the hydrocarbon chain are independently replaced with at least one instance of -S-. In certain embodiments, one or more carbon units of the hydrocarbon chain are independently replaced with at least one instance of -S(=O)O-. In certain embodiments, one or more carbon units of the hydrocarbon chain are independently replaced with at least one instance of -NR(C=O)-, where R is hydrogen, optionally substituted alkyl, or a nitrogen protecting group. In certain embodiments, one or more carbon units of the hydrocarbon chain are independently replaced with at least one instance of -NR(C=O)-, where R is hydrogen or optionally substituted alkyl. In certain embodiments, one or more carbon units of the hydrocarbon chain are independently replaced with at least one instance of -NR-, where R is hydrogen, optionally substituted alkyl, or a nitrogen protecting group. In some embodiments, one or more carbon units of the hydrocarbon chain are independently replaced by at least one instance of -NR-, where R is hydrogen or optionally substituted alkyl. In some embodiments, one or more carbon units of the hydrocarbon chain are independently replaced by at least one instance of optionally substituted carbocyclylene. In some embodiments, one or more carbon units of the hydrocarbon chain are independently replaced by at least one instance of optionally substituted heterocyclylene. In some embodiments, one or more carbon units of the hydrocarbon chain are independently replaced by at least one instance of optionally substituted arylene. In some embodiments, one or more carbon units of the hydrocarbon chain are independently replaced by at least one instance of optionally substituted heteroarylene.
[0108] In some embodiments, L is optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, or optionally substituted heteroarylene. In some embodiments, L is optionally substituted carbocyclylene (e.g., a substituted or unsubstituted 3- to 7-membered monocyclic carbocyclylene containing zero, one, or two double bonds in the carbocyclic ring system). In some embodiments, L is optionally substituted heterocyclylene (e.g., a substituted or unsubstituted 5- to 10-membered monocyclic or bicyclic heterocyclic ring, where one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur). In some embodiments, L is optionally substituted piperidinylene. In some embodiments, L is optionally substituted piperazinylene. In some embodiments, L is optionally substituted morpholinylene. In some embodiments, L is optionally substituted arylene (e.g., a substituted or unsubstituted 6- to 10-membered aryl). In some embodiments, L is optionally substituted benzylene. In some embodiments, L is substituted benzylene. In some embodiments, L is unsubstituted benzylene. In some embodiments, L is substituted or unsubstituted phenylene. In some embodiments, L is unsubstituted phenylene. In some embodiments, L is optionally substituted heteroarylene (e.g., substituted or unsubstituted 5- to 6-membered monocyclic heteroarylene, where 1, 2, 3, or 4 atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or substituted or unsubstituted 9- to 10-membered bicyclic heteroarylene, where 1, 2, 3, or 4 atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur). In some embodiments, L is optionally substituted 6-membered heterocyclylene or optionally substituted arylene. In some embodiments, L is optionally substituted piperidinylene or optionally substituted phenylene.
[0109] In some embodiments, L has the formula: [ka] where: Ring A is optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; Ring B is optionally substituted heterocyclyl or optionally substituted aryl; L x is a bond, —CH—, —C(═O)—, —S(═O)—, or —NH(C═O)—; and lx denotes the point of attachment to -NR-, ly is R 3 Show the attachment points to
[0110] In some embodiments, ring A is an optionally substituted heterocyclyl (e.g., a substituted or unsubstituted 5- to 10-membered monocyclic or bicyclic heterocyclic ring, where one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur). In some embodiments, ring A is an optionally substituted aryl (e.g., a substituted or unsubstituted 6- to 10-membered aryl). In some embodiments, ring A is an optionally substituted heteroaryl (e.g., a substituted or unsubstituted 5- to 6-membered monocyclic heteroaryl, where one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur; or a substituted or unsubstituted 9- to 10-membered bicyclic heteroaryl, where one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur). In some embodiments, Ring B is an optionally substituted heterocyclyl (e.g., a substituted or unsubstituted 5-10 membered monocyclic or bicyclic heterocyclic ring, where one or two atoms in the heterocyclic ring are independently nitrogen, oxygen, or sulfur). In some embodiments, Ring B is an optionally substituted aryl (e.g., a substituted or unsubstituted 6-10 membered aryl). In some embodiments, L x is a bond. x is -CH2-. In some embodiments, L x is —C(═O)—. In some embodiments, L x is -S(=O)2. In some embodiments, L xis -NH(C=O)-. In some embodiments, one of ring A and ring B is optionally substituted heterocyclyl, and the other is optionally substituted aryl. In some embodiments, one of ring A and ring B is optionally substituted heterocyclyl containing one nitrogen atom, and the other is optionally substituted phenyl. In some embodiments, one of ring A and ring B is optionally substituted piperidinyl containing one nitrogen atom, and the other is optionally substituted phenyl. In some embodiments, one of ring A and ring B is optionally substituted pyrrolidinyl containing one nitrogen atom, and the other is optionally substituted phenyl. In some embodiments, L is a group of the formula: [ka] where R A is halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -OR D1 , -N(R D1a )2, or -SR D1 n1 is 0 or 1; and m is 0, 1, 2, 3, or 4. lx denotes the point of attachment to -NR-, ly is R 3 Show the attachment points to
[0111] In some embodiments, R A When at least one of the following occurs, it is halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -OR D1 , -N(R D1a )2, or -SR D1 In some embodiments, n1 is 0. In some embodiments, n1 is 1. In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, L is a group represented by the formula: [ka] It is expressed as:
[0112] In some embodiments, L has the formula: [ka] [ka] In some embodiments, L is represented by the formula: [ka] It is expressed as:
[0113] In some embodiments, L has the formula: [ka] It is expressed as:
[0114] As generally defined herein, formula (I') is a group containing a substituent R 3 ', but in the formula R 3 ' is the expression: [ka] [ka] [ka] A warhead represented by the formula: L 3 is a bond or any substitution C 1~4 a hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain are independently —C═O—, —O—, —S—, —NR L3a-, -NR L3a C(=O)-, -C(=O)NR L3a -, -SC(=O)-, -C(=O)S-, -OC(=O)-, -C(=O)O-, -NR L3a C(=S)-, -C(=S)NR L3a -, trans-CR L3b =CR L3b -, cis-CR L3b =CR L3b -, -CC-, -S(=O)-, -S(=O)O-, -OS(=O)-, -S(=O)NR L3a -, -NR L3a S(=O)-, -S(=O)2-, -S(=O)2O-, -OS(=O)2-, -S(=O)2NR L3a -, or -NR L3a S(=O)2-, where R L3a is hydrogen, substituted or unsubstituted C 1~6 alkyl, or nitrogen protecting group, and where R L3b each occurrence is independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R L3b the groups, when joined, form an optionally substituted carbocyclic ring or an optionally substituted heterocyclic ring; L 4 is a bond or an optionally substituted branched or unbranched C 1~6 It is a hydrocarbon chain; R E1 , R E2 , and R E3 each independently represents hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —CN, —CHOR EE , -CHN(R EE )2, -CH2SR EE , -OR EE , -N(R EE )2, -Si(R EE )3, or -SR EE However, here REE each instance of R is independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R EE the groups are joined to form an optionally substituted heterocyclic ring; or R E1 and R E3 , or R E2 and R E3 , or R E1 and R E2 are joined to form an optionally substituted carbocyclic ring or an optionally substituted heterocyclic ring; R E4 is a leaving group; R E5 is a halogen; R E6 is hydrogen, substituted or unsubstituted C 1~6 alkyl, or nitrogen protecting groups; Each instance of Y is independently O, S, or NR E7 However, here R E7 is hydrogen, substituted or unsubstituted C 1~6 alkyl, or nitrogen protecting groups; a is 1 or 2; and Each instance of z is independently 0, 1, 2, 3, 4, 5, or 6, valence permitting.
[0115] In some embodiments, R 3 ' is R 3 is.
[0116] As generally defined herein, formula (I) includes a substituent R 3 where R 3 is the expression: [ka] [ka] [ka] A warhead represented by the formula: L 3 is a bond or any substitution C 1~4 a hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain are independently —C═O—, —O—, —S—, —NR L3a -, -NR L3a C(=O)-, -C(=O)NR L3a -, -SC(=O)-, -C(=O)S-, -OC(=O)-, -C(=O)O-, -NR L3a C(=S)-, -C(=S)NR L3a -, trans-CR L3b =CR L3b -, cis-CR L3b =CR L3b -, -CC-, -S(=O)-, -S(=O)O-, -OS(=O)-, -S(=O)NR L3a -, -NR L3a S(=O)-, -S(=O)2-, -S(=O)2O-, -OS(=O)2-, -S(=O)2NR L3a -, or -NR L3a S(=O)2-, where R L3a is hydrogen, substituted or unsubstituted C 1~6 alkyl, or nitrogen protecting group, and where R L3b each occurrence is independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R L3b the groups, when joined, form an optionally substituted carbocyclic ring or an optionally substituted heterocyclic ring; L 4 is a bond or an optionally substituted branched or unbranched C 1~6 It is a hydrocarbon chain; R E1 , R E2 , and R E3each independently represents hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —CN, —CHOR EE , -CHN(R EE )2, -CH2SR EE , -OR EE , -N(R EE )2, -Si(R EE )3, or -SR EE However, here R EE each instance of R is independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R EE the groups are joined to form an optionally substituted heterocyclic ring; or R E1 and R E3 , or R E2 and R E3 , or R E1 and R E2 are joined to form an optionally substituted carbocyclic ring or an optionally substituted heterocyclic ring; R E4 is a leaving group; R E5 is a halogen; R E6 is hydrogen, substituted or unsubstituted C 1~6 alkyl, or nitrogen protecting groups; Each instance of Y is independently O, S, or NR E7 However, here R E7 is hydrogen, substituted or unsubstituted C 1~6 alkyl, or nitrogen protecting groups; a is 1 or 2; and Each instance of z is independently 0, 1, 2, 3, 4, 5, or 6, valence permitting.
[0117] In some embodiments, R 3' is a warhead represented by formula (i-1) to (i-43). In some embodiments, the warhead is represented by formula [ka] In some embodiments, R 3 ' is the expression [ka] In some embodiments, R 3 ' is the expression [ka] In some embodiments, R 3 ' is the expression [ka] In some embodiments, R 3 ' is the expression: [ka] In some embodiments, R 3 ' is the expression: [ka] In some embodiments, R 3 ' is the expression: [ka] In some embodiments, R 3 ' is the expression: [ka] In some embodiments, L3 is a bond. In some embodiments, L3 is -NH-. In some embodiments, R E1 and R E2 is hydrogen. In some embodiments, R E1 , R E2 , and R E3 are all hydrogen. E3 is -CH2NMe2. In some embodiments, the warhead has the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead has the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In one embodiment, the warhead is represented by: [ka] In some embodiments, the warhead has the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, R 3 ' is the expression [ka] In some embodiments, R 3 ' is the expression [ka] It is a warhead represented by.
[0118] In some embodiments, R 3 is a warhead represented by formula (i-1) to (i-41). In one embodiment, the warhead is represented by formula [ka] In some embodiments, R 3 is expressed as [ka] In one embodiment, R 3 is the expression [ka] In some embodiments, R 3 is the expression [ka] In some embodiments, R 3 is the expression [ka] In some embodiments, R 3 is the expression [ka] In some embodiments, R 3 is the expression [ka] In some embodiments, R 3 is the expression [ka] In some embodiments, L3 is a bond. In some embodiments, L3 is -NH-. In some embodiments, R E1 and R E2 is hydrogen. In some embodiments, R E1 , R E2, and R E3 are all hydrogen. E3 is -CH2NMe2.
[0119] In some embodiments, the warhead has the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In one embodiment, the warhead is represented by: [ka] In some embodiments, the warhead has the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] It is expressed as:
[0120] In some embodiments, the warhead has the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In one embodiment, the warhead is represented by: [ka] In some embodiments, the warhead has the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] It is expressed as:
[0121] In some embodiments, the warhead has the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] In some embodiments, the warhead is represented by the formula [ka] It is expressed as:
[0122] In some embodiments, the warhead has the formula [ka] It is expressed as:
[0123] In one embodiment, L 3 is a bond (e.g., a single bond, a double bond, or a triple bond). 3 is a single bond. 3 is a double bond. 3 is a triple bond. 3 is an arbitrary substitution C 1~4 a hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain are independently —C═O—, —O—, —S—, —NR L3a -, -NR L3aC(=O)-, -C(=O)NR L3a -, -SC(=O)-, -C(=O)S-, -OC(=O)-, -C(=O)O-, -NR L3a C(=S)-, -C(=S)NR L3a -, trans-CR L3b =CR L3b -, cis-CR L3b =CR L3b -, -CC-, -S(=O)-, -S(=O)O-, -OS(=O)-, -S(=O)NR L3a -, -NR L3a S(=O)-, -S(=O)2-, -S(=O)2O-, -OS(=O)2-, -S(=O)2NR L3a -, or -NR L3a S(=O)2-, where R L3a is hydrogen, substituted or unsubstituted C 1~6 alkyl, or nitrogen protecting group, and where R L3b each occurrence of is independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R L3b The groups are joined to form an optionally substituted carbocyclic or an optionally substituted heterocyclic ring. 4 is a bond (e.g., a single bond, a double bond, or a triple bond). 4 is a branch C of any substitution 1~6 In some embodiments, L is a hydrocarbon chain (e.g., i-Pr). 4 is an unbranched C 1~6 A hydrocarbon chain (e.g., n-Pr or n-Bu). In some embodiments, R E1 is H. In some embodiments, R E1 is halogen (e.g., F, Cl, Br, or I). E1 At least one instance of R is optionally substituted alkyl (e.g., Me, or Et). E1At least one instance of R is optionally substituted alkenyl (e.g., optionally substituted vinyl). E1 is optionally substituted alkynyl. E1 At least one of R is a substituted or unsubstituted carbocyclyl (e.g., a substituted or unsubstituted 3- to 7-membered, monocyclic carbocyclyl containing zero, one, or two double bonds in the carbocyclic ring system). E1 is a substituted or unsubstituted heterocyclyl (e.g., a substituted or unsubstituted 3- to 7-membered, monocyclic heterocyclyl containing zero, one, or two double bonds in the heterocyclic ring system, where one, two, or three atoms in the heterocyclic ring system are independently nitrogen, oxygen, or sulfur). E1 At least one of R is substituted or unsubstituted aryl (e.g., substituted or unsubstituted 6- to 10-membered aryl). E1 is substituted or unsubstituted phenyl. E1 is a substituted or unsubstituted heteroaryl (e.g., a substituted or unsubstituted 5-6 membered, monocyclic heteroaryl, where 1, 2, 3, or 4 atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur). E1 In some embodiments, at least one of R E1 If at least one of the following is true, -CH2OR EE However, here R EE is independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. E1 If at least one of the following occurs, -CH2N(R EF )2 or -N(R EF )2, where R EFis independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, and optionally wherein two R EF The groups may be joined to form an optionally substituted heterocyclic ring. E1 If at least one of the following occurs, -CH2SR EE or -SR EE (e.g., —CHSMe or —SMe). In some embodiments, R E1 -OR if at least one of EE (For example, -OMe). In some embodiments, R E1 If at least one of the following is true, -Si(R EG )3, where R EG is independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl (e.g., -Si(Me)3).
[0124] In some embodiments, R E2 is H. In some embodiments, R E2 is halogen (e.g., F, Cl, Br, or I). E2 At least one instance of R is optionally substituted alkyl (e.g., Me, or Et). E2 At least one instance of R is optionally substituted alkenyl (e.g., optionally substituted vinyl). E2 is optionally substituted alkynyl. E2 At least one of R is a substituted or unsubstituted carbocyclyl (e.g., a substituted or unsubstituted 3- to 7-membered, monocyclic carbocyclyl containing zero, one, or two double bonds in the carbocyclic ring system). E2is a substituted or unsubstituted heterocyclyl (e.g., a substituted or unsubstituted 3- to 7-membered, monocyclic heterocyclyl containing zero, one, or two double bonds in the heterocyclic ring system, where one, two, or three atoms in the heterocyclic ring system are independently nitrogen, oxygen, or sulfur). E2 At least one of R is substituted or unsubstituted aryl (e.g., substituted or unsubstituted 6- to 10-membered aryl). E If at least one of 2 is substituted or unsubstituted phenyl. In some embodiments, R E2 is a substituted or unsubstituted heteroaryl (e.g., a substituted or unsubstituted 5-6 membered, monocyclic heteroaryl, where 1, 2, 3, or 4 atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur). E2 In some embodiments, at least one of R E2 If at least one of the following is true, -CH2OR EE However, here R EE is independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. E2 If at least one of the following occurs, -CH2N(R EF )2 or N(R EF )2, where R EF is independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, and optionally wherein two R EF The groups may be joined to form an optionally substituted heterocyclic ring. E2 If at least one of the following occurs, -CH2SR EE or -SREE (e.g., —CHSMe or —SMe). In some embodiments, R E2 -OR if at least one of EE (For example, -OMe). In some embodiments, R E2 If at least one of the following is true, -Si(R EG )3, where R EG is independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl (e.g., -Si(Me)). In certain embodiments, R E3 is H. In some embodiments, R E3 is halogen (e.g., F, Cl, Br, or I). E3 At least one instance of R is optionally substituted alkyl (e.g., Me, or Et). E3 At least one instance of R is optionally substituted alkenyl (e.g., optionally substituted vinyl). E3 is optionally substituted alkynyl. E3 At least one of R is a substituted or unsubstituted carbocyclyl (e.g., a substituted or unsubstituted 3- to 7-membered, monocyclic carbocyclyl containing zero, one, or two double bonds in the carbocyclic ring system). E3 is a substituted or unsubstituted heterocyclyl (e.g., a substituted or unsubstituted 3- to 7-membered, monocyclic heterocyclyl containing zero, one, or two double bonds in the heterocyclic ring system, where one, two, or three atoms in the heterocyclic ring system are independently nitrogen, oxygen, or sulfur). E3 At least one of R is substituted or unsubstituted aryl (e.g., substituted or unsubstituted 6- to 10-membered aryl). E3is substituted or unsubstituted phenyl. E3 is a substituted or unsubstituted heteroaryl (e.g., a substituted or unsubstituted 5-6 membered, monocyclic heteroaryl, where 1, 2, 3, or 4 atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur). E3 In some embodiments, at least one of R E3 If at least one of the following is true, -CH2OR EE However, here R EE is independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. E3 If at least one of the following occurs, -CH2N(R EF )2 or -N(R EF )2, where R EF is independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, and optionally wherein two R EF The groups may be joined to form an optionally substituted heterocyclic ring. E3 If at least one of the following occurs, -CH2SR EE or -SR EE (e.g., —CHSMe or —SMe). In some embodiments, R E3 -OR if at least one of EE (For example, -OMe). In some embodiments, R E3 If at least one of the following is true, -Si(R EG )3, where R EGis independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl (e.g., -Si(Me)). In certain embodiments, R E1 and R E3 are joined to form an optionally substituted carbocyclic ring (e.g., a substituted or unsubstituted 3- to 7-membered monocyclic carbocyclyl containing zero, one, or two double bonds in the carbocyclic ring system). E1 and R E3 are joined to form an optionally substituted heterocyclic ring (e.g., a substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl containing zero, one, or two double bonds in the heterocyclic ring system, where one, two, or three atoms in the heterocyclic ring system are independently nitrogen, oxygen, or sulfur). E2 and R E3 are joined to form an optionally substituted carbocyclic ring (e.g., a substituted or unsubstituted 3- to 7-membered monocyclic carbocyclyl containing zero, one, or two double bonds in the carbocyclic ring system). E2 and R E3 are joined to form an optionally substituted heterocyclic ring (e.g., a substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl containing zero, one, or two double bonds in the heterocyclic ring system, where one, two, or three atoms in the heterocyclic ring system are independently nitrogen, oxygen, or sulfur). E1 and R E2 are joined to form an optionally substituted carbocyclic ring (e.g., a substituted or unsubstituted 3- to 7-membered monocyclic carbocyclyl containing zero, one, or two double bonds in the carbocyclic ring system). E1 and R E2are joined to form an optionally substituted heterocyclic ring (e.g., a substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl containing zero, one, or two double bonds in the heterocyclic ring system, where one, two, or three atoms in the heterocyclic ring system are independently nitrogen, oxygen, or sulfur). E4 is a leaving group (e.g., a halogen or a sulfonate ester, e.g., —O(tosylate) or —O(mesylate)). In some embodiments, R E5 is a halogen (e.g., F, Cl, Br, or I). In some embodiments, R E6 is H. In some embodiments, R E6 is a substituted or unsubstituted C 1~6 alkyl (e.g., Me, —CF, Bn, Et, perfluoroethyl, Pr, perfluoropropyl, Bu, or perfluorobutyl). E6 is a nitrogen protecting group (e.g., Bn, Boc, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, or Ts). In some embodiments, at least one instance of Y is O. In some embodiments, at least one instance of Y is S. In some embodiments, at least one instance of Y is NR E7 However, here R E7 is hydrogen, substituted or unsubstituted C 1~6 In some embodiments, a is an alkyl, or a nitrogen protecting group (e.g., NMe). In some embodiments, a is 1. In some embodiments, a is 2. In some embodiments, at least one instance of z is 0. In some embodiments, at least one instance of z is 1. In some embodiments, at least one instance of z is 2. In some embodiments, at least one instance of z is 3. In some embodiments, at least one instance of z is 4. In some embodiments, at least one instance of z is 5. In some embodiments, at least one instance of z is 6.
[0125] In some embodiments, the compound of formula (I) has the formula: [ka] [ka] [ka] [ka] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof.
[0126] In some embodiments, the compound of formula (I) has the formula: [ka] [ka] [ka] [ka] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof.
[0127] In some embodiments, the compound of formula (I) has the formula: [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof.
[0128] In some embodiments, the compound represented by formula (I') or (I) is the compound provided in any one of the examples below. In some embodiments, the compound represented by formula (I') or (I) is the compound provided in example 2 below.
[0129] In some embodiments, the compound of Formula (I) is the compound provided in any one of the Examples below. In some embodiments, the compound of Formula (I) is the compound provided in Example 2 below.
[0130] In certain embodiments, the compounds described herein are compounds represented by formula (I') or (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof. In certain embodiments, the compounds described herein are compounds represented by formula (I') or (I), or a pharmaceutically acceptable salt thereof.
[0131] Certain compounds described herein bind to, covalently modulate, and / or inhibit protein kinases. In certain embodiments, compounds described herein irreversibly inhibit protein kinases. In certain embodiments, compounds described herein reversibly inhibit protein kinases. In certain embodiments, the protein kinase is a CDK. In certain embodiments, the protein kinase is a TAIRE family kinase. In certain embodiments, the protein kinase is CDK14. In certain embodiments, the protein kinase is CDK15. In certain embodiments, the protein kinase is CDK16. In certain embodiments, the protein kinase is CDK17. In certain embodiments, the protein kinase is CDK18. In certain embodiments, compounds described herein covalently bind to a protein kinase (e.g., a CDK (e.g., CDK14)). In certain embodiments, compounds described herein reversibly bind to a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)). In some embodiments, the compounds described herein irreversibly bind to a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)). In some embodiments, the compounds described herein modulate the activity of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)). In some embodiments, the compounds described herein inhibit the activity of a protein kinase (e.g., a TAIRE family kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)). In some embodiments, the compounds described herein reversibly inhibit the activity of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)).
[0132] The binding affinity of the compounds described herein to a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) can be determined using a method known in the art (e.g., isothermal titration calorimetry (ITC)) to determine the dissociation constant (K d In some embodiments, the K d The value is about 100 μM or less, about 10 μM or less, about 1 μM or less, about 100 nM or less, about 10 nM or less, or about 1 nM or less.
[0133] In some embodiments, the activity of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) is inhibited by a compound described herein. The inhibition of the activity of a protein kinase (e.g., a TAIRE family kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) by a compound described herein is measured by measuring the half maximal inhibitory concentration (IC) of the compound when the compound or a pharmaceutical composition thereof is contacted with a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)). 50 ) may be measured by determining the IC 50 The IC values may be obtained using methods known in the art (e.g., by competitive binding assays). In some embodiments, the IC values of the compounds described herein are 50 The value is about 1 mM or less, about 100 μM or less, about 10 μM or less, about 1 μM or less, about 100 nM or less, about 10 nM or less, or about 1 nM or less.
[0134] The compounds described herein may selectively modulate the activity of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)). In some embodiments, the compounds selectively increase the activity of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)). In some embodiments, the compounds selectively inhibit the activity of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)). In some embodiments, the compounds inhibit the activity of two or more protein kinases (e.g., CDKs (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) to the same extent. In some embodiments, the compound increases the activity of two or more protein kinases (eg, CDKs (eg, CDK14, CDK15, CDK16, CDK17, CDK18)) to the same extent.
[0135] The selectivity of a compound described herein in inhibiting the activity of a first protein kinase (e.g., a CDK) over a second protein kinase is measured by the IC 50 The IC value of the compound in inhibiting the activity of a second protein kinase (e.g., a CDK) 50 The selectivity of a compound described herein in inhibiting the activity of a first protein kinase (e.g., a CDK) over a second protein kinase may also be measured by the quotient of the K d K of the adduct of the compound and the second protein kinase d In certain embodiments, the selectivity is at least about 1-fold, at least about 3-fold, at least about 10-fold, at least about 30-fold, at least about 100-fold, at least about 300-fold, at least about 1,000-fold, at least about 3,000-fold, at least about 10,000-fold, at least about 30,000-fold, or at least about 100,000-fold.
[0136] It is expected that the compounds described herein may be useful for treating and / or preventing diseases associated with abnormal activity (e.g., increased activity, unwanted activity, abnormal activity) of protein kinases (e.g., CDKs (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)). Protein kinases are known in the art to be involved in a wide range of diseases and conditions, such as proliferative diseases, metabolic disorders, autoimmune diseases, neurological diseases, and male reproduction. Accordingly, the compounds described herein are expected to be useful for treating and / or preventing diseases (e.g., proliferative diseases, metabolic disorders, autoimmune diseases, and neurological diseases). The compounds described herein are also expected to be useful for male contraception in subjects (e.g., human males) in need thereof.
[0137] Pharmaceutical Compositions, Kits, and Administration The present disclosure also provides pharmaceutical compositions comprising a compound described herein and, optionally, a pharmaceutically acceptable excipient. In some embodiments, the compound described herein is a compound represented by Formula (I') or (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0138] In some embodiments, the compound described herein is provided in an effective amount in a pharmaceutical composition. In some embodiments, the effective amount is a therapeutically effective amount. In some embodiments, the effective amount is a prophylactically effective amount. In some embodiments, the therapeutically effective amount is an amount effective to inhibit abnormal activity of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)). In some embodiments, the therapeutically effective amount is an amount effective to treat a disease (e.g., a disease associated with abnormal activity of a CDK (e.g., a proliferative disease, a metabolic disorder, an autoimmune disease, or a neurological disease)). In some embodiments, the therapeutically effective amount is an amount effective to inhibit the abnormal activity of a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18) and to treat a disease (e.g., a disease associated with the abnormal activity of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18) (e.g., a proliferative disease, a metabolic disorder, an autoimmune disease, or a neurological disease)). In some embodiments, the therapeutically effective amount is an amount effective to induce apoptosis of a cell (e.g., a cell in vivo or in vitro). In some embodiments, the prophylactically effective amount is an amount effective to inhibit the abnormal activity of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)). In some embodiments, a prophylactically effective amount is an amount effective to prevent or maintain in a subject in need thereof a disease (e.g., a disease associated with abnormal activity of a CDK (e.g., a proliferative disease, metabolic disorder, autoimmune disease, or neurological disease)) in remission). In some embodiments, a prophylactically effective amount is an amount effective to inhibit abnormal activity of a CDK and to prevent or maintain in a subject in need thereof a disease (e.g., a disease associated with abnormal activity of a CDK (e.g., a proliferative disease, metabolic disorder, autoimmune disease, or neurological disease)) in remission).
[0139] In some embodiments, an effective amount is an amount effective to inhibit the activity of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98%. In some embodiments, an effective amount is an amount effective to inhibit the activity of a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) by 10% or less, 20% or less, 30% or less, 40% or less, 50% or less, 60% or less, 70% or less, 80% or less, 90% or less, 95% or less, or 98% or less.
[0140] In some embodiments, the subject is an animal. The animal may be of either sex and at any stage of development. In some embodiments, the subject described herein is a human. In some embodiments, the subject is a non-human animal. In some embodiments, the subject is a mammal. In some embodiments, the subject is a non-human mammal. In some embodiments, the subject is a domesticated animal, such as a dog, cat, cow, pig, horse, sheep, or goat. In some embodiments, the subject is a companion animal, such as a dog or cat. In some embodiments, the subject is a livestock animal, such as a cow, pig, horse, sheep, or goat. In some embodiments, the subject is a zoo animal. In other embodiments, the subject is a research animal, such as a rodent (e.g., mouse, rat), dog, pig, or non-human primate animal. In some embodiments, the animal is a genetically engineered animal. In some embodiments, the subject is a transgenic animal (e.g., transgenic mouse and transgenic pig). In some embodiments, the subject is a fish or reptile.
[0141] In some embodiments, the cells contacted with the compounds or compositions described herein are in vitro. In some embodiments, the cells contacted with the compounds or compositions described herein are in vivo.
[0142] The pharmaceutical compositions described herein can be prepared by any method known in the art of pharmacology. In general, such methods of preparation include bringing into association a compound described herein (i.e., the "active ingredient") with the carrier or excipient, and / or one or more other accessory ingredients, and then, if necessary and / or desired, shaping and / or packaging the product into a desired single-dose or multi-dose unit.
[0143] Pharmaceutical compositions can be prepared, packaged, and / or sold in bulk, as a single unit dose, and / or as a plurality of single unit doses. A "unit dose" is a discrete amount of pharmaceutical composition containing a predetermined amount of an active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient that would be administered to a subject, and / or a convenient fraction of such a dosage, such as one-half or one-third of such a dosage.
[0144] The relative amounts of the active ingredient, pharmaceutically acceptable excipient, and / or any additional ingredients in the pharmaceutical compositions described herein may vary depending on the identity, size, and / or condition of the subject being treated, and further depending on the route by which the composition is to be administered. The compositions may contain between 0.1% and 100% (w / w) of the active ingredient.
[0145] Pharmaceutically acceptable excipients used in the preparation of the provided pharmaceutical compositions include inert diluents, dispersing and / or granulating agents, surfactants and / or emulsifying agents, disintegrating agents, binders, preservatives, buffers, lubricants, and / or oils. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening agents, flavoring agents, and perfuming agents may also be present in the compositions.
[0146] Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate, lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, corn starch, powdered sugar, and mixtures thereof.
[0147] Exemplary granulating and / or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clay, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose, and wood products, natural sponge, cation exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethylcellulose, cross-linked sodium carboxymethylcellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water-insoluble starch, calcium carboxymethylcellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, and mixtures thereof.
[0148] Exemplary surfactants and / or emulsifiers include natural emulsifiers (e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g., bentonite (aluminum silicate) and Veegum (magnesium aluminum silicate)), long-chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g., carboxypolymethylene, polyacrylic acid, acrylic acid polymers, and carboxyvinyl polymers), carrageenan, cellulose derivatives (e.g., sodium carboxymethylcellulose, powdered cellulose, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose), Sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monolaurate (Tween® 20), polyoxyethylene sorbitan (Tween® 60), polyoxyethylene sorbitan monooleate (Tween® 80), sorbitan monopalmitate (Span® 40), sorbitan monostearate (Span® 60), sorbitan tristearate (Span® 65), glyceryl monooleate, sorbitan monooleate (Span® 80)), Polyoxyethylene esters (e.g., polyoxyethylene monostearate (Myrj® 45), polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and Solutol®), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g., Cremophor®), polyoxyethylene ethers (e.g., polyoxyethylene lauryl ether (Brij® 30)), poly(vinylpyrrolidone), diethylene glycol monolaurate,Triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic® F-68, Poloxamer® P-188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, and / or mixtures thereof.
[0149] Exemplary binders include starches (e.g., corn starch and starch paste), gelatin, sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.), natural and synthetic gums (e.g., acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, isapol husk mucilage, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinylpyrrolidone), magnesium aluminum silicate (Veegum®), and larch arabogalactan), alginates, polyethylene oxide, polyethylene glycol, inorganic calcium salts, silicic acid, polymethacrylates, waxes, water, alcohol, and / or mixtures thereof.
[0150] Exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, antiprotozoan preservatives, alcohol preservatives, acidic preservatives, and other preservatives. In some embodiments, the preservative is an antioxidant. In other embodiments, the preservative is a chelating agent.
[0151] Exemplary antioxidants include alpha tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.
[0152] Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and its salts and hydrates (e.g., edetate sodium, edetate disodium, edetate trisodium, edetate calcium disodium, edetate dipotassium, etc.), citric acid and its salts and hydrates (e.g., citric acid monohydrate), fumaric acid and its salts and hydrates, malate and its salts and hydrates, phosphoric acid and its salts and hydrates, and tartaric acid and its salts and hydrates. Exemplary antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
[0153] Exemplary antifungal preservatives include butylparaben, methylparaben, ethylparaben, propylparaben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
[0154] Exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.
[0155] Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.
[0156] Other preservatives include tocopherol, tocopheryl acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant® Plus, Phenonip®, methylparaben, Germall® 115, Germaben® II, Neolone®, Kathon®, and Euxyl®.
[0157] Exemplary buffers include citrate buffer, acetate buffer, phosphate buffer, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, and mixtures thereof.
[0158] Exemplary lubricants include magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behenate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and mixtures thereof.
[0159] Exemplary natural oils include almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, chamomile, canola, caraway, carnauba, castor oil, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cottonseed, emu, eucalyptus, evening primrose, fish, linseed, geraniol, loofah, grape seed, hazelnut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, and lemon. Exemplary synthetic oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and mixtures thereof.
[0160] Liquid dosage forms for oral and parenteral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.In addition to active ingredients, liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl acetate carbonate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (such as cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof.In addition to inert diluents, oral compositions may contain adjuvants such as wetting agents, emulsifiers and suspending agents, sweeteners, flavorings and perfumes. In certain embodiments for parenteral administration, the conjugates described herein are mixed with a solubilizing agent such as Cremophor®, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and mixtures thereof.
[0161] Injectable preparations, for example, sterile injectable aqueous or oily suspensions can be formulated according to known techniques using suitable dispersing or wetting agents and suspending agents.Sterile injectable preparations can be sterile injectable solutions, suspensions, or emulsions in non-toxic parenterally acceptable diluents or solvents, such as solutions in 1,3-butanediol.Among acceptable vehicles and solvents, water, Ringer's solution (USP), and isotonic sodium chloride solution can be used.In addition, sterile fixed oils are conventionally used as solvents or suspending media.For this purpose, any non-irritating fixed oil, including synthetic mono- or diglycerides, can be used.In addition, fatty acids such as oleic acid are used in injectable preparations.
[0162] Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[0163] In order to prolong the effect of a drug, it is often desirable to delay the absorption of the drug from subcutaneous or intramuscular injection. This can be achieved by using a liquid suspension of crystalline or amorphous material with low water solubility. The absorption rate of the drug depends on its dissolution rate at that time, which in turn depends on the crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form can be achieved by dissolving or suspending the drug in an oil vehicle.
[0164] Compositions for rectal or vaginal administration are typically suppositories which can be prepared by mixing a conjugate described herein with a suitable non-irritating excipient or carrier such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity to release the active ingredient.
[0165] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active ingredient is mixed with at least one inert, pharmaceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate, and / or (a) a filler or extender, such as starch, lactose, sucrose, glucose, mannitol, and silicic acid; (b) a binder, such as carboxymethylcellulose, alginate, gelatin, polyvinylpyrrolidinone, sucrose, and acacia; (c) a humectant, such as glycerol; (d) a disintegrating agent, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (e) a solution retarding agent, such as paraffin; (f) an absorption accelerator, such as a quaternary ammonium compound; (g) a wetting agent, such as cetyl alcohol and glycerol monostearate. (h) absorbents such as kaolin and bentonite clay, and (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also comprise buffering agents.
[0166] Solid compositions of a similar type may be employed as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols. Solid dosage forms such as tablets, dragees, capsules, pills, and granules may be prepared with coatings and shells, such as enteric coatings and other coatings known in the pharmacological arts. They may optionally contain opacifying agents and may be of a composition that releases the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally in a delayed manner. Examples of encapsulating compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may be employed as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols.
[0167] The active ingredient may be in microencapsulated form with one or more excipients as described above. Solid dosage forms such as tablets, dragees, capsules, pills, and granules may be prepared with coatings and shells, such as enteric coatings, release-controlling coatings, and other coatings known in the pharmaceutical formulation art. In such solid dosage forms, the active ingredient may be admixed with at least one inert diluent, such as sucrose, lactose, or starch. Such solid dosage forms may contain, as is common practice, additional substances other than inert diluents, such as tableting lubricants and other tableting aids (such as magnesium stearate and microcrystalline cellulose). In the case of capsules, tablets, and pills, the dosage forms may also contain buffering agents. They may optionally contain opacifying agents and may be of a composition that releases the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally in a delayed manner. Examples of encapsulating compositions that can be used include polymeric substances and waxes.
[0168] Dosage forms for topical and / or transdermal administration of the compounds described herein may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and / or patches. Generally, the active ingredient is mixed under sterile conditions with a pharmaceutically acceptable carrier or excipient, and / or any necessary preservatives and / or buffers as needed. In addition, the present disclosure contemplates the use of transdermal patches, which often have the additional advantage of providing controlled delivery of the active ingredient to the body. Such dosage forms can be prepared, for example, by dissolving and / or dispensing the active ingredient in a suitable medium. Alternatively or additionally, the rate can be controlled by either providing a rate-controlling membrane and / or dispersing the active ingredient in a polymer matrix and / or gel.
[0169] Devices suitable for use in delivering the intradermal pharmaceutical compositions described herein include short needle devices. Intradermal compositions can be administered by devices that limit the effective penetration depth of the needle into the skin. Alternatively or additionally, a conventional syringe can be used in the classic Mantoux method of intradermal administration. Jet injection devices that deliver liquid vaccines to the dermis via a liquid jet source and / or via a needle that generates a jet that penetrates the stratum corneum and reaches the dermis are suitable. Ballistic powder / particle delivery devices that use compressed gas to accelerate a powdered compound through the outer layers of the skin into the dermis are suitable.
[0170] Formulations suitable for topical administration include, but are not limited to, liquid and / or semi-liquid preparations such as liniments, lotions, oil-in-water and / or water-in-oil emulsions such as creams, ointments, and / or pastes, and / or solutions and / or suspensions. Topically administrable formulations may contain, for example, from about 1% to about 10% (w / w) active ingredient, although the concentration of the active ingredient may be increased up to the solubility limit of the active ingredient in the solvent. Formulations for topical administration may further include one or more additional ingredients as described herein.
[0171] The pharmaceutical compositions described herein may be prepared, packaged, and / or sold in a formulation suitable for pulmonary administration via the oral cavity. Such formulations may comprise dry particles containing the active ingredient and having a diameter ranging from about 0.5 to about 7 nanometers, or from about 1 to about 6 nanometers. Such compositions are conveniently in the form of a dry powder for administration using a device containing a dry powder reservoir (into which a continuous stream of propellant can be introduced to disperse the powder) and / or using a self-propelling solvent / powder dispensing container (such as a device containing the active ingredient dissolved and / or suspended in a low-boiling propellant in a sealed container). Such powders comprise particles in which at least 98% of the particles by weight have a diameter greater than 0.5 nanometers and at least 95% of the particles by number have a diameter less than 7 nanometers. Alternatively, at least 95% of the particles by weight have a diameter greater than 1 nanometer and at least 90% of the particles by number have a diameter less than 6 nanometers. Dry powder compositions may include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form.
[0172] Low-boiling propellants generally include liquid propellants having a boiling point below 65°F at atmospheric pressure. Generally, the propellant may comprise 50-99.9% (w / w) of the composition, and the active ingredient may comprise 0.1-20% (w / w) of the composition. The propellant may further comprise additional ingredients, such as liquid nonionic and / or solid anionic surfactants, and / or solid diluents (which may have particle sizes similar to those of the particles containing the active ingredient).
[0173] Pharmaceutical compositions described herein formulated for pulmonary delivery may provide the active ingredient in the form of droplets of a solution and / or suspension. Such formulations may be prepared, packaged, and / or sold as aqueous and / or dilute alcoholic solutions and / or suspensions containing the active ingredient, optionally sterilized, and may be conveniently administered using either a nebulizer and / or atomizer device. Such formulations may further contain one or more additional ingredients, including, but not limited to, flavoring agents such as saccharin sodium, volatile oils, buffers, surfactants, and / or preservatives such as methylhydroxybenzoate. The droplets provided by this route of administration may have an average diameter ranging from about 0.1 to about 200 nanometers.
[0174] The formulations described herein as being useful for pulmonary delivery are also useful for intranasal delivery of the pharmaceutical compositions described herein. Another formulation suitable for intranasal administration is a coarse powder containing the active ingredient and having an average particle size of about 0.2 micrometers to 500 micrometers. Such formulations are administered by rapid inhalation through the nasal passages from a container of powder held close to the nostrils.
[0175] Formulations for nasal administration may contain, for example, as little as about 0.1% (w / w) to as much as 100% (w / w) of the active ingredient, and may include one or more additional ingredients described herein. The pharmaceutical compositions described herein may be prepared, packaged, and / or sold in formulations for buccal administration. Such formulations may be in the form of, for example, tablets and / or lozenges made using conventional methods and may contain, for example, 0.1-20% (w / w) of the active ingredient, the remainder comprising an orally dissolvable and / or disintegrable composition, and optionally one or more additional ingredients described herein. Alternatively, formulations for buccal administration may comprise a powder and / or an aerosolized and / or atomized solution and / or suspension comprising the active ingredient. Such powdered, aerosolized, and / or aerosolized formulations, when dispersed, may have an average particle and / or droplet size ranging from about 0.1 to about 200 nanometers, and may further comprise one or more additional ingredients described herein.
[0176] The pharmaceutical compositions described herein may be prepared, packaged, and / or sold in a formulation for administration to the eye. Such formulations may be in the form of, for example, eye drops, including, for example, a 0.1 / 1.0% (w / w) solution and / or suspension of the active ingredient in an aqueous or oily liquid carrier or excipient. Such drops may further include buffering agents, salts, and / or one or more other of the additional ingredients described herein. Other useful ophthalmically administrable formulations include those comprising the active ingredient in microcrystalline form and / or in a liposomal preparation. Ear drops and / or eye drops are also contemplated as being within the scope of the present disclosure.
[0177] Although the description of pharmaceutical compositions provided herein is primarily directed to pharmaceutical compositions suitable for administration to humans, it will be understood by those skilled in the art that such compositions are generally suitable for administration to any and all animals. The modification of pharmaceutical compositions suitable for administration to humans to make them suitable for administration to a variety of animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and / or perform such modifications using routine experimentation.
[0178] The compound provided herein is typically formulated in dosage unit form for ease of administration and dosage uniformity.However, it will be understood that the total daily use amount of compositions described herein will be determined by physician within the scope of sound medical judgment.The specific therapeutically effective dose level for any specific subject or organism will depend on a variety of factors, including the severity of the disease and disorder being treated; the activity of the specific active ingredient being used; the specific composition being used; the age, weight, general health, sex and dietary habits of subject; the time of administration, route of administration and the excretion rate of the specific active ingredient being used; the duration of treatment; the drug that is used in combination with or at the same time as the specific active ingredient being used; and similar factors well known in the medical field.
[0179] The compounds and compositions provided herein can be administered by any route, including enteral (e.g., oral), parenteral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, subcutaneous, intracerebroventricular, transdermal, intradermal, rectal, vaginal, intraperitoneal, topical (such as by powder, ointment, cream, and / or drops), mucosal, nasal, buccal, sublingual; by intratracheal instillation, bronchial instillation, and / or inhalation; and / or oral spray, nasal spray, and / or aerosol.Specifically contemplated routes are oral administration, intravenous administration (e.g., systemic intravenous injection), local administration via blood and / or lymphatic supply, and / or direct administration to the affected area.In general, the most appropriate route of administration will depend on various factors, including the properties of the agent (e.g., its stability in the gastrointestinal environment) and / or the condition of the subject (e.g., whether the subject can tolerate oral administration). In certain embodiments, the compounds or pharmaceutical compositions described herein are suitable for topical administration to the eye of a subject.
[0180] The exact amount of compound required to achieve an effective dose will vary from subject to subject, depending, for example, on the subject's species, age, and general condition, the severity of side effects or disorders, the identity of the particular compound(s), the mode of administration, etc. An effective amount may be contained in a single dose (e.g., a single oral dose) or multiple doses (e.g., multiple oral doses). In some embodiments, when multiple doses are administered to a subject or applied to a biological sample, tissue, or cell, any two doses of the multiple doses contain different or substantially the same amounts of a compound described herein. In some embodiments, when multiple doses are administered to a subject or applied to a biological sample, tissue, or cell, the frequency with which the multiple doses are administered to a subject or applied to a biological sample, tissue, or cell is 3 doses per day, 2 doses per day, 1 dose per day, 1 dose every other day, 1 dose every 3 days, 1 dose every week, 1 dose every other week, 1 dose every 3 weeks, or 1 dose every 4 weeks. In some embodiments, the frequency of administering multiple doses to a subject or applying multiple doses to a biological sample, tissue, or cell is one dose per day. In some embodiments, the frequency of administering multiple doses to a subject or applying multiple doses to a biological sample, tissue, or cell is two doses per day. In some embodiments, the frequency of administering multiple doses to a subject or applying multiple doses to a biological sample, tissue, or cell is three doses per day. In some embodiments, when administering multiple doses to a subject or applying multiple doses to a biological sample, tissue, or cell, the period between the first dose and the last dose of the multiple doses is 1 day, 2 days, 4 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 6 months, 9 months, 1 year, 2 years, 3 years, 4 years, 5 years, 7 years, 10 years, 15 years, 20 years, or the lifespan of the subject, tissue, or cell. In some embodiments, the period between the first and last dose of the multiple doses is 3 months, 6 months, or 1 year. In some embodiments, the period between the first and last dose of the multiple doses is the lifespan of the subject, tissue, or cell.In some embodiments, the doses described herein (e.g., either in a single dose or multiple doses) independently comprise between 0.1 μg and 1 μg, inclusive, between 0.001 mg and 0.01 mg, between 0.01 mg and 0.1 mg, between 0.1 mg and 1 mg, between 1 mg and 3 mg, between 3 mg and 10 mg, between 10 mg and 30 mg, between 30 mg and 100 mg, between 100 mg and 300 mg, between 300 mg and 1,000 mg, or between 1 g and 10 g of a compound described herein. In some embodiments, the doses described herein independently comprise between 1 mg and 3 mg, inclusive, of a compound described herein. In some embodiments, the doses described herein independently comprise between 3 mg and 10 mg, inclusive, of a compound described herein. In some embodiments, the doses described herein independently comprise between 10 mg and 30 mg, inclusive, of a compound described herein. In some embodiments, the doses described herein independently encompass between 30 mg and 100 mg, inclusive, of a compound described herein.
[0181] The dosage ranges described herein provide guidelines for administering provided pharmaceutical compositions to adults.For example, the amount to be administered to children or adolescents can be determined by a doctor or person skilled in the art, and can be less than or the same as that administered to adults.In some embodiments, the dosages described herein are for adults with a body weight of 70 kg.
[0182] The compound or composition can be administered in combination with one or more additional pharmaceutical agents (e.g., therapeutically and / or prophylactically active agents) as described herein.The compound or composition can be administered in combination with an additional pharmaceutical agent that improves its activity (e.g., activity (e.g., efficacy and / or effectiveness) in treating a disease in a subject in need thereof, in preventing a disease in a subject in need thereof, and / or in inhibiting the activity of a protein kinase (e.g., CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) in a subject, biological sample, tissue, or cell), improves bioavailability, improves safety, reduces drug resistance, reduces and / or alters metabolism, inhibits excretion, and / or alters distribution in a subject, biological sample, tissue, or cell.It will also be understood that the treatment employed can achieve the desired effect for the same disorder, and / or it can achieve different effects. In certain embodiments, pharmaceutical compositions described herein that include a compound described herein and an additional pharmaceutical agent exhibit a synergistic effect that is not present in pharmaceutical compositions that include either the compound or the additional pharmaceutical agent, but not both.
[0183] The compound or composition may be administered simultaneously with, prior to, or subsequent to one or more additional pharmaceutical agents, which may be useful, for example, as a combination therapy. Pharmaceutical agents include therapeutically active agents. Pharmaceutical agents also include prophylactically active agents. Pharmaceutical agents include small organic molecules such as drug compounds (e.g., compounds approved for human or veterinary use by the U.S. Food and Drug Administration as provided in the U.S. Code of Federal Regulations (CFR)), peptides, proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides or proteins, small molecules linked to proteins, glycoproteins, steroids, nucleic acids, DNA, RNA, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, lipids, hormones, vitamins, and cells. In some embodiments, the additional pharmaceutical agent is a pharmaceutical agent useful for the treatment and / or prevention of a disease (e.g., a proliferative disease, a metabolic disorder, an autoimmune disease, or a neurological disease). Each additional pharmaceutical agent may be administered at a dose and / or on a schedule determined for that pharmaceutical. The additional pharmaceutical agents may also be administered together with each other and / or with the compounds or compositions described herein in a single dose, or may be administered separately in different doses. The specific combination employed in the regimen will take into consideration the compatibility of the compounds described herein with the additional pharmaceutical agent(s) and / or the desired therapeutic and / or prophylactic effect to be achieved. In general, it is expected that the additional pharmaceutical agent(s) in the combination will be utilized at levels that do not exceed the levels utilized individually. In some embodiments, the levels utilized in the combination will be lower than the levels utilized individually.
[0184] Additional pharmaceutical agents include, but are not limited to, antiproliferative agents, anticancer agents, antiangiogenic agents, anti-inflammatory agents, immunosuppressants, antibacterial agents, antiviral agents, cardiovascular agents, cholesterol-lowering agents, antidiabetic agents, antiallergic agents, contraceptives, analgesics, and combinations thereof. In some embodiments, the additional pharmaceutical agent is an antiproliferative agent (e.g., an anticancer agent). In some embodiments, the additional pharmaceutical agent is an anti-leukemia agent. In some embodiments, the additional pharmaceutical agent is ABITREXATE (methotrexate), ADE, adriamycin RDF (doxorubicin hydrochloride), ambochlorin (chlorambucil), ARRANON (nelarabine), ARZERRA (ofatumumab), BOSULIF (bosutinib), BUSULFEX (busulfan), CAMPATH (alemtuzumab), CERUBIDINE (daunorubicin hydrochloride), CLAFEN (cyclophosphamide), CLOFAREX (clofarabine), CLOLAR (clofarabine), CVP, CYTOSAR-U (cytarabine), CYTOXAN (cyclophosphamide), ERWINAZE (Erwinia chrysanthemi asparaginase), FLUDARA (fludarabine phosphate), FOLEX (methotrexate), FOLEX (anticoagulant). PFS (methotrexate), GAZYVA (obinutuzumab), GLEEVEC (imatinib mesylate), Hyper-CVAD, ICLUSIG (ponatinib hydrochloride), IMBRUVICA (ibrutinib), LEUKERAN (chlorambucil), LINFOLIZIN (chlorambucil), MARQIBO (vincristine sulfate liposome), METHOTREXATE LPF (methotrexate), MEXATE (methotrexate), MEXATE-AQ (methotrexate), mitoxantrone hydrochloride, MUSTARGEN (mechlorethamine hydrochloride), MYLERAN (busulfan), NEOSAR (cyclophosphamide), ONCASPAR (peguaspargase), PURINETHOL (mercaptopurine), PURIXAN (mercaptopurine), rubidomycin (daunorubicin hydrochloride), SPRYCEL (dasatinib), SYNRIBO (omacetaxin mepesuxinate), TARABINEPFS (cytarabine), TASIGNA (nilotinib), TREANDA (bendamustine hydrochloride), TRISENOX (arsenic trioxide), VINCASAR PFS (vincristine sulfate), ZYDELIG (idelalisib), or a combination thereof. In some embodiments, the additional pharmaceutical agent is an anti-lymphoma agent. In some embodiments, the additional pharmaceutical agent is ABITREXATE (methotrexate), ABVD, ABVE, ABVE-PC, ADCETRIS (brentuximab vedotin), ADRIAMYCIN PFS (doxorubicin hydrochloride), ADRIAMYCIN RDF (doxorubicin hydrochloride), AMBOCHLORIN (chlorambucil), AMBOCLORIN (chlorambucil), ARRANON (nelarabine), BEACOPP, BECENUM (carmustine), BELEODAQ (belinostat), BEXXAR (tositumomab and iodine I-131 tositumomab), BICNU (carmustine), BLENOXANE (bleomycin), CARMUBRIS (carmustine), CHOP, CLAFEN (cyclophosphamide), COPP, COPP-ABV, CVP, CYTOXAN (cyclophosphamide), DEPOCYT (liposomal cytarabine), DTIC-DOME (dacarbazine), EPOCH, FOLEX (methotrexate), FOLEX PFS (methotrexate), FOLOTYN (pralatrexate), HYPER-CVAD, ICE, IMBRUVICA (ibrutinib), INTRON (recombinant interferon alfa-2b), ISTODAX (romidepsin), LEUKERAN (chlorambucil), LINFOLIZIN (chlorambucil), lomustine, MATULANE (procarbazine hydrochloride), METHOTREXATE LPF (methotrexate), MEXATE (methotrexate), MEXATE-AQ (methotrexate), MOPP, MOZOBIL (plelixafor), MUSTARGEN (mechlorethamine hydrochloride), NEOSAR (cyclophosphamide), OEPA, ONTAK (denileukin diftitox), OPPA, R-CHOP, REVLIMID (lenalidomide), RITUXAN (rituximab), STANFORDV, TREANDA (bendamustine hydrochloride), VAMP, VELBAN (vinblastine sulfate), VELCADE (bortezomib), VELSAR (vinblastine sulfate), VINCASAR PFS (vincristine sulfate), ZEVALIN (ibritumomab tiuxetan), ZOLINZA (vorinostat), ZYDELIG (idelalisib), or a combination thereof. In some embodiments, the additional pharmaceutical agent is REVLIMID (lenalidomide), DACOGEN (decitabine), VIDAZA (azacitidine), CYTOSAR-U (cytarabine), IDAMYCIN (idarubicin), CERUBIDINE (daunorubicin), LEUKERAN (chlorambucil), NEOSAR (cyclophosphamide), FLUDARA (fludarabine), LEUSTATIN (cladribine), or a combination thereof. In some embodiments, the additional pharmaceutical agent is ABITREXATE (methotrexate), ABRAXANE (paclitaxel albumin-stabilized nanoparticle formulation), AC, AC-T, ADE, ADRIAMYCIN PFS (doxorubicin hydrochloride), ADRUCIL (fluorouracil), AFINITOR (everolimus), AFINITORDISPERZ (everolimus), ALDARA (imiquimod), ALIMTA (pemetrexed disodium), AREDIA (pamidronate disodium), ARIMIDEX (anastrozole), AROMASIN (exemestane), AVASTIN (bevacizumab), BECENUM (carmustine), BEP, BICNU (carmustine), BLENOXANE (bleomycin), CAF, CAMPTOSAR (irinotecan hydrochloride), CAPOX, CAPRELSA (vandetanib), CARBOPLATIN-TAXOL, CARMUBRIS (carmustine), CA SODEX (bicalutamide), CEENU (lomustine), CERUBIDINE (daunorubicin hydrochloride), CERVARIX (recombinant HPV bivalent vaccine), CLAFEN (cyclophosphamide), CMF, COMETRIQ (cabozantinib-s-malate), COSMEGEN (dactinomycin), CYFOS (ifosfamide), CYRAMZA (ramucirumab), CYTOSAR-U (cytarabine), CYTOXAN (cyclophosphamide), DACOGEN (decitabine), DEGARELIX, DOXIL (doxorubicin hydrochloride liposomal), DOXORUBICIN HYDROCHLORIDE, DOX-SL (doxorubicin hydrochloride liposome), DTIC-DOME (dacarbazine), EFUDEX (fluorouracil), ELLENCE (epirubicin hydrochloride), ELOXATIN (oxaliplatin), ERBITUX (cetuximab), ERIVEDGE (vismodegib), ETOPOPHOS (etoposide phosphate), EVACET (doxorubicin hydrochloride liposome), FARESTON (toremifene), FASLODEX (fulvestrant), FEC, FEMARA (letrozole), FLUOROPLEX (fluorouracil), FOLEX (methotrexate), FOLEXPFS (methotrexate), FOLFIRI, FOLFIRI-BEVACIZUMAB, FOLFIRI-CETUXIMAB, FOLFIRINOX, FOLFOX, FU-LV, GARDASIL (recombinant human papillomavirus (HPV) quadrivalent vaccine), GEMCITABINE-CISPLATIN, GEMCITABINE-OXALIPLATIN, GEMZAR (gemcitabine hydrochloride), GILOTRIF (afatinib dimaleate), GLEEVEC (imatinib mesylate), GLIADEL (carmustine implant), GLIADEL WAFER (Carmustine Implant), HERCEPTIN (Trastuzumab), HYCAMTIN (Topotecan Hydrochloride), IFEX (Ifosfamide), IFOSFAMIDUM (Ifosfamide), INLYTA (Axitinib), INTRON (Recombinant Interferon Alfa-2b), IRESSA (Gefitinib), IXEMPRA (Ixabepilone), JAKAFI (Ruxolitinib), JEVTANA (Cabazitaxel), KADCYLA (Ado-trastuzumab emtansine), KEYTRUDA (Pembrolizumab), KYPROLIS (Carfilzomib), LIPODOX (Doxorubicin Hydrochloride Liposome), LUPRON (Leuprolide Acetate), LUPRON DEPOT (Leuprolide Acetate), LUPRON DEPOT-3 MONTH (leuprolide acetate), LUPRON DEPOT-4 MONTH (leuprolide acetate), LUPRON DEPOT-PED (leuprolide acetate), MEGACE (megestrol acetate), MEKINIST (trametinib), METHAZOLASTONE (temozolomide), METHOTREXATE LPF (methotrexate), MEXATE (methotrexate), MEXATE-AQ (methotrexate), MITOXANTRONEHYDROCHLORIDE, MITOZYTREX (mitomycin C), MOZOBIL (plelixafor), MUSTARGEN (mechlorethamine hydrochloride), MUTAMYCIN (mitomycin C), MYLOSAR (azacytidine), NAVELBINE (vinorelbine tartrate), NEOSAR (cyclophosphamide), NEXAVAR (sorafenib tosylate), NOLVADEX (tamoxifen citrate), NOVALDEX (tamoxifen citrate), OFF, PAD, PARAPLAT (carboplatin), PARAPLATIN (carboplatin), PEG-INTRON (peginterferon alfa-2b), PEMETREXED DISODIUM, PERJETA (pertuzumab), PLATINOL (cisplatin), PLATINOL-AQ (cisplatin), POMALYST (pomalidomide), prednisone, PROLEUKIN (aldesleukin), PROLIA (denosumab), PROVENGE (sipuleucel-t), REVLIMID (lenalidomide), RUBIDOMYCIN (daunorubicin hydrochloride), SPRYCEL (dasatinib), STIVARGA (regorafenib), SUTENT (sunitinib malate), SYLATRON (peginterferon alfa-2b), SYLVANT (siltuximab), SYNOVIR (thalidomide), TAC, TAFINLAR (dabrafenib), TARABINE PFS (cytarabine), TARCEVA (erlotinib hydrochloride), TASIGNA (nilotinib), TAXOL (paclitaxel), TAXOTERE (docetaxel), TEMODAR (temozolomide), THALOMID (thalidomide), TOPOSAR (etoposide), TORISEL (temsirolimus), TPF, TRISENOX (arsenic trioxide), TYKERB (lapatinib ditosylate), VECTIBIX (panitumumab), VEIP, VELBAN (vinblastine sulfate), VELCADE (bortezomib), VELSAR (vinblastine sulfate), VEPESID (etoposide), VIADUR (leuprolide acetate), VIDAZA (azacitidine), VINCASARPFS (vincristine sulfate), VOTRIENT (pazopanib hydrochloride), WELLCOVORIN (leucovorin calcium), XALKORI (crizotinib), XELODA (capecitabine), XELOX, XGEVA (denosumab), XOFIGO (radium-223 dichloride), XTANDI (enzalutamide), YERVOY (ipilimumab), ZALTRAP (ziv-aflibercept), ZELBORAF (vemurafenib), ZOLADEX (goserelin acetate), ZOMETA (zoledronic acid), ZYKADIA (ceritinib), ZYTIGA (abiraterone acetate), ENMD-2076, PCI-32765, AC220, dovitinib lactate (TKI258, CHIR-258), BIBW 2992 (TOVOK (trademark)), SGX523, PF-04217903, PF-02341066, PF-299804, BMS-777607, ABT-869, MP470, BIBF 1120 (VARGATEF®), AP24534, JNJ-26483327, MGCD265, DCC-2036, BMS-690154, CEP-11981, tivozanib (AV-951), OSI-930, MM-121, XL-184, XL-647, and / or XL228), proteasome inhibitors (e.g., bortezomib (Velcade)), mTOR inhibitors (e.g., rapamycin, temsirolimus (CCI-779), everolimus (RAD-001), ridaforolimus, AP23573 (Ariad), AZD8055 (AstraZeneca), BEZ235 (Novartis), BGT226 (Norvartis), XL765 (SanofiAventis), PF-4691502 (Pfizer), GDC0980 (Genetech), SF1126 (Semafoe), and OSI-027 (OSI), oblimersen, gemcitabine, carminomycin, leucovorin, pemetrexed, cyclophosphamide, dacarbazine, procarbazine, prednisolone, dexamethasone, camptothecin, plicamycin, asparaginase, aminopterin, methopterin, porfiromycin, melphalan, leurocidin, leurosine, chlorambucil, trabectedin, procarbazine, discodermolide, carminomycin, aminopterin, and hexamethylmelamine, or a combination thereof. In some embodiments, the additional pharmaceutical agent is ibrutinib. In some embodiments, the additional pharmaceutical agent is a protein kinase inhibitor (e.g., a tyrosine protein kinase inhibitor). In some embodiments, the additional pharmaceutical agent is a binder or inhibitor of a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18). In some embodiments, the additional pharmaceutical agent is a binder or inhibitor of a CDK. In some embodiments, the additional pharmaceutical agent is a binder or inhibitor of CDK14. In some embodiments, the additional pharmaceutical agent is a binder or inhibitor of CDK15. In some embodiments, the additional pharmaceutical agent is a binder or inhibitor of CDK16. In some embodiments, the additional pharmaceutical agent is a binder or inhibitor of CDK17. In some embodiments, the additional pharmaceutical agent is a binder or inhibitor of CDK18. In some embodiments, the additional pharmaceutical agent is a binder or inhibitor of PFTAIRE1. In some embodiments, the additional pharmaceutical agent is a binder or inhibitor of Bruton's tyrosine kinase (BTK). In some embodiments, the additional pharmaceutical agent is an epigenetic or transcriptional modulator (e.g., a DNA methyltransferase inhibitor, a histone deacetylase inhibitor (HDAC inhibitor), a lysine methyltransferase inhibitor), an antimitotic drug (e.g., a taxane and a vinca alkaloid), a hormone The compound or pharmaceutical composition described herein may be selected from the group consisting of receptor modulators (e.g., estrogen receptor modulators and androgen receptor modulators), cell signaling pathway inhibitors (e.g., tyrosine protein kinase inhibitors), modulators of protein stability (e.g., proteasome inhibitors), Hsp90 inhibitors, glucocorticoids, all-trans retinoic acid, and other agents that promote differentiation. In some embodiments, the compound or pharmaceutical composition described herein may be administered in combination with anti-cancer treatments, including, but not limited to, surgery, radiation therapy, transplantation (e.g., stem cell transplantation, bone marrow transplantation), immunotherapy, and chemotherapy.
[0185] Also encompassed by the present disclosure are kits (e.g., pharmaceutical packs). The provided kits may include a pharmaceutical composition or compound described herein and a container (e.g., a vial, ampoule, bottle, syringe, and / or dispenser package, or other suitable container). In some embodiments, the provided kits optionally further include a second container containing a pharmaceutical excipient for diluting or suspending the pharmaceutical composition or compound described herein. In some embodiments, the pharmaceutical composition or compound described herein provided in the first container and the second container are combined to form a single unit dosage form.
[0186] Thus, in one aspect, provided is a kit comprising a first container containing a compound or pharmaceutical composition described herein. In some embodiments, the kit is useful for treating a disease (e.g., a proliferative disease, a metabolic disorder, an autoimmune disease, or a neurological disease) in a subject in need thereof. In some embodiments, the kit is useful for preventing a disease (e.g., a proliferative disease, a metabolic disorder, an autoimmune disease, or a neurological disease) in a subject in need thereof. In some embodiments, the kit is useful for inhibiting the activity (e.g., abnormal or unwanted activity, such as increased activity) of a protein kinase (e.g., a CDK) in a subject, biological sample, tissue, or cell. In some embodiments, the kit is useful for inducing apoptosis in a cell (e.g., a cell in vivo or in vitro).
[0187] In some embodiments, the kits described herein further include instructions for using the compound or pharmaceutical composition included in the kit. The kits described herein may also include information from regulatory authorities, such as the U.S. Food and Drug Administration (FDA), if necessary. In some embodiments, the information included in the kit is prescribing information. In some embodiments, the kit and instructions provide for treating a disease (e.g., a proliferative disease, a metabolic disorder, an autoimmune disease, or a neurological disease) in a subject in need thereof. In some embodiments, the kit and instructions provide for preventing a disease (e.g., a proliferative disease, a metabolic disorder, an autoimmune disease, or a neurological disease) in a subject in need thereof. In some embodiments, the kit and instructions provide for modulating (e.g., inhibiting) the activity (e.g., abnormal activity, such as increased activity) of a protein kinase (e.g., a CDK) in a subject, biological sample, tissue, or cell. In some embodiments, the kit and instructions provide for inducing apoptosis in a cell. The kits described herein may also include one or more additional pharmaceutical agents described herein as separate compositions.
[0188] Treatment Methods and Uses The present disclosure provides methods for modulating (e.g., inhibiting or increasing) the activity (e.g., abnormal activity, such as increased or decreased activity) of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)). The present disclosure provides methods for modulating (e.g., inhibiting or increasing) the activity (e.g., abnormal activity, such as increased or decreased activity) of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) in a subject, biological sample, or cell. The present disclosure also provides methods for treating a wide range of diseases, such as diseases associated with abnormal activity (e.g., increased activity) of a protein kinase, e.g., proliferative diseases, metabolic disorders, autoimmune diseases, and neurological diseases, in a subject in need thereof. The present disclosure provides methods for the treatment and / or prevention of proliferative diseases (e.g., cancer (e.g., carcinoma); lung cancer, breast cancer, liver cancer, pancreatic cancer, gastric cancer, ovarian cancer, colon cancer, colorectal cancer)), metabolic disorders (e.g., diabetes), autoimmune diseases, or neurological diseases (e.g., Alzheimer's disease, gliosis, spinal cord injury). The present disclosure provides methods for male contraception (e.g., reducing or inhibiting spermatogenesis in fertile, healthy male subjects, inducing azoospermia, oligozoospermia, and / or asthenozoospermia; reducing male fertility rates in fertile, healthy male subjects).
[0189] The present disclosure also provides a compound of Formula (I') or (I), or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or prodrug, or composition thereof, for use in treating a disease, such as a proliferative disease, a metabolic disorder, an autoimmune disease, or a neurological disease, in a subject in need thereof.
[0190] The present disclosure also provides the use of a compound of Formula (I') or (I), or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or prodrug, or composition thereof, in the manufacture of a medicament for the treatment of a disease, such as a proliferative disease, a metabolic disorder, an autoimmune disease, or a neurological disease, in a subject in need thereof.
[0191] In another aspect, the present disclosure provides methods of modulating the activity of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) in a subject, biological sample, or cell. In some embodiments, provided are methods of inhibiting the activity of a protein kinase in a subject. In some embodiments, provided are methods of inhibiting the activity of a protein kinase in a cell. In some embodiments, provided are methods of increasing the activity of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) in a subject. The compounds described herein may exhibit kinase inhibitory activity; the ability to inhibit TAIRE family kinases; the ability to inhibit CDKs; the ability to inhibit CDK14 without inhibiting another kinase (e.g., a CDK); the ability to inhibit CDK15 without inhibiting another kinase (e.g., a CDK); the ability to inhibit CDK16 without inhibiting another kinase (e.g., a CDK); the ability to inhibit CDK17 without inhibiting another kinase (e.g., a CDK); the ability to inhibit CDK18 without inhibiting another kinase (e.g., a CDK); the ability to inhibit PFTAIRE1 without inhibiting another kinase (e.g., another CDK); therapeutic and / or prophylactic effects in the treatment of cancer; therapeutic and / or prophylactic effects in the treatment of proliferative diseases, metabolic disorders, autoimmune diseases, or neurological diseases; and / or a therapeutic profile (e.g., optimal safety and curative effect) that is superior to current chemotherapeutic agents or agents for treating metabolic disorders, autoimmune diseases, or neurological diseases.
[0192] In one embodiment, provided is a method of reducing the activity of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) in a subject or biological sample (e.g., a cell, a tissue) by at least about 1%, at least about 3%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% using a method described herein. In some embodiments, the activity of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) in a subject or cell is reduced by at least about 1%, at least about 3%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% by the methods described herein. In some embodiments, the activity of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) in a subject or cell is selectively inhibited by the method. In some embodiments, the activity of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) in a subject or cell is selectively reduced by the method.
[0193] While not wishing to be bound by any particular theory, the compounds described herein are capable of binding to (e.g., covalently modifying) the protein kinase to be inhibited. In certain embodiments, the compounds described herein are capable of binding to (e.g., covalently modifying) the protein kinase. In certain embodiments, the compounds described herein are capable of covalently binding to a cysteine residue of a protein kinase. In certain embodiments, the compounds are capable of covalently binding to C218 of CDK14. In certain embodiments, the compounds are capable of covalently binding to CDK14. In certain embodiments, the compounds are capable of covalently modifying CDK14 (e.g., C218 of CDK14). In certain embodiments, the compounds are capable of covalently modifying C218 of CDK14. In certain embodiments, the compounds are capable of covalently modifying CDK14. In certain embodiments, the compounds are capable of covalently modifying CDK15. In certain embodiments, the compounds are capable of covalently modifying CDK16. In certain embodiments, the compounds are capable of covalently modifying CDK17. In certain embodiments, the compounds are capable of covalently modifying CDK18. In some embodiments, the compound is capable of non-covalently inhibiting CDK15. In some embodiments, the compound is capable of non-covalently inhibiting CDK16. In some embodiments, the compound is capable of non-covalently inhibiting CDK17. In some embodiments, the compound is capable of non-covalently inhibiting CDK18.
[0194] In another aspect, the present disclosure provides a method for inhibiting the activity of a protein kinase in a subject, the method comprising administering to the subject an effective amount (e.g., a therapeutically effective amount) of a compound as described herein or a pharmaceutical composition thereof. In another aspect, the present disclosure provides a method for inhibiting the activity of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) in a biological sample, the method comprising contacting the biological sample with an effective amount of a compound as described herein or a pharmaceutical composition thereof. In another aspect, the present disclosure provides a method for inhibiting the activity of a protein kinase in a tissue or cell, the method comprising contacting the tissue or cell with an effective amount of a compound as described herein or a pharmaceutical composition thereof.
[0195] In another aspect, the present disclosure provides a method for inhibiting the activity of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) in a cell, the method comprising contacting the cell with an effective amount of a compound as described herein or a pharmaceutical composition thereof.
[0196] In some embodiments, the subject to be treated is a mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a human male. In some embodiments, the subject is a fertile human male. In some embodiments, the subject is a domestic animal such as a dog, cat, cow, pig, horse, sheep, or goat. In some embodiments, the subject is a companion animal such as a dog or cat. In some embodiments, the subject is a livestock animal such as a cow, pig, horse, sheep, or goat. In some embodiments, the subject is a zoo animal. In other embodiments, the subject is a research animal such as a rodent, dog, or non-human primate. In some embodiments, the subject is a non-human transgenic animal such as a transgenic mouse or a transgenic pig.
[0197] In some embodiments, the biological sample that is contacted with compound or composition is breast tissue, bone marrow, lymph node, lymphatic tissue, spleen, or blood.In some embodiments, the biological sample that is contacted with compound or composition is tumor or cancerous tissue.In some embodiments, the biological sample that is contacted with compound or composition is serum, cerebrospinal fluid, interstitial fluid, mucus, tears, sweat, pus, biopsy tissue (for example, obtained by surgical biopsy or needle biopsy), nipple aspirate, milk, vaginal fluid, saliva, swab (such as oral swab), or any material that contains biomolecules from the first biological sample.
[0198] In some embodiments, the cell or tissue contacted with the compound or composition is present in vitro. In some embodiments, the cell or tissue contacted with the compound or composition is present in vivo. In some embodiments, the cell or tissue contacted with the compound or composition is present ex vivo. In some embodiments, the cell or tissue contacted with the compound or composition is a malignant cell (e.g., a malignant blood cell). In some embodiments, the cell contacted with the compound or composition is a malignant hematopoietic stem cell (e.g., a malignant myeloid cell or a malignant lymphoid cell). In some embodiments, the cell contacted with the compound or composition is a malignant lymphocyte (e.g., a malignant T cell or a malignant B cell). In some embodiments, the cell contacted with the compound or composition is a malignant leukocyte. In some embodiments, the cell contacted with the compound or composition is a malignant neutrophil, a malignant macrophage, or a malignant plasma cell. In some embodiments, the cell contacted with the compound or composition is a cancer cell. In some embodiments, the cell contacted with the compound or composition is a breast cancer cell. In some embodiments, the cells contacted with the compound or composition are sarcoma cells. In some embodiments, the cells contacted with the compound or composition are sarcoma cells from breast tissue.
[0199] The disease (e.g., a proliferative disease) to be treated or prevented using the compounds described herein may be associated with increased activity of a kinase such as a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18). The disease (e.g., a proliferative disease) to be treated or prevented using the compounds described herein may be associated with overexpression of a kinase such as a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18).
[0200] In certain embodiments, the disease (e.g., a proliferative disease, metabolic disorder, autoimmune disease, or neurological disease) to be treated or prevented using the compounds described herein may be associated with overexpression of a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18). The disease (e.g., a proliferative disease, metabolic disorder, autoimmune disease, or neurological disease) may be associated with abnormal activity of a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18). The abnormal activity of a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18) may be elevated activity and / or inappropriate or undesirable activity of the CDK. The compounds described herein, and their pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof, may inhibit the activity of CDKs (e.g., CDK14, CDK15, CDK16, CDK17, CDK18) and may be useful for treating and / or preventing diseases (e.g., proliferative diseases, metabolic disorders, autoimmune diseases, or neurological diseases). The compounds described herein, and their pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof, may inhibit the activity of CDKs and may be useful for treating and / or preventing diseases (e.g., proliferative diseases, metabolic disorders, autoimmune diseases, or neurological diseases). The compounds described herein, and their pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions, may inhibit the activity of CDKs and may be useful for treating and / or preventing diseases (e.g., proliferative diseases, metabolic disorders, autoimmune diseases, or neurological diseases).
[0201] All types of biological samples described herein or known in the art are contemplated as being within the scope of the present invention. In some embodiments, the disease to be treated or prevented using the compounds described herein (e.g., a proliferative disease, metabolic disorder, autoimmune disease, or neurological disease) is cancer. All types of cancer disclosed herein or known in the art are contemplated as being within the scope of the present invention. In some embodiments, the proliferative disease is a hematological malignancy. In some embodiments, the proliferative disease is a blood cancer. In some embodiments, the proliferative disease is a hematological malignancy. In some embodiments, the proliferative disease is leukemia. In some embodiments, the proliferative disease is chronic lymphocytic leukemia (CLL). In some embodiments, the proliferative disease is acute lymphoblastic leukemia (ALL). In some embodiments, the proliferative disease is T-cell acute lymphoblastic leukemia (T-ALL). In some embodiments, the proliferative disease is chronic myeloid leukemia (CML). In some embodiments, the proliferative disease is acute myeloid leukemia (AML). In some embodiments, the proliferative disease is acute monocytic leukemia (AMoL). In some embodiments, the proliferative disease is Waldenstrom's macroglobulinemia. In some embodiments, the proliferative disease is Waldenstrom's macroglobulinemia associated with the MYD88 L265P somatic mutation. In some embodiments, the proliferative disease is myelodysplastic syndrome (MDS). In some embodiments, the proliferative disease is cancer. In some embodiments, the proliferative disease is lymphoma. In some embodiments, the proliferative disease is T-cell lymphoma. In some embodiments, the proliferative disease is Burkitt's lymphoma. In some embodiments, the proliferative disease is Hodgkin's lymphoma. In some embodiments, the proliferative disease is non-Hodgkin's lymphoma. In some embodiments, the proliferative disease is multiple myeloma. In some embodiments, the proliferative disease is melanoma. In some embodiments, the proliferative disease is colorectal cancer. In some embodiments, the proliferative disease is colon cancer. In some embodiments, the proliferative disease is breast cancer. In some embodiments, the proliferative disease is recurring breast cancer.In some embodiments, the proliferative disease is mutant breast cancer. In some embodiments, the proliferative disease is HER2+ breast cancer. In some embodiments, the proliferative disease is HER2- breast cancer. In some embodiments, the proliferative disease is triple-negative breast cancer (TNBC). In some embodiments, the proliferative disease is bone cancer. In some embodiments, the proliferative disease is osteosarcoma. In some embodiments, the proliferative disease is Ewing's sarcoma. In some embodiments, the proliferative disease is brain cancer. In some embodiments, the proliferative disease is neuroblastoma. In some embodiments, the proliferative disease is lung cancer. In some embodiments, the proliferative disease is small cell lung cancer (SCLC). In some embodiments, the proliferative disease is non-small cell lung cancer. In some embodiments, the proliferative disease is liver cancer. In some embodiments, the proliferative disease is pancreatic cancer. In some embodiments, the proliferative disease is gastric cancer. In some embodiments, the proliferative disease is ovarian cancer. In some embodiments, the proliferative disease is ovarian cancer. In some embodiments, the proliferative disease is a benign neoplasm. All types of benign neoplasms disclosed herein or known in the art are contemplated as being within the scope of the present invention. In some embodiments, the proliferative disease is associated with angiogenesis. All types of angiogenesis disclosed herein or known in the art are contemplated as being within the scope of the present invention.
[0202] In some embodiments, the metabolic disorder to be treated or prevented using the compounds described herein is diabetes (e.g., type I diabetes, type II diabetes, gestational diabetes). In some embodiments, the metabolic disorder is hyperglycemia. In some embodiments, the metabolic disorder is hyperinsulinemia. In some embodiments, the metabolic disorder is insulin resistance. In some embodiments, the metabolic disorder is obesity. In some embodiments, the neurological disease to be treated or prevented using the compounds described herein is Alzheimer's disease. In some embodiments, the neurological disease is gliosis. In some embodiments, the neurological disease is spinal cord injury. In some embodiments, the neurological disease is Parkinson's disease. In some embodiments, the neurological disease is amyotrophic lateral sclerosis.
[0203] Another aspect of the present disclosure relates to a method of male contraception in a subject (e.g., a fertile male human) in need thereof using a compound described herein. In some embodiments, the method comprises administering a compound or a salt thereof in an amount sufficient to reduce sperm count and / or reduce sperm motility. In some embodiments, the method comprises administering a compound or a salt thereof in an amount sufficient to induce azoospermia, oligozoospermia, and / or asthenozoospermia. One aspect of the present disclosure relates to a method of reducing male fertility in a fertile, healthy male subject in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound described herein. One aspect of the present disclosure relates to a method of inducing apoptosis in cells in a biological sample or in a subject, the method comprising administering to the biological sample or subject a therapeutically effective amount of a compound described herein.
[0204] Another aspect of the present disclosure relates to methods for inhibiting the activity of a kinase in a biological sample, tissue, cell, or subject. In some embodiments, the kinase is a CDK. In some embodiments, the CDK is a TAIRE family kinase. In some embodiments, the kinase is CDK14. In some embodiments, the kinase is CDKCDK15. In some embodiments, the kinase is CDK16. In some embodiments, the kinase is CDK17. In some embodiments, the kinase is CDK18. In some embodiments, the kinase is PFTAIRE1. In some embodiments, the activity of the kinase is abnormal activity of the kinase. In some embodiments, the activity of the kinase is increased activity of the kinase. In some embodiments, the inhibition of the activity of the kinase is irreversible. In other embodiments, the inhibition of the activity of the kinase is reversible. In some embodiments, the method of inhibiting the activity of a kinase comprises attaching a compound described herein to the kinase. In some embodiments, the method comprises covalently inhibiting a CDK (e.g., CDK14). In some embodiments, the method comprises reversibly inhibiting a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18). The present invention provides methods for inhibiting cell growth in a biological sample, tissue, cell, or subject.
[0205] In certain embodiments, the methods described herein include administering to a subject or contacting a biological sample with an effective amount of a compound described herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, or a pharmaceutical composition thereof. In certain embodiments, the methods described herein include administering to a subject or contacting a biological sample with an effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In certain embodiments, the compound is contacted with a biological sample. In certain embodiments, the compound is administered to a subject. In certain embodiments, the compound is administered in combination with one or more additional pharmaceutical agents described herein. The additional pharmaceutical agent may be an antiproliferative agent. In certain embodiments, the additional pharmaceutical agent is an anti-cancer agent. The additional pharmaceutical agent may also be a kinase inhibitor. In certain embodiments, the additional pharmaceutical agent is an inhibitor of a CDK. In certain embodiments, the additional pharmaceutical agent is an inhibitor of a TAIRE family kinase. In certain embodiments, the additional pharmaceutical agent is an inhibitor of CDK14. In some embodiments, the additional pharmaceutical agent is an inhibitor of CDK15. In some embodiments, the additional pharmaceutical agent is an inhibitor of CDK16. In some embodiments, the additional pharmaceutical agent is an inhibitor of CDK17. In some embodiments, the additional pharmaceutical agent is an inhibitor of CDK18. In some embodiments, the additional pharmaceutical agent is a selective inhibitor of CDK14. In some embodiments, the additional pharmaceutical agent is a selective inhibitor of CDK15. In some embodiments, the additional pharmaceutical agent is a selective inhibitor of CDK16. In some embodiments, the additional pharmaceutical agent is a selective inhibitor of CDK17. In some embodiments, the additional pharmaceutical agent is a selective inhibitor of CDK18. In some embodiments, the additional pharmaceutical agent is a non-selective inhibitor of CDK14. In some embodiments, the additional pharmaceutical agent is a non-selective inhibitor of CDK15. In some embodiments, the additional pharmaceutical agent is a non-selective inhibitor of CDK16. In certain embodiments, the additional pharmaceutical agent is a non-selective inhibitor of CDK17.In some embodiments, the additional pharmaceutical agent is a non-selective inhibitor of CDK18. In some embodiments, the additional pharmaceutical agent includes an anti-cancer agent (e.g., a chemotherapeutic agent), an anti-inflammatory agent, a steroid, an immunosuppressant, a radiotherapeutic agent, or other agent. In some embodiments, the additional pharmaceutical agent is an anti-proliferative agent. In some embodiments, the additional pharmaceutical agent is an inhibitor of a kinase. In some embodiments, the additional pharmaceutical agent is a non-selective inhibitor of a kinase. In some embodiments, the additional pharmaceutical agent is an immunotherapeutic agent (e.g., a PD1 inhibitor, a PDL1 inhibitor). In some embodiments, the additional pharmaceutical agent is an immune checkpoint inhibitor.
[0206] In some embodiments, the additional pharmaceutical agent is a topoisomerase inhibitor, an MCL1 inhibitor, a BCL-2 inhibitor, a BCL-xL inhibitor, a BRD4 inhibitor, a BRCA1 inhibitor, a BRCA2 inhibitor, a HER1 inhibitor, a HER2 inhibitor, a CDK9 inhibitor, a Jumonji histone demethylase inhibitor, or a DNA damage inducer. In some embodiments, the additional pharmaceutical agent is etoposide, obatoclax, navitoclax, JQ1, 4-(((5'-chloro-2'-(((1R,4R)-4-(((R)-1-methoxypropan-2-yl)amino)cyclohexyl)amino)-[2,4'-bipyridin]-6-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile, JIB04, or cisplatin. Exemplary chemotherapeutic agents include alkylating agents such as nitrogen mustards, ethyleneimines, methylmelamines, alkyl sulfonates, nitrosoureas, and triazenes; antimetabolites such as folic acid analogs, pyrimidine analogs, especially fluorouracil and cytosine arabinoside, and purine analogs; natural products such as vinca alkaloids, epipodophyllotoxins, antibiotics, enzymes, and biological response modifiers; and miscellaneous products such as platinum coordination complexes, anthracenediones, substituted ureas such as hydroxyurea, methylhydrazine derivatives, and adrenocorticoid inhibitors. Exemplary chemotherapeutic agents also include anthracycline antibiotics, actinomycin D, plicamycin, puromycin, gramicidin D, paclitaxel, colchicine, cytochalasin B, emetine, maytansine, amsacrine, cisplatin, carboplatin, mitomycin, altretamine, cyclophosphamide, lomustine, and carmustine. In certain embodiments, the pharmaceutical compositions described herein further comprise a combination of additional pharmaceutical agents described herein.
[0207] A compound or composition of the invention may synergistically enhance the inhibition of CDK induced by an additional pharmaceutical agent(s) in a biological sample or subject. Thus, a combination of a compound or composition of the invention with an additional pharmaceutical agent(s) may be useful for treating a proliferative disease that is resistant to treatment with the additional pharmaceutical agent(s) without a compound or composition of the invention.
[0208] In some embodiments, the activity of a protein kinase is non-selectively inhibited by a compound or pharmaceutical composition described herein. In some embodiments, the activity of the inhibited protein kinase is selectively inhibited by a compound or pharmaceutical composition described herein compared to the activity of a protein (e.g., a different protein kinase). In certain embodiments, the activity of a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18) is selectively inhibited by a compound or pharmaceutical composition described herein compared to the activity of a different protein. In certain embodiments, the activity of CDK14 is selectively inhibited by a compound or pharmaceutical composition described herein compared to the activity of another CDK (e.g., CDK15, CDK16, CDK17, or CDK18). In certain embodiments, the activity of CDK14 is selectively inhibited by a compound or pharmaceutical composition described herein compared to the activity of another CDK (e.g., CDK16).
[0209] The selectivity of a compound or pharmaceutical composition described herein in inhibiting the activity of a protein kinase over a different protein (e.g., a different protein kinase) can be measured by the IC of the compound or pharmaceutical composition in inhibiting the activity of the protein kinase. 50 IC of the compound or pharmaceutical composition in inhibiting the activity of different proteins, 50 The selectivity of a compound or pharmaceutical composition described herein in inhibiting a protein kinase over a different protein may also be measured by the quotient of the K of the adduct of the compound or pharmaceutical composition and the protein kinase. dK of the adduct between the compound or pharmaceutical composition and the different protein d The selectivity may also be measured by the quotient of the values. In some embodiments, the selectivity is at least 2-fold, at least 3-fold, at least 5-fold, at least 10-fold, at least 30-fold, at least 100-fold, at least 300-fold, at least 1,000-fold, at least 3,000-fold, at least 10,000-fold, at least 30,000-fold, or at least 100,000-fold. In some embodiments, the selectivity is 100,000-fold or less, 10,000-fold or less, 1,000-fold or less, 100-fold or less, 10-fold or less, or 2-fold or less. Combinations of the above-referenced ranges (e.g., at least 2-fold and 10,000-fold or less) are also within the scope of the present disclosure.
[0210] In some embodiments, the kits described herein include a first container containing a compound or pharmaceutical composition described herein. In some embodiments, the kits described herein are useful for treating and / or preventing diseases such as proliferative diseases (e.g., cancer (e.g., carcinoma); lung cancer, breast cancer, liver cancer, pancreatic cancer, gastric cancer, ovarian cancer, colon cancer, colorectal cancer)), metabolic disorders (e.g., diabetes), autoimmune diseases, or neurological diseases (e.g., Alzheimer's disease, gliosis, spinal cord injury); for treating and / or preventing metabolic disorders (e.g., diabetes), autoimmune diseases, neurological diseases (e.g., Alzheimer's disease, gliosis, spinal cord injury) in a subject in need thereof, for inhibiting the activity of protein kinases (e.g., CDKs (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) in a subject, biological sample, tissue, or cell, and / or for inducing apoptosis in cells.
[0211] In some embodiments, the kits described herein further include instructions for using the compound or pharmaceutical composition included in the kit. The kits described herein may also include information from regulatory authorities, such as the U.S. Food and Drug Administration (FDA), if desired. In some embodiments, the information included in the kit is prescribing information. In some embodiments, the kit and instructions provide for treating a proliferative disease in a subject in need thereof; preventing a disease, such as a proliferative disease, metabolic disorder, autoimmune disease, or neurological disease, in a subject in need thereof; inhibiting the activity of a protein kinase (e.g., a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18)) in a subject, biological sample, tissue, or cell; and / or inducing apoptosis in a cell. The kits described herein may also include one or more additional pharmaceutical agents described herein as separate compositions.
[0212] example In order that this disclosure may be more fully understood, the following examples are set forth: The synthetic and biological examples described in this application are offered to illustrate the compounds, pharmaceutical compositions, and methods provided herein, and are not to be construed as in any way limiting the scope thereof.
[0213] Example 1. Cdk14 Biology assay. Pull-down / Cellular Pull-down Protocol HEK293 cells overexpressing Cdk14-flag fusion proteins were treated with candidate compounds for 4 hours. Cells were washed with PBS, harvested, and lysed with protease and phosphatase inhibitors (Roche) in Pierce IP buffer. The lysate was clarified by centrifugation and then incubated with 1 μM biotin-FMF-03-198 (or 1 μM biotin-ATP mimetic) overnight at 4°C. To enhance pull-down, the lysate was incubated for another 2 hours at room temperature. The lysate was then incubated with streptavidin agarose (Thermo Scientific, cat. #20349) for 2 hours at 4°C. The beads were then washed three times with Pierce IP buffer and then boiled in 2×LDS + 10% β-mercaptoethanol at 95°C for 5 minutes. The proteins of interest bound by the biotinylated compounds were then assessed using Western blotting. The results of dose-dependent CDK14 inhibition by exemplary compounds in the cellular pull-down assay are provided in Figure 4B. The results of the cellular pull-down protocol are provided below in Tables 1 and 2A, 2B, 2C, and 2D (columns titled "CDK2 pull-down," "CDK9 pull-down," "Blocked CDK12 pull-down," "Blocked CDK14 pull-down," and "Cellular potency pull-down").
[0214] To wash out the pull-down, 4 hours after compound treatment, cells were washed with 1x PBS and 1x medium (DMEM + 10% FBS + 1% Penn / Strep), then replaced with fresh medium. Cells were incubated at 37°C and 5% CO2. Cells were harvested at the indicated times from lysis and subsequent wash-out for pull-down as described above. The results are shown in Figure 3C.
[0215] Antiproliferation assay protocol HCT116 cells were seeded at 750 cells / well in 50 ul fresh media (McCoy's 5A + 10% FBS + 1% Penn / Strep) in 384-well plates and treated with 0.1 μl of candidate compounds in 4-fold serial dilutions using a Janus pinner. Cells were incubated with compounds for 72 hours at 37°C in 5% CO2. The antiproliferative effects of these compounds were assessed 72 hours after compound addition using Cell Titer Glo (Promega cat# G7571) by luminescence measurement using an Envision plate reader as described in the product instructions. All proliferation assays were performed in biological quadruplicate. IC 50 Values were determined using non-linear regression curve fitting in GraphPad Prism 6. The results of the assay are shown below in Tables 1 and 2A, 2B, 2C and 2D under the column "HCT116 IC 50 "Provided to: Table 1. IC for example compounds 50 Assay [Table 1]
[0216] In vitro kinase assay The Lanthascreen Eu kinase binding assay was performed for Cdk14 / CycY, much as performed in the commercial assay service by Life Technologies, but included a 30-minute pre-incubation step of the candidate compound with the kinase to facilitate covalent bond formation. The results of the assay are shown in Table 1 above and in Tables 2A, 2B, 2C, and 2D below under the column "CDK14 IC 50 " will be provided to
[0217] The Lanthascreen Eu kinase binding assay was performed at Life Technologies for CDK16 / CycY. The results of the assay are shown in Table 1 above and Tables 2A, 2B, 2C and 2D below in the column "CDK2 IC 50 " and CDK16 IC 50 " will be provided to Z'LYTE kinase assays were performed at Life Technologies using the Km ATP concentration for CDK2 / CycA. 33 P kinase assays were performed by Reaction Biology Corp. The results of the assays are shown below in Tables 2A, 2B, 2C and 2D, in the column "IC 50 CDK14 33 P kinase assay.
[0218] Kinativ Live Cell Profiling Protocol HCT116 cells were seeded in 15cm plates in fresh medium (McCoy's 5A + 10% FBS + 1% Penn / Strep) and treated with candidate compounds for 4 hours. For the washout condition, compound-containing medium was removed from the cells, and the cells were washed with 1x PBS and 1x medium before being replaced with fresh medium. The cells were incubated for another 2 hours after washing. To harvest the cells, the plates were washed with 1x cold PBS and then collected by scraping and centrifugation. The cell pellets were immediately frozen in liquid nitrogen.
[0219] The remainder of the Kinativ profiling experiment was performed by ActivX Biosciences (La Jolla, CA) as described below. Cell pellets were lysed by sonication in lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 0.1% Triton X-100, phosphatase inhibitor [Cocktail II AG Scientific #P-1518]). After lysis, samples were clarified by centrifugation and the supernatant was collected for probe labeling. The kinetics of the kinetics of the kinetics of the kinetics of the cell pellet were as previously described. 1 As synthesized, 50 μl of a 10× aqueous solution of desthiobiotin-ATP-acylphosphate probe (ATP probe) was added to each sample to give a final probe concentration of 20 μM, and the samples were incubated with the probe for 10 min.
[0220] As previously described 2Samples were prepared for MS analysis. Briefly, probe-labeled lysates were denatured and reduced (6 M urea, 10 mM DTT, 65°C, 15 min), alkylated (40 mM iodoacetamide, 37°C, 30 min), and gel-filtered (Biorad Econo-Pac 10G) into 10 mM ammonium bicarbonate, 2 M urea, and 5 mM methionine. The desalted protein mixture was digested with trypsin (0.015 mg / ml) at 37°C for 1 h, and desthiobiotinylated peptides were captured using 12.5 μl high-capacity streptavidin resin (Thermo Scientific). The captured peptides were then extensively washed, and the probe-labeled peptides were eluted from the streptavidin beads using two 35 μl washes of a 50% CH3CN / water mixture containing 0.1% TFA at 20–25°C.
[0221] Samples were prepared as previously described. 3 , and analyzed by LC-MS / MS. A custom target list containing 352 unique kinase peptides identified so far during the characterization of various kinase peptides in a data-dependent mode. 3,4 Samples were analyzed on a Thermo LTQ ion trap mass spectrometer coupled with an autosampler Agilent 1100 series micro-HPLC system essentially as described using the method described in. The results are provided in Figures 2B and 3B.
[0222] For signal extraction / quantification, typically up to four ions were selected based on their presence, intensity, and correlation to the reference MS / MS spectrum. The resulting chromatographic peaks from each run were then integrated, and the integrated peak areas were used to determine percent inhibition values compared to the control run. For each quantified peptide, the MS signal of the compound-treated sample was expressed as a fold-change compared to the MS signal of the DMSO-treated control. All data points were visually inspected to ensure that they exhibited variation outside of normal limits. The significance of data points varying more than two-fold was determined according to a Student's t-test using Excel 2010.
[0223] Protein labeling and mass spectrometry
[0224] Recombinant Cdk14 was incubated with a 10-fold molar excess of compound for 2 h at room temperature and then assayed as described. 5 The proteins were analyzed by LC / ESI-MS. For each analysis, 5 μg protein was injected onto a self-packed reverse-phase column (1 / 32'' OD x 500 μm ID, 5 cm of POROS 50R2 resin). After 4 min of desalting, the proteins were eluted with an HPLC gradient (0-100% B in 4 min, A = 0.2 M acetic acid in water, B = 0.2 M acetic acid in acetonitrile, flow rate = 10 μL / min) into an LTQ ion trap mass spectrometer (ThermoFisher). Mass spectra were acquired using MagTran 1.03b2 software. 6To determine modification sites, proteins were reduced with DTT (10 mM final concentration), alkylated with iodoacetamide (22.5 mM final concentration), digested with chymotrypsin (37°C overnight), desalted using SOLA-C18 plates (ThermoFisher Scientific, Madison, WI), and dried by vacuum centrifugation. After reconstitution in 50% acetonitrile, 1% formic acid, and 100 mM ammonium acetate, peptides were analyzed using a ZipChip CE system and a QExactive HF mass spectrometer. 7 Analysis was performed by CE-MS using an autosampler coupled to a ThermoFisher Scientific (San Jose, CA). Peptide solutions were loaded for 30 seconds and run on the HR tip at 500 V / cm for 10 minutes with a background electrolyte of 1% formic acid in 50% acetonitrile. Pressure assist was used, starting at 1 minute. The mass spectrometer was operated in data-dependent mode, and the five most abundant ions in each MS scan (60k resolution, 1E6 target, lock mass enabled) were subjected to MS / MS (15k resolution, 2E5 target, 100 ms maximum injection time). Dynamic exclusion was enabled with a repeat count of 1 and an exclusion time of 6 seconds. MS / MS data were analyzed using mulitplierz scripts. 8,9 The sequences were extracted to .mgf using qPCR and searched against the forward-reverse human NCBI refseq database using Mascot version 2.2. Search parameters specified fixed carbamidomethylation of cysteine and variable oxidation (methionine) and modification (cysteine) of FMF-4-107-2 or FMF-3-198-2. The precursor mass tolerance was set to 10 ppm, and the product ion tolerance was 25 mmu. The results of the assay are provided in Table 1 above, under the column "MS Labeling of CDK14*." Example 2. Exemplary Compounds Table 2A. Exemplary compounds and assay data [Table 2A-1]
Table 2A-2
Table 2A-3
Table 2A-4
Table 2A-5
Table 2A-6
Table 2A-7
Table 2A-8
Table 2A-9
Table 2A-10
Table 2A-11
Table 2A-12
Table 2A-13
Table 2A-14
Table 2A-15
Table 2A-16
Table 2A-17
[0225] Method 1 [ka] tert-Butyl (1-((3-nitrophenyl)sulfonyl)piperidin-4-yl)carbamate tert-Butyl piperidin-4-ylcarbamate (1.0 g, 5.0 mmol), 3-nitrobenzenesulfonyl chloride (1.22 g, 5.5 mmol), and triethylamine (1.1 mL, 7.5 mmol) were stirred in DCM (20 mL) at room temperature ("rt") for 2 h. The reaction mixture was concentrated in vacuo, diluted with saturated aqueous sodium bicarbonate (50 mL), and extracted three times with 100 mL DCM. The organics were combined, dried over sodium sulfate, filtered, and concentrated in vacuo. The product was used without further purification. Off-white solid (1.8 g, 4.7 mmol). MS (ESI) m / z 386 (M+H) + . chemical formula C 16 H 23 Predicted mass from N3O6: 385.44 Da.
[0226] [ka] 1-((3-nitrophenyl)sulfonyl)piperidin-4-amine Intermediate 1 (1.8 g, 4.7 mmol) and TFA (2 mL) were stirred in DCM (20 mL) at rt for 16 h. The reaction mixture was concentrated in vacuo to afford the product as a white solid (1.87 g, 4.7 mmol). 1H NMR(500MHz,DMSO-d6)δ9.09(s,2H),8.56(dd,J=8.2,2.2Hz,1H),8.39(t,J=2.0Hz,1H),8.19(dt,J=7.8,1.2Hz,1H),7.97(t,J=8.0Hz,1H),3.7 2(d,J=9.1Hz,1H),3.61(ddt,J=10.5,6.6,3.9Hz,2H),3.13(dd,J=7.4,4.2Hz,3H),1.98(dd,J=13.5,3.8Hz,2H),1.58(qd,J=11.9,4.2Hz,2H). MS(ESI) m / z 286(M+H) + . chemical formula C 16 H 23 Predicted mass from N3O6: 285.32 Da.
[0227] [ka] Methyl 4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxylate Methyl 4-amino-1H-pyrazole-3-carboxylate (1.0 g, 7.09 mmol) and triethylamine (1.5 mL, 8.5 mmol) were stirred in dioxane (10 mL) at 0° C. A solution of 2,6-dichlorobenzoyl chloride (1.5 g, 7.17 mmol) in THF (5 mL) was added dropwise until the starting material was consumed. The reaction was filtered and the resulting solid was washed with dioxane (3×20 mL). The combined filtrate was used directly in the next reaction.
[0228] MS(ESI) m / z 315(M+H) + . chemical formula C 12 Predicted mass for H9N3O3: 314.12 Da.
[0229] [ka] 4-(2,6-Dichlorobenzamido)-1H-pyrazole-3-carboxylic acid Intermediate 3 in dioxane (15 mL) was added to 2N aq. NaOH (15 mL). The solution was stirred at rt for 6 h. The reaction mixture was concentrated in vacuo and dissolved in water (30 mL). The solution was cooled to 0 °C and concentrated HCl was added dropwise to pH 1. The precipitate was filtered and washed with water (3 × 5 mL). The precipitate was azeotroped with toluene to yield the title compound as a light gray solid (1.58 g, 0.52 mmol). 1 H NMR (500MHz, DMSO-d6) δ9.86 (s, 1H), 8.28 (s, 1H), 7.57-7.44 (m, 5H). MS(ESI) m / z 301(M+H) + . chemical formula C 11 Predicted mass for H7N3O3: 300.10 Da.
[0230] [ka] 4-(2,6-Dichlorobenzamido)-N-(1-((3-nitrophenyl)sulfonyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide Intermediate 2 (144 mg, 0.36 mmol), Intermediate 4 (100 mg, 0.33 mmol), HoBt (60 mg, 0.44 mmol), and EDCI.HCl (80 mg, 0.42 mmol) were dissolved in DMF (2 mL) and stirred at rt for 16 h. The reaction was diluted with saturated aqueous sodium bicarbonate (25 mL) and extracted with EtOAc (3 × 50 mL). The combined organics were dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (50–100% EtOAc in hexanes) to afford the title compound as a yellow solid (150 mg, 0.26 mmol).
[0231] MS(ESI) m / z 568(M+H) + . chemical formula C 22 H 20 Predicted mass from N6O6S: 567.40 Da.
[0232] [ka] N-(1-((3-aminophenyl)sulfonyl)piperidin-4-yl)-4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxamide Intermediate 5 (155 mg, 0.26 mmol), SnCl.2HO (146 mg, 0.65 mmol), and HCl (cat.) were dissolved in EtOAc (4 mL) and MeOH (1 mL). The reaction was stirred at 80 °C for 16 h. The reaction mixture was cooled to rt and quenched with saturated aqueous sodium bicarbonate (5 mL). The reaction was diluted with saturated aqueous sodium bicarbonate (25 mL) and extracted with EtOAc (3 × 50 mL). The combined organics were dried over sodium sulfate, filtered, and concentrated in vacuo to afford the title compound as a yellow powder (122 mg, 0.22 mmol). 1 H NMR(500MHz,DMSO-d6)δ10.13(s,1H),8.43(dd,J=8.2,3.7Hz,1H),8.39-8.31(m,1H),7.59-7.54( m,2H),7.54-7.46(m,2H),7.24(td,J=7.8,3.4Hz,1H),6.92(dt,J=9.1,2.1Hz,1H),6.85-6.77(m, 2H),5.63(d,J=3.1Hz,2H),3.71(dtd,J=11.2,7.5,4.1Hz,1H),3.66-3.54(m,2H),2.67-2.55(m,2 H),2.31(td,J=12.0,2.7Hz,1H),1.80(dd,J=12.9,3.5Hz,2H),1.70(pd,J=12.4,11.1,3.0Hz,2H). MS(ESI) m / z 538(M+H) + . chemical formula C 22 H 22 Predicted mass from N6O4S: 537.42 Da.
[0233] [ka] FMF-03-198-1 N-(1-((3-acrylamidophenyl)sulfonyl)piperidin-4-yl)-4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxamide Intermediate 6 (50 mg, 0.09 mmol) was dissolved in THF (5 mL) along with saturated aqueous sodium bicarbonate (5 mL). The reaction was cooled to 0 °C, and acryloyl chloride (12 mg, 0.14 mmol) in THF (1 mL) was added dropwise until the starting material was consumed. The reaction was diluted with saturated aqueous sodium bicarbonate (25 mL) and extracted with iPrOH:CHCl (1:4, 3 × 50 mL). The combined organics were dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by HPLC to yield the title compound (10 mg, 0.02 mmol) as a white powder. 1 H NMR(500MHz,DMSO-d6)δ13.42(s,1H),10.52(s,1H),10.11(s,1H),8.44(d,J=8.2Hz,1H),8.35(s,1H),8.15 (t,J=2.0Hz,1H),7.94(ddd,J=8.2,2.1,1.0Hz,1H),7.63-7.54(m,3H),7.51(dd,J=9.2,6.9Hz,1H),7.42(dt ,J=8.1,1.2Hz,1H),6.43(dd,J=17.0,10.1Hz,1H),6.31(dd,J=17.0,2.0Hz,1H),5.82(dd,J=10.1,2.0Hz,1 H),3.77-3.67(m,1H),3.62(d,J=11.7Hz,2H),2.41-2.32(m,2H),1.80(d,J=12.7Hz,2H),1.75-1.64(m,2H). MS(ESI) m / z 592(M+H) + . chemical formula C 25 H 24 Predicted mass for Cl2N6O5S: 591.46
[0234] [ka] FMF-03-198-2 (E)-4-(2,6-Dichlorobenzamido)-N-(1-((3-(4-(dimethylamino)but-2-enamido)phenyl)sulfonyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide Intermediate 6 (50 mg, 0.09 mmol) and DIPEA (100 μL, 1.1 mmol) were dissolved in DCM (10 mL). The reaction was cooled to 0° C., and (E)-4-bromobut-2-enoyl chloride (26 mg, 0.14 mmol) in DCM (1 mL) was added dropwise until the starting material was consumed. The reaction mixture was concentrated in vacuo. The residue was purified by HPLC to yield the title compound (2 mg, 0.004 mmol) as a white powder. 1 H NMR(500MHz,DMSO-d6)δ13.44(s,1H),10.73(s,1H),10.11(s,1H),10.01(s,1H),8.45(d,J=8.4Hz,1H ),8.35(s,1H),8.18(t,J=2.0Hz,1H),7.95-7.88(m,1H),7.66-7.48(m,4H),7.45(dt,J=7.8,1.3Hz,1 H),6.79(dt,J=14.8,7.2Hz,1H),6.51-6.40(m,1H),3.97(d,J=7.1Hz,2H),3.77-3.67(m,1H),3.63(d ,J=11.5Hz,2H),2.81(s,6H),2.34(d,J=11.9Hz,2H),1.80(d,J=12.3Hz,2H),1.70(d,J=12.7Hz,2H). MS(ESI) m / z 649(M+H) + . chemical formula C 28 H 31 Predicted mass for Cl2N7O5S: 648.56
[0235] final compound [ka] FMF-03-177-1 N-(1-Acryloylpiperidin-4-yl)-4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (4 mg, 0.009 mmol). 1 H NMR(500MHz,DMSO-d6)δ13.42(s,1H),10.17(s,1H),8.42(d,J=8.3Hz,1H),8.36 (s,1H),7.65-7.46(m,3H),6.82(dd,J=16.7,10.5Hz,1H),6.09(dd,J=16.7,2.5 Hz,1H),5.67(dd,J=10.4,2.5Hz,1H),4.41(d,J=13.2Hz,1H),4.12-3.91(m,3H) ,3.09(t,J=13.2Hz,1H),2.75-2.62(m,1H),1.78(s,2H),1.49(d,J=14.7Hz,3H). MS(ESI) m / z 437(M+H) + . chemical formula C 19 H 19 Predicted mass from Cl2N5O3: 436.29 Da.
[0236] [ka] FMF-03-177-2 (E)-4-(2,6-Dichlorobenzamido)-N-(1-(4-(dimethylamino)but-2-enoyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (5 mg, 0.01 mmol). 1 H NMR(500MHz,DMSO-d6)δ13.45(s,1H),10.16(s,1H),9.90(s,1H),8.55-8.23(m,2H) ,7.67-7.43(m,3H),6.94(dd,J=15.0,1.4Hz,1H),6.58(dt,J=14.7,7.1Hz,1H),4.40 (d,J=13.1Hz,1H),4.12-3.94(m,2H),3.87(d,J=7.2Hz,2H),3.13(t,J=13.0Hz,1H), 2.78(s,6H),2.71(d,J=12.5Hz,1H),1.81(t,J=14.2Hz,2H),1.52(t,J=12.6Hz,2H). MS(ESI) m / z 494(M+H)+ . chemical formula C 22 H 26 Predicted mass from Cl2N6O3: 493 Da.
[0237] [ka] FMF-03-183-1 (R)-N-(1-Acryloylpiperidin-3-yl)-4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (8 mg, 0.01 mmol). 1 H NMR(500MHz,DMSO-d6)δ13.44(s,1H),10.19-10.06(m,1H),8.36(d,J=13.0Hz,2H),7.65-7.46( m,3H),6.76(ddd,J=39.4,16.6,10.5Hz,1H),6.07(dd,J=16.7,7.3Hz,1H),5.64(t,J=13.2Hz,1H ),4.23(dd,J=81.1,12.6Hz,1H),3.92(t,J=15.3Hz,1H),3.76(s,1H),3.09(dt,J=86.6,12.2Hz, 1H),2.77(dt,J=22.6,11.8Hz,1H),1.86(d,J=11.3Hz,1H),1.73(d,J=13.2Hz,2H),1.38(s,1H). MS(ESI) m / z 437(M+H) + . chemical formula C 19 H 19 Predicted mass from Cl2N5O3: 436.29
[0238] [ka] FMF-03-183-2 (R,E)-4-(2,6-dichlorobenzamido)-N-(1-(4-(dimethylamino)but-2-enoyl)piperidin-3-yl)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (3 mg, 0.006 mmol). 1 H NMR(500MHz,DMSO-d6)δ13.49(d,J=12.6Hz,1H),10.11(d,J=16.2Hz,1H),9.85(s,1H),8 .41(d,J=34.1Hz,2H),7.65-7.47(m,3H),6.88(dd,J=32.3,15.1Hz,1H),6.63-6.46(m,1H ),4.38-4.10(m,1H),4.00-3.62(m,3H),3.13(dt,J=98.2,12.1Hz,1H),2.84-2.78(m,1H ),2.77(s,3H),2.69(s,3H),1.87(d,J=11.9Hz,1H),1.73(s,2H),1.41(d,J=15.5Hz,1H). MS(ESI) m / z 494(M+H) + . chemical formula C 22 H 26 Predicted mass from Cl2N6O3: 493.39
[0239] [ka] FMF-03-184-1 (S)-N-(1-Acryloylpiperidin-3-yl)-4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (4 mg, 0.005 mmol). 1 H NMR(500MHz,DMSO-d6)δ13.44(s,1H),10.13(d,J=14.1Hz,1H),8.37(s,1H),7.66-7 .46(m,3H),6.76(ddd,J=40.3,16.6,10.4Hz,1H),6.07(dd,J=16.8,7.9Hz,1H),5.6 4(dd,J=16.1,10.2Hz,1H),4.37-4.03(m,1H),3.92(t,J=15.3Hz,1H),3.76(s,1H), 3.22-2.92(m,1H),2.87-2.64(m,1H),1.93-1.79(m,1H),1.72(s,2H),1.38(s,1H). MS(ESI) m / z 437(M+H)+ . chemical formula C 19 H 19 Predicted mass from Cl2N5O3: 436.29
[0240] [ka] FMF-03-184-2 (S,E)-4-(2,6-dichlorobenzamido)-N-(1-(4-(dimethylamino)but-2-enoyl)piperidin-3-yl)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (10 mg, 0.01 mmol). 1 H NMR(500MHz,DMSO-d6)δ13.48(d,J=11.7Hz,1H),10.11(d,J=16.0Hz,1H),9.77(s,1H),8.4 1(d,J=28.7Hz,2H),7.65-7.44(m,3H),6.88(dd,J=32.4,15.1Hz,1H),6.55(dq,J=20.2,7.0 Hz,1H),4.24(dd,J=88.3,12.7Hz,1H),3.85(qd,J=24.7,21.0,14.7Hz,4H),3.27-2.98(m, 1H),2.77(s,3H),2.69(s,3H),1.87(d,J=12.0Hz,1H),1.74(d,J=13.1Hz,2H),1.39(s,1H). MS(ESI) m / z 494(M+H) + . chemical formula C 22 H 26 Predicted mass from Cl2N6O3: 493.39
[0241] [ka] FMF-03-188-1 N-(3-acrylamidophenyl)-4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (2 mg, 0.005 mmol). 1H NMR(500MHz,DMSO-d6)δ10.07(s,1H),8.51(s,1H),7.98-7.88(m,2H),7.80-7.73(m,2H),7.65(dd, J=7.7,1.7Hz,1H),7.50(ddd,J=8.7,7.3,1.8Hz,1H),7.27(d,J=8.3Hz,1H),7.19(d,J=7.4Hz,3H). MS(ESI) m / z 445(M+H) + . chemical formula C 20 H 15 C l2 Predicted mass from N5O3: 444.27
[0242] [ka] FMF-03-188-2 (E)-4-(2,6-dichlorobenzamido)-N-(3-(4-(dimethylamino)but-2-enamido)phenyl)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (2 mg, 0.004 mmol). 1 H NMR(500MHz,DMSO-d6)δ13.65(s,1H),10.35(d,J=17.6Hz,2H),10.10(d,J=28.8Hz,2H),8.44(s,1H),8.23(t,J=2.1Hz,1H),7.63-7.43(m,4H), 7.39(dt,J=8.2,1.3Hz,1H),7.27(t,J=8.1Hz,1H),6.74(dt,J=14.7,7.2Hz,1H),6.46(dd,J=15.3,1.4Hz,1H),3.99-3.84(m,2H),2.80(s,6H). MS(ESI) m / z 502(M+H) + . chemical formula C 23 H 22 Predicted mass from Cl2N6O3: 501.37
[0243] [ka] FMF-03-182-1 N-(4-acrylamidophenyl)-4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (10 mg, 0.02 mmol). 1 H NMR(500MHz,DMSO-d6)δ13.58(s,1H),10.30(s,1H),10.14(d,J=16.4Hz,2H),8.44(d,J=1.5Hz,1H),7.78-7.65(m, 2H),7.65-7.43(m,5H),6.42(dd,J=16.9,10.1Hz,1H),6.24(dd,J=17.0,2.1Hz,1H),5.74(dd,J=10.1,2.1Hz,1H). MS(ESI) m / z 445(M+H) + . chemical formula C 20 H 15 Predicted mass for Cl2N5O3: 444.27
[0244] [ka] FMF-03-182-2 (E)-4-(2,6-dichlorobenzamido)-N-(4-(4-(dimethylamino)but-2-enamido)phenyl)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (10 mg, 0.02 mmol).
[0245] 1 H NMR(500MHz,DMSO-d6)δ13.61(s,1H),10.32(d,J=12.6Hz,2H),10.14(s,1H),9.87(s,1H),8.45(s,1H),7.75(d,J=9.0 Hz,2H),7.65-7.47(m,5H),6.73(dt,J=14.7,7.2Hz,1H),6.44(dd,J=15.2,1.5Hz,1H),4.00-3.85(m,2H),2.80(s,6H). MS(ESI) m / z 502(M+H) + . chemical formula C 23 H 22 Predicted mass from Cl2N6O3: 501.37
[0246] [ka] FMF-03-186-1 N-(1-(4-acrylamidobenzoyl)piperidin-4-yl)-4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (3 mg, 0.006 mmol). 1 H NMR(500MHz,DMSO-d6)δ13.42(s,1H),10.31(s,1H),10.16(s,1H),8.48-8.25(m,2H),7.77 -7.64(m,2H),7.63-7.45(m,3H),7.42-7.30(m,2H),6.45(dd,J=17.0,10.2Hz,1H),6.29(d d,J=17.0,2.0Hz,1H),5.79(dd,J=10.1,2.0Hz,1H),4.59-3.54(m,1H),4.02(ddp,J=11.8, 8.5,4.3Hz,1H),3.22-2.70(m,1H),1.77(s,2H),1.59(d,J=12.6Hz,2H),1.33-1.10(m,1H).
[0247] MS(ESI) m / z 556(M+H) + . chemical formula C 26 H 24 Predicted mass for Cl2N6O4: 555.42
[0248] [ka] FMF-03-187-1 (E)-4-(2,6-Dichlorobenzamido)-N-(1-(4-(4-(dimethylamino)but-2-enamido)benzoyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (4 mg, 0.005 mmol). 1H NMR(500MHz,DMSO-d6)δ13.45(s,1H),10.52(s,1H),10.16(s,1H),9.98(d,J=37.2Hz,1H),8 .39(d,J=8.2Hz,1H),8.35(s,1H),7.79-7.68(m,2H),7.62-7.49(m,3H),7.42-7.34(m,2H),6 .77(dt,J=14.7,7.2Hz,1H),6.48(dd,J=15.3,1.5Hz,1H),4.56-4.17(m,1H),4.02(tdd,J=11 .4,7.9,4.1Hz,1H),3.96(d,J=7.2Hz,2H),2.80(d,J=15.8Hz,7H),1.78(s,2H),1.60(s,2H).
[0249] MS(ESI) m / z 613(M+H) + . chemical formula C 29 H 31 Predicted mass from Cl2N7O4: 612.51
[0250] [ka] FMF-03-196-1 N-(1-(3-acrylamidobenzoyl)piperidin-4-yl)-4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (2 mg, 0.003 mmol).
[0251] 1H NMR(500MHz,DMSO-d6)δ13.43(s,1H),10.29(s,1H),10.17(s,1H),8.44(d,J=8.1Hz,1H),8.35(s,1H),7.82(d,J =1.9Hz,1H),7.67-7.46(m,4H),7.40(t,J=7.9Hz,1H),7.06(dt,J=7.6,1.3Hz,1H),6.44(dd,J=17.0,10.1Hz,1H) ,6.28(dd,J=17.0,2.0Hz,1H),5.78(dd,J=10.1,2.0Hz,1H),4.46(s,1H),4.03(ddp,J=11.6,8.3,4.2Hz,1H),3. 89(t,J=6.2Hz,1H),3.63(s,1H),3.14(d,J=38.6Hz,1H),2.97-2.77(m,1H),1.78(d,J=49.1Hz,3H),1.61(s,3H).
[0252] MS(ESI) m / z 556(M+H) + . chemical formula C 26 H 24 Predicted mass for Cl2N6O4: 555.42
[0253] [ka] FMF-03-196-2 (E)-4-(2,6-Dichlorobenzamido)-N-(1-(3-(4-(dimethylamino)but-2-enamido)benzoyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (10 mg, 0.01 mmol). 1H NMR(500MHz,DMSO-d6)δ13.45(s,1H),10.50(s,1H),10.16(s,1H),10.07(s,1H),8.43(d,J=8.4Hz,1H),8.35(s,1H),7.82 (d,J=1.9Hz,1H),7.64(dt,J=8.3,1.4Hz,1H),7.60(d,J=1.6Hz,1H),7.58(s,1H),7.53(dd,J=9.2,6.8Hz,1H),7.42(t,J=7 .9Hz,1H),7.12-7.03(m,1H),6.77(dt,J=14.7,7.2Hz,1H),6.47(d,J=15.5Hz,1H),4.45(s,2H),4.02(dt,J=11.5,5.7Hz, 1H),3.96(d,J=7.2Hz,2H),3.62(s,1H),3.14-2.99(m,1H),2.88(s,1H),2.80(s,6H),1.78(d,J=47.5Hz,2H),1.58(s,2H). MS(ESI) m / z 613(M+H) + . chemical formula C 29 H 31 Predicted mass from Cl2N7O4: 612.51
[0254] [ka] FMF-03-199-1 N-(1-(4-acrylamidobenzyl)piperidin-4-yl)-4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (2 mg, 0.003 mmol).
[0255] 1H NMR(500MHz,DMSO-d6)δ13.50(d,J=22.8Hz,1H),10.33(s,1H),10.11(d,J=8.4Hz,1H),8.37(s,1H), 7.89(s,1H),7.77-7.72(m,2H),7.61-7.56(m,2H),7.55-7.51(m,1H),7.46-7.41(m,2H),6.45(dd,J= 17.0,10.1Hz,1H),6.28(dd,J=17.0,1.9Hz,1H),5.79(dd,J=10.1,2.0Hz,1H),4.23(d,J=5.0Hz,2H) ,3.96(dd,J=7.6,4.0Hz,1H),3.03(q,J=11.8Hz,2H),1.97(d,J=13.3Hz,2H),1.84(q,J=12.8Hz,2H). MS(ESI) m / z 542(M+H) + . chemical formula C 26 H 26 Predicted mass from Cl2N6O3: 541.43.
[0256] [ka] FMF-03-199-2 (E)-4-(2,6-dichlorobenzamido)-N-(1-(4-(4-(dimethylamino)but-2-enamido)benzyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (2 mg, 0.003 mmol). 1H NMR(500MHz,DMSO-d6)δ10.54(s,1H),10.12(s,1H),8.67(d,J=7.9Hz,1H),8.36(s,1H),7.75(d ,J=8.3Hz,2H),7.63-7.56(m,3H),7.53(dd,J=9.2,6.8Hz,1H),7.50-7.42(m,2H),6.77(dt,J=14 .8,7.2Hz,1H),6.49(d,J=15.3Hz,1H),4.31(s,1H),4.23(s,2H),3.96(d,J=7.0Hz,2H),3.37(d, J=12.6Hz,2H),3.28-3.21(m,2H),2.81(s,6H),2.01-1.91(m,2H),1.85(q,J=12.9,12.2Hz,2H). MS(ESI) m / z 599(M+H) + . chemical formula C 28 H 33 Predicted mass from Cl2N7O3: 598.53
[0257] [ka] FMF-03-200-1 N-(1-(3-acrylamidobenzyl)piperidin-4-yl)-4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (2 mg, 0.003 mmol). 1H NMR(500MHz,DMSO-d6)δ13.49(s,1H),10.34(d,J=4.7Hz,1H),10.12(d,J=8.3Hz,1H),8.68(d,J=7.9Hz,1H),8.3 6(s,1H),7.98(s,1H),7.64-7.48(m,5H),7.44(q,J=7.8Hz,1H),7.21(t,J=8.8Hz,1H),6.47(dd,J=17.0,10.1Hz ,1H),6.28(dd,J=16.9,2.0Hz,1H),5.79(dd,J=10.1,2.0Hz,1H),4.27(d,J=5.0Hz,2H),3.96(dt,J=7.9,3.9Hz, 1H),3.39(d,J=12.3Hz,2H),3.07(q,J=11.8,11.4Hz,2H),1.97(d,J=13.3Hz,2H),1.86(dd,J=18.5,8.4Hz,2H). MS(ESI) m / z 542(M+H) + Chemical formula C 26 H 26 Cl2N6O3からEstimated mass: 541.43.
[0258]
change
[0259] [ka] FMF-04-172-1(FMF-03-200-R) 4-(2,6-Dichlorobenzamido)-N-(1-(3-propionamidobenzyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (20 mg, 0.036 mmol). 1 H NMR(500MHz,DMSO-d6)δ13.48(s,1H),10.12(d,J=8.9Hz,1H),10.03(d,J=4.8Hz,1H),9.52(s,1H),8. 79-8.59(m,1H),8.38(d,J=16.9Hz,1H),7.92(t,J=1.9Hz,1H),7.64-7.42(m,5H),7.39(t,J=7.9Hz,1 H),7.15(dt,J=7.6,1.3Hz,1H),4.25(d,J=5.2Hz,2H),3.96(dt,J=11.8,4.0Hz,1H),3.37(d,J=11.8H z,2H),3.03(dd,J=22.2,10.7Hz,2H),2.34(q,J=7.5Hz,2H),1.99-1.82(m,4H),1.09(t,J=7.5Hz,3H). MS(ESI) m / z 544(M+H) + . chemical formula C 28 H 33 Predicted mass from Cl2N7O3: 543.45
[0260] [ka] FMF-03-197-1 N-(1-((4-acrylamidophenyl)sulfonyl)piperidin-4-yl)-4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (2 mg, 0.004 mmol). 1 H NMR(500MHz,DMSO-d6)δ13.41(s,1H),10.57(s,1H),10.12(s,1H),8.34(s,1H),7.94-7.89( m,2H),7.73-7.68(m,2H),7.59-7.54(m,2H),7.51(dd,J=9.2,6.9Hz,1H),6.46(dd,J=17.0,1 0.1Hz,1H),6.32(dd,J=17.0,1.9Hz,1H),5.83(dd,J=10.1,1.9Hz,1H),3.74-3.67(m,1H),3. 61(d,J=12.3Hz,2H),2.31(t,J=11.7Hz,2H),1.79(d,J=12.7Hz,2H),1.68(d,J=11.9Hz,2H). MS(ESI) m / z 592(M+H) + . chemical formula C 25 H 24 Predicted mass for Cl2N6O5S: 591.46
[0261] [ka] FMF-03-197-2 (E)-4-(2,6-Dichlorobenzamido)-N-(1-((4-(4-(dimethylamino)but-2-enamido)phenyl)sulfonyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (2 mg, 0.004 mmol). 1H NMR(500MHz,DMSO-d6)δ13.44(s,1H),10.77(s,1H),10.12(d,J=7.7Hz,1H),10.00(s,1H),8.44 (d,J=8.5Hz,1H),8.35(s,1H),7.96-7.87(m,2H),7.77-7.67(m,2H),7.60-7.47(m,4H),6.80(d t,J=14.7,7.2Hz,1H),6.49(dt,J=15.3,1.3Hz,1H),3.97(d,J=7.1Hz,2H),3.75-3.65(m,1H),3 .62(d,J=11.5Hz,2H),2.81(s,6H),2.29(t,J=11.7Hz,2H),1.78(s,2H),1.69(d,J=12.1Hz,2H). MS(ESI) m / z 649(M+H) + . chemical formula C 28 H 31 Predicted mass for Cl2N7O5S: 648.56
[0262] [ka] FMF-04-060-1(FMF-03-198-R) 4-(2,6-Dichlorobenzamido)-N-(1-((3-propionamidophenyl)sulfonyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (12 mg, 0.02 mmol). 1H NMR(500MHz,DMSO-d6)δ13.41(d,J=1.5Hz,1H),10.23(s,1H),10.12(s,1H),8.44(d,J=8.2Hz,1H) ,8.35(d,J=1.4Hz,1H),8.08(t,J=2.0Hz,1H),7.85(ddd,J=8.2,2.1,1.0Hz,1H),7.60-7.46(m,4H) ,7.37(dt,J=7.8,1.3Hz,1H),4.09(s,3H),3.71(ddp,J=11.5,8.2,4.3Hz,1H),3.61(d,J=11.8Hz, 2H), 2.35(q,J=7.5Hz,2H),1.80(dd,J=13.0,3.8Hz,2H),1.74-1.64(m,2H),1.09(t,J=7.5Hz,3H). MS(ESI) m / z 594(M+H) + . chemical formula C 25 H 26 Predicted mass for Cl2N6O5S: 593.48
[0263] [ka] FMF-04-153-1 (Biotin-FMF-03-198-2) 4-(2,6-Dichlorobenzamido)-N-(1-((3-((E)-5-methyl-8,22-dioxo-26-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-12,15,18-trioxa-5,9,21-triazahexacos-2-enamido)phenyl)sulfonyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide This compound was prepared as a white powder according to Method 1 (4 mg, 0.003 mmol). MS(ESI) m / z 1108 (M+H) + , 554[(M+H) + / 2]. chemical formula C 48 H 65 Cl2N 11 O 11 Predicted mass from S2: 1107.13
[0264] [ka] FMF-04-058-1 (R)-N-(1-(4-acrylamidobenzoyl)piperidin-3-yl)-4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxamide This compound was prepared according to Method 1 (8 mg, 0.014 mmol) as a white powder. 1 H NMR(500MHz,DMSO-d6)δ13.28(s,1H),10.47(d,J=40.2Hz,1H),10.35(s,1H),8.31(s,1H),8.22(s,1H),7 .81(d,J=8.4Hz,2H),7.76-7.69(m,2H),7.63-7.54(m,2H),7.50(dd,J=9.1,7.0Hz,1H),6.46(dd,J=17.0 ,10.1Hz,1H),6.29(dd,J=17.0,1.9Hz,1H),5.80(dd,J=10.1,2.0Hz,1H),4.61(d,J=90.4Hz,1H),4.47-4 .12(m,1H),3.91(d,J=17.2Hz,1H),2.96(s,0H),2.89-2.75(m,1H),2.00-1.73(m,2H),1.73-1.44(m,2H). MS(ESI) m / z 556(M+H) + . chemical formula C 26 H 24 Predicted mass for Cl2N6O4: 555.42
[0265] [ka] FMF-04-058-2 (R,E)-4-(2,6-dichlorobenzamido)-N-(1-(4-(4-(dimethylamino)but-2-enamido)benzoyl)piperidin-3-yl)-1H-pyrazole-3-carboxamide This compound was prepared according to Method 1 (4 mg, 0.007 mmol) as a white powder. 1H NMR(500MHz,DMSO-d6)δ13.28(s,1H),10.47(d,J=40.2Hz,1H),10.35(s,1H),8.31(s,1H),8.22(s,1H),7.81(d,J=8.4H z,2H),7.76-7.69(m,2H),7.60-7.54(m,2H),7.50(dd,J=9.1,7.0Hz,1H),6.46(dd,J=17.0,10.1Hz,1H),6.29(dd,J=17 .0,1.9Hz,1H),5.80(dd,J=10.1,2.0Hz,1H),4.61(d,J=89.6Hz,1H),4.42(d,J=12.4Hz,1H),4.18(s,1H),3.99-3.88(m ,2H),3.18(s,6H),2.96(s,1H),2.90-2.77(m,1H),2.00-1.91(m,1H),1.79(s,1H),1.63(d,J=12.2Hz,1H),1.51(s,1H). MS(ESI) m / z 613(M+H) + . chemical formula C 29 H 31 Predicted mass from Cl2N7O4: 612.51
[0266] [ka] FMF-04-059-1 (R)-N-(1-(3-acrylamidobenzoyl)piperidin-3-yl)-4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxamide This compound was prepared according to Method 1 (10 mg, 0.018 mmol) as a white powder. 1H NMR(500MHz,DMSO-d6)δ13.28(s,1H),10.46(d,J=38.9Hz,1H),10.28(s,1H),8.35(d,J=8.0Hz,1H),8.02(s,1H),7.88( d,J=8.0Hz,1H),7.62-7.54(m,2H),7.50(dd,J=9.2,6.8Hz,2H),7.39(d,J=7.5Hz,1H),6.44(dd,J=16.9,10.1Hz,1H),6. 28(dd,J=17.0,2.0Hz,1H),5.78(dd,J=10.1,2.0Hz,1H),4.66(d,J=118.3Hz,1H),4.47-4.18(m,1H),3.91(d,J=21.1Hz, 1H), 2.90(d,J=8.2Hz,1H),2.83(dd,J=13.7,8.7Hz,1H),1.95(s,1H),1.79(s,1H),1.63(d,J=11.7Hz,1H),1.52(s,1H). MS(ESI) m / z 556(M+H) + . chemical formula C 26 H 24 Predicted mass for Cl2N6O4: 555.42
[0267] [ka] FMF-04-059-2 (R,E)-4-(2,6-dichlorobenzamido)-N-(1-(3-(4-(dimethylamino)but-2-enamido)benzoyl)piperidin-3-yl)-1H-pyrazole-3-carboxamide This compound was prepared according to Method 1 (10 mg, 0.016 mmol) as a white powder. 1H NMR(500MHz,DMSO-d6)δ13.29(s,1H),10.48(s,1H),9.94(s,1H),8.36(d,J=7.9Hz,1H),8.31(s,1H),8.05 (s,1H),7.88(d,J=8.1Hz,1H),7.59-7.48(m,4H),7.40(d,J=7.3Hz,1H),6.77(dt,J=15.3,7.2Hz,1H),6.47 (dt,J=15.2,1.2Hz,1H),4.62(d,J=109.9Hz,1H),4.47-4.17(m,1H),4.00-3.88(m,3H),3.39-3.29(m,1H) ,2.98-2.84(m,1H),2.81(s,6H),1.95(d,J=12.1Hz,1H),1.79(s,1H),1.64(d,J=11.3Hz,1H),1.52(s,1H). MS(ESI) m / z 613(M+H) + . chemical formula C 29 H 31 Predicted mass from Cl2N7O4: 612.51
[0268] [ka] FMF-04-056-1 (R)-N-(1-((4-acrylamidophenyl)sulfonyl)piperidin-3-yl)-4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxamide This compound was prepared according to Method 1 (10 mg, 0.016 mmol) as a white powder. 1H NMR(500MHz,DMSO-d6)δ13.26(s,1H),10.49(d,J=15.2Hz,1H),10.39(d,J=27.3Hz,1H),8.29(s, 1H),7.94-7.75(m,1H),7.71(d,J=6.9Hz,1H),7.61-7.53(m,2H),7.50(dd,J=9.2,6.9Hz,1H),6.4 7(dd,J=16.9,10.2Hz,1H),6.32(dd,J=17.0,1.9Hz,1H),5.83(dd,J=10.1,1.9Hz,1H),4.40-4.0 0(m,1H),3.09(d,J=25.5Hz,2H),2.93-2.60(m,1H),2.57-2.53(m,1H),1.64(s,2H),1.34(s,2H). MS(ESI) m / z 592(M+H) + . chemical formula C 25 H 24 Predicted mass for Cl2N6O5S: 591.46
[0269] [ka] FMF-04-056-2 (R,E)-4-(2,6-dichlorobenzamido)-N-(1-((4-(4-(dimethylamino)but-2-enamido)phenyl)sulfonyl)piperidin-3-yl)-1H-pyrazole-3-carboxamide This compound was prepared according to Method 1 (8 mg, 0.014 mmol) as a white powder. 1H NMR(500MHz,DMSO-d6)δ13.26(s,1H),10.68(d,J=18.9Hz,1H),10.38(d,J=27.3Hz,1H),9.98( s,1H),8.29(s,1H),7.82(d,J=23.4Hz,4H),7.72(s,1H),7.58-7.54(m,2H),7.50(dd,J=9.2,6 .8Hz,1H),6.80(dt,J=15.4,7.1Hz,1H),6.49(d,J=15.3Hz,1H),4.17(d,J=110.5Hz,2H),3.97 (d,J=7.2Hz,2H),3.15-2.98(m,2H),2.81(s,6H),2.76-2.61(m,1H),1.64(s,2H),1.34(s,2H). MS...
Claims
1. Formula (I): [Formula 1] or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled compound thereof, wherein: R 1 each occurrence independently represents halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -OR D1 , -N(R D1a ) 2 , and -SR D1 where R D1 is independently selected from hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group when attached to a sulfur atom; R D1a each occurrence of is independently selected from the group consisting of hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, and a nitrogen protecting group; or R D1a may, together with their intervening atoms, form a substituted or unsubstituted heterocyclic ring or a substituted or unsubstituted heteroaryl ring; R 2 is hydrogen, halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; Each instance of R is independently selected from the group consisting of hydrogen, optionally substituted alkyl, and a nitrogen protecting group; R x is selected from the group consisting of hydrogen, optionally substituted alkyl, and a nitrogen protecting group; n is 0, 1, 2, 3, 4, or 5; X is N, -NR, as far as valence permits. x -, S, or O; Y1 is N, -NR x -, S, or O; L is an arbitrary substitution C 1~6 a hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain are independently replaced by -C(=O)-, -O-, -S-, -S(=O)O-, -NR(C=O)-, -NR-, an optionally substituted carbocyclylene, an optionally substituted heterocyclylene, an optionally substituted arylene, or an optionally substituted heteroarylene; or L is a group represented by the formula: [Case 2] wherein ring A is an optionally substituted heterocyclyl, an optionally substituted aryl, or an optionally substituted heteroaryl; Ring B is optionally substituted heterocyclyl or optionally substituted aryl; L x is a bond, -CH 2 -, -C(=O)-, -S(=O) 2 - or -NH(C=O)-; lx indicates the point of attachment to -NR-; and ly is R 3 indicates the point of attachment to; R 3 is the expression: [C3] wherein: L 3 is a bond or any substitution C 1~4 a hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain are independently -C(=O)-, -O-, -S-, -NR L3a -, -NR L3a C(=O)-, -C(=O)NR L3a -, -SC(=O)-, -C(=O)S-, -OC(=O)-, -C(=O)O-, -NR L3a C(=S)-, -C(=S)NR L3a-, trans-CR L3b =CR L3b -, cis-CR L3b =CR L3b -, -C≡C-, -S(=O)-, -S(=O)O-, -OS(=O)-, -S(=O)NR L3a -, -NR L3a S(=O)-, -S(=O) 2 -, -S(=O) 2 O-, -OS(=O) 2 -, -S(=O) 2 NR L3a -, or -NR L3a S(=O) 2 - may be replaced by, where R L3a each occurrence independently represents hydrogen, substituted or unsubstituted C 1~6 alkyl, or a nitrogen protecting group, and L3b each occurrence is independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R L3b the groups, when joined, form an optionally substituted carbocyclic ring or an optionally substituted heterocyclic ring; R E1 , R E2 , and R E3 each independently represents hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -CN, -CH 2 OR EE , -CH 2 N(R EE ) 2 , -CH 2 S.R. EE , -OR EE , -N(R EE ) 2 , -Si(R EE ) 3 , or -SR EE Here, R EEeach occurrence is independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R EE the groups, when joined, form an optionally substituted heterocyclic ring; Each occurrence of Y is independently O, S, or NR E7 Here, R E7 is hydrogen, substituted or unsubstituted C 1~6 alkyl, or nitrogen protecting groups; When the substituent is attached to a carbon atom, the substituent is a halogen, -CN, -NO 2 , -N 3 , -SO 2 H, -SO 3 H, -OH, -OR aa , -ON(R bb ) 2 , -N(R bb ) 2 , -N(R bb ) 3 + X - , -N(OR cc )R bb , -SH, -SR aa , -SSR cc , -C(=O)R aa , -CO 2 H, -CHO, -CO 2 R aa , -OC(=O)R aa , -OCO 2 R aa , -C(=O)N(R bb ) 2 , -OC(=O)N(R bb ) 2 , -NR bb C(=O)R aa , -NR bb CO 2 R aa , -NR bb C(=O)N(R bb ) 2 , -C(=NR bb )R aa , -C(=NR bb ) OR aa 、-OC(=NR bb )R aa 、-OC(=NR bb )OR aa 、-C(=NR bb )N(R bb ) 2 、-OC(=NR bb )N(R bb ) 2 、-NR bb C(=NR bb )N(R bb ) 2 、-C(=O)NR bb SO 2 R aa 、-NR bb SO 2 R aa 、-SO 2 N(R bb ) 2 、-SO 2 R aa 、-SO 2 OR aa 、-OSO 2 R aa 、-S(=O)R aa 、-OS(=O)R aa 、-Si(R aa ) 3 、-OSi(R aa ) 3 、-C(=S)N(R bb ) 2 、-C(=O)SR aa 、-C(=S)SR aa 、-SC(=S)SR aa 、-SC(=O)SR aa 、-OC(=O)SR aa 、-SC(=O)OR aa 、-SC(=O)R aa 、-P(=O)(R aa ) 2 、-P(=O)(OR cc ) 2 、-OP(=O)(R aa ) 2 、-OP(=O)(OR cc ) 2 、-P(=O)(N(R bb ) 2 ) 2, -OP(=O)(N(R bb ) 2 ) 2 , -NR bb P(=O)(R aa ) 2 , -NR bb P(=O)(OR cc ) 2 , -NR bb P(=O)(N(R bb ) 2 ) 2 , -P(R cc ) 2 , -P(OR cc ) 2 , -P(R cc ) 3 + X - , -P(OR cc ) 3 + X - , -P(R cc ) 4 , -P(OR cc ) 4 , -OP(R cc ) 2 , -OP(R cc ) 3 + X - , -OP(OR cc ) 2 , -OP(OR cc ) 3 + X - , -OP(R cc ) 4 , -OP(OR cc ) 4 , -B(R aa ) 2 , -B(OR cc ) 2 , -BR aa (OR cc ), C 1~10 Alkyl, C 1~10 Perhaloalkyl, C 2~10 Alkenyl, C 2~10 Alkynyl, Hetero C 1~10 Alkyl, Hetero C 2~10 Alkenyl, Hetero C 2~10 Alkynyl, C 3~10Carbocyclyl, 3- to 14-membered heterocyclyl, C 6~14 aryl, and 5- to 14-membered heteroaryl, where each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently selected from 0, 1, 2, 3, 4, or 5 R dd substituted with a group; Alternatively, the two geminal hydrogens on the carbon atom can be substituted with the groups =O, =S, =NN(R bb ) 2 , =NNR bb C(=O)R aa , =NNR bb C(=O)OR aa , =NNR bb S(=O) 2 R aa , =NR bb , or =NOR cc has been replaced by; R aa In each case, independently, C 1~10 Alkyl, C 1~10 Perhaloalkyl, C 2~10 Alkenyl, C 2~10 Alkynyl, Hetero C 1~10 Alkyl, Hetero C 2~10 Alkenyl, Hetero C 2~10 Alkynyl, C 3~10 Carbocyclyl, 3- to 14-membered heterocyclyl, C 6~14 aryl, and 5- to 14-membered heteroaryl, or two R aa The groups are joined to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered heteroaryl ring, where each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently represent 0, 1, 2, 3, 4, or 5 R dd substituted with a group; R bb Each of the cases is independently hydrogen, -OH, -OR aa , -N(R cc ) 2, -CN, -C(=O)R aa , -C(=O)N(R cc ) 2 , -CO 2 R aa , -SO 2 R aa , -C(=NR cc ) OR aa , -C(=NR cc )N(R cc ) 2 , -SO 2 N(R cc ) 2 , -SO 2 R cc , -SO 2 OR cc , -SOR aa , -C(=S)N(R cc ) 2 , -C(=O)SR cc , -C(=S)SR cc , -P(=O)(R aa ) 2 , -P(=O)(OR cc ) 2 , -P(=O)(N(R cc ) 2 ) 2 , C 1~10 Alkyl, C 1~10 Perhaloalkyl, C 2~10 Alkenyl, C 2~10 Alkynyl, Hetero C 1~10 Alkyl, Hetero C 2~10 Alkenyl, Hetero C 2~10 Alkynyl, C 3~10 Carbocyclyl, 3- to 14-membered heterocyclyl, C 6~14 aryl, and 5- to 14-membered heteroaryl, or two R bb The groups are joined to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered heteroaryl ring, where each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently represent 0, 1, 2, 3, 4, or 5 R dd substituted with a group; R cceach occurrence independently represents hydrogen, C 1~10 Alkyl, C 1~10 Perhaloalkyl, C 2~10 Alkenyl, C 2~10 Alkynyl, Hetero C 1~10 Alkyl, Hetero C 2~10 Alkenyl, Hetero C 2~10 Alkynyl, C 3~10 Carbocyclyl, 3- to 14-membered heterocyclyl, C 6~14 aryl, and 5- to 14-membered heteroaryl, or two R cc The groups are joined to form a 3- to 14-membered heterocyclyl ring or a 5- to 14-membered heteroaryl ring, where each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently represent 0, 1, 2, 3, 4, or 5 R dd substituted with a group; R dd In each case, independently, halogen, -CN, -NO 2 , -N 3 , -SO 2 H, -SO 3 H, -OH, -OR ee , -ON(R ff ) 2 , -N(R ff ) 2 , -N(R ff ) 3 + X - , -N(OR ee )R ff , -SH, -SR ee , -SSR ee , -C(=O)R ee , -CO 2 H, -CO 2 R ee , -OC(=O)R ee , -OCO 2 R ee , -C(=O)N(R ff ) 2 , -OC(=O)N(R ff ) 2 , -NR ff C(=O)R ee , -NR ff CO 2 R ee , -NR ff C(=O)N(R ff ) 2 , -C(=NR ff ) OR ee , -OC(=NR ff )R ee , -OC(=NR ff ) OR ee , -C(=NR ff )N(R ff ) 2 , -OC(=NR ff )N(R ff ) 2 , -NR ff C(=NR ff )N(R ff ) 2 , -NR ff SO 2 R ee , -SO 2 N(R ff ) 2 , -SO 2 R ee , -SO 2 OR ee , -OSO 2 R ee , -S(=O)R ee , -Si(R ee ) 3 , -OSi(R ee ) 3 , -C(=S)N(R ff ) 2 , -C(=O)SR ee , -C(=S)SR ee , -SC(=S)SR ee , -P(=O)(OR ee ) 2 , -P(=O)(R ee ) 2 , -OP(=O)(R ee ) 2 ,-OP(=O)(OR ee ) 2 , C 1~6 Alkyl, C 1~6 Perhaloalkyl, C 2~6 Alkenyl, C 2~6Alkynyl, Hetero C 1~6 Alkyl, Hetero C 2~6 Alkenyl, Hetero C 2~6 Alkynyl, C 3~10 Carbocyclyl, 3- to 10-membered heterocyclyl, C 6~10 aryl, and 5- to 10-membered heteroaryl, where each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently selected from 0, 1, 2, 3, 4, or 5 R gg substituted with a group or two geminal R dd The substituents may be combined to form =O or =S; R ee In each case, independently, C 1~6 Alkyl, C 1~6 Perhaloalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, Hetero C 1~6 Alkyl, Hetero C 2~6 Alkenyl, Hetero C 2~6 Alkynyl, C 3~10 Carbocyclyl, C 6~10 aryl, 3- to 10-membered heterocyclyl, and 3- to 10-membered heteroaryl, where each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently selected from 0, 1, 2, 3, 4, or 5 R gg substituted with a group; R ff each occurrence independently represents hydrogen, C 1~6 Alkyl, C 1~6 Perhaloalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, Hetero C 1~6 Alkyl, Hetero C 2~6 Alkenyl, Hetero C 2~6 Alkynyl, C 3~10 Carbocyclyl, 3- to 10-membered heterocyclyl, C 6~10aryl, and 5- to 10-membered heteroaryl, or two R ff The groups are joined to form a 3- to 10-membered heterocyclyl ring or a 5- to 10-membered heteroaryl ring, where each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently represent 0, 1, 2, 3, 4, or 5 R gg substituted with a group; R gg In each case, independently, halogen, -CN, -NO 2 , -N 3 , -SO 2 H, -SO 3 H, -OH, -OC 1~6 Alkyl, -ON(C 1~6 Alkyl) 2 , -N(C 1~6 Alkyl) 2 , -N(C 1~6 Alkyl) 3 + X - , -NH(C 1~6 Alkyl) 2 + X - , -NH 2 (C 1~6 Alkyl) + X - , -NH 3 + X - , -N(OC 1~6 Alkyl)(C 1~6 alkyl), -N(OH)(C 1~6 alkyl), -NH(OH), -SH, -SC 1~6 Alkyl, -SS(C 1~6 alkyl), -C(=O)(C 1~6 Alkyl), -CO 2 H, -CO 2 (C 1~6 alkyl), -OC(=O)(C 1~6 Alkyl), -OCO 2 (C 1~6 alkyl), -C(=O)NH 2 , -C(=O)N(C 1~6Alkyl) 2 , -OC(=O)NH(C 1~6 alkyl), -NHC(=O)(C 1~6 alkyl), -N(C 1~6 Alkyl)C(=O)(C 1~6 alkyl), -NHCO 2 (C 1~6 alkyl), -NHC(=O)N(C 1~6 Alkyl) 2 , -NHC(=O)NH(C 1~6 alkyl), -NHC(=O)NH 2 , -C(=NH)O(C 1~6 alkyl), -OC(=NH)(C 1~6 alkyl), -OC(=NH)OC 1~6 Alkyl, -C(=NH)N(C 1~6 Alkyl) 2 , -C(=NH)NH(C 1~6 alkyl), -C(=NH)NH 2 , -OC(=NH)N(C 1~6 Alkyl) 2 , -OC(NH)NH(C 1~6 alkyl), -OC(NH)NH 2 , -NHC(NH)N(C 1~6 Alkyl) 2 , -NHC(=NH)NH 2 , -NHSO 2 (C 1~6 Alkyl), -SO 2 N(C 1~6 Alkyl) 2 , -SO 2 NH(C 1~6 Alkyl), -SO 2 NH 2 , -SO 2 C 1~6 Alkyl, -SO 2 O.C. 1~6 Alkyl, -OSO 2 C 1~6 Alkyl, -SOC 1~6 Alkyl, -Si(C 1~6 Alkyl) 3 , -OSi(C 1~6 Alkyl) 3 -C(=S)N(C 1~6 Alkyl) 2 , C(=S)NH(C 1~6 alkyl), C(=S)NH 2 , -C(=O)S(C 1~6 Alkyl), -C(=S)SC 1~6 Alkyl, -SC(=S)SC 1~6 Alkyl, -P(=O)(OC 1~6 Alkyl) 2 , -P(=O)(C 1~6 Alkyl) 2 , -OP(=O)(C 1~6 Alkyl) 2 , -OP(=O)(OC 1~6 Alkyl) 2 , C 1~6 Alkyl, C 1~6 Perhaloalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, Hetero C 1~6 Alkyl, Hetero C 2~6 Alkenyl, Hetero C 2~6 Alkynyl, C 3~10 Carbocyclyl, C 6~10 aryl, 3- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl; or two geminal R gg The substituents may be combined to form =O or =S; X - is the counterion; When a substituent is attached to a nitrogen atom, the substituent may be a nitrogen protecting group, hydrogen, -OH, -OR aa , -N(R cc ) 2 , -CN, -C(=O)R aa , -C(=O)N(R cc ) 2 , -CO 2 R aa , -SO 2 R aa , -C(=NR bb )R aa , -C(=NR cc ) OR aa , -C(=NR cc )N(R cc ) 2 , -SO 2 N(R cc ) 2 , -SO 2 R cc , -SO 2 OR cc , -SOR aa , -C(=S)N(R cc ) 2 , -C(=O)SR cc , -C(=S)SR cc , -P(=O)(OR cc ) 2 , -P(=O)(R aa ) 2 , -P(=O)(N(R cc ) 2 ) 2 , C 1~10 Alkyl, C 1~10 Perhaloalkyl, C 2~10 Alkenyl, C 2~10 Alkynyl, Hetero C 1~10 Alkyl, Hetero C 2~10 Alkenyl, Hetero C 2~10 Alkynyl, C 3~10 Carbocyclyl, 3- to 14-membered heterocyclyl, C 6~14 aryl, and 5- to 14-membered heteroaryl, where each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently selected from 0, 1, 2, 3, 4, or 5 R dd substituted with a group; The nitrogen protecting groups are independently -OH, -OR aa , -N(R cc ) 2 , -C(=O)R aa , -C(=O)N(R cc ) 2 , -CO 2 R aa , -SO 2 R aa , -C(=NR cc )R aa , -C(=NR cc ) OR aa , -C(=NR cc )N(R cc ) 2 , -SO 2 N(R cc ) 2 , -SO 2 R cc , -SO 2 OR cc , -SOR aa , -C(=S)N(R cc ) 2 , -C(=O)SR cc , -C(=S)SR cc , C 1~10 Alkyl, C 2~10 Alkenyl, C 2~10 Alkynyl, C 3~10 Carbocyclyl, 3- to 14-membered heterocyclyl, C 6~14 aryl, and 5- to 14-membered heteroaryl groups, where each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd substituted with a group; When the substituents are attached to an oxygen atom, the substituents are oxygen protecting groups, where each oxygen protecting group is independently -R aa , -N(R bb ) 2 , -C(=O)SR aa , -C(=O)R aa , -CO 2 R aa , -C(=O)N(R bb ) 2 , -C(=NR bb )R aa , -C(=NR bb ) OR aa , -C(=NR bb )N(R bb ) 2 , -S(=O)R aa , -SO 2 R aa , -Si(R aa ) 3 , -P(R cc ) 2 , -P(R cc ) 3 + X - , -P(OR cc ) 2 , -P(OR cc ) 3 + X - 、-P(=O)(R aa ) 2 、-P(=O)(OR cc ) 2 、-P(=O)(N(R bb ) 2 ) 2, methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacol methyl (GUM), t-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethyl Silyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl S,S-dioxide, 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl (CTMP), 1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a- Octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl, t-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl (Bn), p-methoxybenzyl, 3,4-dimethoxybenzyl, o -Nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl N-oxide, diphenylmethyl, p,p'-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, α-naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4'-bromophenacyloxyphenyl)diphenylmethyl, 4,4',4''-Tris(4,5-dichlorophthalimidophenyl)methyl, 4,4',4''-tris(levulinoyloxyphenyl)methyl, 4,4',4''-tris(benzoyloxyphenyl)methyl, 3-(imidazol-1-yl)bis(4',4''-dimethoxyphenyl)methyl, 1,1-bis(4-methoxyphenyl)-1'-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, 1,3-benzodisulfuran-2-yl, Benzisothiazolyl S ,S-dioxide, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethylhexylsilyl, t-butyldimethylsilyl (TBDMS), t-butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), and t-butylmethoxyphenylsilyl (TBMPS); and When the substituents are attached to a sulfur atom, the substituents are sulfur protecting groups, where each sulfur protecting group is independently -R aa , -N(R bb ) 2 , -C(=O)SR aa , -C(=O)R aa , -CO 2 R aa , -C(=O)N(R bb ) 2 , -C(=NR bb )R aa , -C(=NR bb ) OR aa , -C(=NR bb )N(R bb ) 2 , -S(=O)R aa , -SO 2 R aa , -Si(R aa ) 3 , -P(R cc ) 2 , -P(R cc ) 3 + X -, -P(OR cc ) 2 , -P(OR cc ) 3 + X - , -P(=O)(R aa ) 2 , -P(=O)(OR cc ) 2 , and -P(=O)(N(R bb ) 2 ) 2 Selected from: The compound or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof.
2. 4. The compound of formula: [C4] [C5] [C6] [C7] 2. The compound of claim 1, wherein the compound is:
3. 4. The compound of formula: [C8] [C9] [C10] [C11] 2. The compound of claim 1, wherein the compound is:
4. 2. The compound of claim 1, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled compound thereof, wherein L is optionally substituted piperidinylene or optionally substituted phenylene.
5. L is of the formula: [C12] During the ceremony: Ring A is optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; Ring B is optionally substituted heterocyclyl, or optionally substituted aryl; L x is a bond, -CH 2 -, -C(=O)-, -S(=O) 2 or -NH(C=O)-; and lx indicates the point of attachment to -NR-, and ly is R 3 indicates the attachment point to 2. The compound of claim 1, wherein the compound is:
6. L is of the formula: [C13] Represented by; R A each occurrence independently represents halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -OR D1 , -N(R D1a ) 2 , or -SR D1 is; n1 is 0 or 1; and m is 0, 1, 2, 3, or 4; 6. The compound of claim 5, wherein:
7. L is of the formula: [C14] Represented by; lx indicates the point of attachment to -NR-; ly is R 3 indicates the point of attachment to; and n1 is 0 or 1; 2. The compound of claim 1, wherein the compound is:
8. L is of the formula: [C15] [C16] 6. The compound of claim 5, wherein:
9. L is of the formula: [C17] Represented by; lx indicates the point of attachment to -NR-; and ly is R 3 indicates the attachment point to 2. The compound of claim 1, wherein the compound is:
10.
18. The compound according to any one of claims 1 to 2 and 4 to 9, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled compound thereof, wherein
11. R 1 At least one of the following is halogen or -OR D1 is; and R D1 is independently selected from hydrogen or optionally substituted alkyl; 11. The compound of any one of claims 1 to 10, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled compound thereof.
12.
19. The compound according to any one of claims 1 and 4 to 11, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled compound thereof, wherein
13.
20. 12. The compound according to any one of claims 1 and 4 to 11, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled compound thereof, wherein:
14. R 2 is hydrogen, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled compound thereof.
15. R 2 But any substitution C 1~6 14. The compound of any one of claims 1 and 4-13, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled compound thereof, wherein R is an alkyl or an optionally substituted aryl.
16. R 3 But the formula: [C21] 16. The compound according to any one of claims 1 to 15, wherein the compound is represented by: or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled compound thereof.
17. 4. The compound of formula: [C22] [C23] [C24] [C25] [C26] [C27] [C28] [C29] [C30] [C31] [C32] [C33] [C34] [C35] [C36] [C37] [C38] [C39] 2. The compound of claim 1, wherein the compound is:
18. 4. The compound of formula: [C40] [C41] or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled compound thereof.
19. 19. A compound according to any one of claims 1 to 18, or a pharma- ceutically acceptable salt thereof.
20. 19. A pharmaceutical composition comprising a compound according to any one of claims 1 to 18, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled compound thereof, and, optionally, a pharma- ceutically acceptable excipient.
21. 21. The pharmaceutical composition of claim 20 for use in treating a disease in a subject in need thereof.
22. 21. The pharmaceutical composition of claim 20, further comprising an additional pharmaceutical agent for use in treating a disease in a subject in need thereof.
23. 21. The pharmaceutical composition of claim 20 for use in preventing a disease in a subject in need thereof.
24. The method of any one of claims 21 to 23, wherein the disease is a proliferative disease, a metabolic disorder, an autoimmune disease, or a neurological disease.
25. 25. The pharmaceutical composition of claim 24, wherein the disease is cancer.
26. 26. The pharmaceutical composition of claim 25, wherein the cancer is cancer.
27. The pharmaceutical composition of claim 25, wherein the cancer is lung cancer.
28. 28. The pharmaceutical composition of claim 27, wherein the lung cancer is non-small cell lung cancer.
29. The pharmaceutical composition of claim 25, wherein the cancer is breast cancer.
30. The pharmaceutical composition of claim 25, wherein the cancer is liver cancer.
31. 26. The pharmaceutical composition of claim 25, wherein the cancer is pancreatic cancer.
32. The pharmaceutical composition according to claim 25, wherein the cancer is gastric cancer.
33. 26. The pharmaceutical composition of claim 25, wherein the cancer is ovarian cancer.
34. 26. The pharmaceutical composition of claim 25, wherein the cancer is colon cancer or colorectal cancer.
35. 25. The pharmaceutical composition of claim 24, wherein the disease is diabetes.
36. 25. The pharmaceutical composition of claim 24, wherein the disease is Alzheimer's disease.
37. 25. The pharmaceutical composition of claim 24, wherein the disease is gliosis.
38. The pharmaceutical composition of claim 24, wherein the disease is spinal cord injury.
39. The pharmaceutical composition according to any one of claims 20 to 38, wherein the subject is a human.
40. 21. The pharmaceutical composition of claim 20 for use in providing male contraception in a male subject in need thereof.
41. 21. The pharmaceutical composition of claim 20 for use in reducing male reproductive rate in fertile healthy male subjects in a subject in need thereof.
42. An in vitro method for inhibiting cyclin-dependent kinase (CDK) activity in a biological sample, tissue, or cell, the method comprising contacting an effective amount of the pharmaceutical composition of claim 20 with the biological sample, tissue, or cell.
43. 21. The pharmaceutical composition of claim 20 for use in inhibiting the activity of a cyclin-dependent kinase (CDK) in a biological sample, tissue, cell, or subject.
44. 21. An in vitro method of inducing apoptosis in cells in a biological sample, the method comprising contacting an effective amount of the pharmaceutical composition of claim 20 with the biological sample.
45. 21. The pharmaceutical composition of claim 20 for use in inducing apoptosis in a cell in a biological sample or in a subject.
46. A compound according to any one of claims 1 to 18, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, isotopically labeled compound thereof, or a pharmaceutical composition according to claim 20; and Instructions for using the compound, or a pharma- ceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, isotopically labeled compound, or pharmaceutical composition thereof Including the kit.
Citation Information
Patent Citations
Pyrazolecarboxamide derivatives and application thereof
CN107235906A
Novel compound as CDK 4 / 6 inhibitor and application of novel compound
CN107686477A
3,4-disubstituted 1h-pyrazole compounds and their use as cyclin-dependent kinase (cdk) and glycogen synthetase kinase-3 (gsk-3) modulators
JP2006528163A
pharmaceutical compound
JP2007516201A
Pyrazole derivatives for inhibition of cdk and gsk
JP2008528465A
